var title_f23_30_24032="Classification jaundice I";
var content_f23_30_24032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50896%7EGAST%2F62683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50896%7EGAST%2F62683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Classification of jaundice due to mainly unconjugated hyperbilirubinemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 301px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Classification of jaundice due to both conjugated and unconjugated hyperbilirubinemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 271px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24032=[""].join("\n");
var outline_f23_30_24032=null;
var title_f23_30_24033="PBC xanthomas on elbows";
var content_f23_30_24033=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    PBC xanthomas on elbows",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Xanthomas on elbows from primary biliary cirrhosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24033=[""].join("\n");
var outline_f23_30_24033=null;
var title_f23_30_24034="Chalazion 2";
var content_f23_30_24034=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chalazion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chronic meibomian gland plugging leads to granulomatous inflammation seen as a yellow-white bump on the inner aspect of the mid-lower lid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24034=[""].join("\n");
var outline_f23_30_24034=null;
var title_f23_30_24035="Loteprednol and tobramycin: Drug information";
var content_f23_30_24035=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Loteprednol and tobramycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/21/1364?source=see_link\">",
"    see \"Loteprednol and tobramycin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zylet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F190358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic/Corticosteroid, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F190346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Instill 1-2 drops into the affected eye(s) every 4-6 hours; may increase frequency during the first 24-48 hours to every 1-2 hours. Interval should increase as signs and symptoms improve. Further evaluation should occur for use of greater than 20 mL.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10822104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F190347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16265715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16265716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Zylet&reg;: Loteprednol etabonate 0.5% and tobramycin 0.3% (2.5 mL, 5 mL, 10 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F190337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contact lenses should not be worn during therapy. Shake well before using; Tilt head back, instill suspension in conjunctival sac and close eye(s). Do not touch dropper to eye. Apply light finger pressure on lacrimal sac for 1 minute following instillation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F190336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of steroid-responsive ocular inflammatory conditions where either a superficial bacterial ocular infection or the risk of a superficial bacterial ocular infection exists",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F190356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Superficial punctate keratitis (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     4% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Burning &amp; stinging (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Intraocular pressure increased (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;4%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Discharge, itching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Corneal deposits, eye disorders unspecified, eyelid disorder, lacrimation disorder, ocular discomfort, photophobia, secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F190340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tobramycin, loteprednol, other corticosteroids, or any component of the formulation; viral disease of the cornea and conjunctiva (including epithelial herpes simplex keratitis, vaccinia, varicella); mycobacterial or fungal infection of the eye",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F190328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Steroids may mask infection or enhance existing ocular infection; prolonged use may result in secondary bacterial or fungal superinfection due to immunosuppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Avoid prolonged use of corticosteroids, which may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Monitor intraocular pressure if used for &ge;10 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sensitivity reactions: Sensitivity to tobramycin may develop; discontinue if sensitivity reaction occurs. Cross-sensitivity to other aminoglycoside antibiotics may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cataract surgery patients: Use following cataract surgery may delay healing or increase the incidence of bleb formation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzalkonium chloride: Suspension contains benzalkonium chloride which may be adsorbed by contact lenses; contact lenses should not be worn during treatment of ophthalmic infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For ophthalmic use only.  A maximum of 20 mL of suspension should be prescribed initially; patients should be re-evaluated if symptoms do not improve after 2 days and prior to additional refills. Prescriptions extending beyond 14 days should include exams using magnification.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F190332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F190341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate or well-controlled studies in pregnant women. Use only if the potential benefit to the mother justifies the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F190349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Zylet Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-0.3% (5 mL): $174.18",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F190333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Re-evaluate if signs and symptoms persist beyond 2 days; measure intraocular pressure if used for &gt;10 days; culture for fungus with long-term use. Re-examine with use of &gt;20 mL; exams for use &gt;14 days should include magnification and  (when appropriate) fluorescein staining",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Zylet (IL, SG, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F190327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F190339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9720 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E927C15C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24035=[""].join("\n");
var outline_f23_30_24035=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190345\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190358\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190346\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10822104\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190347\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265715\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265716\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190335\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190326\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190337\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190336\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190356\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190340\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190328\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299618\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221373\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190332\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190341\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190349\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422262\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190333\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961922\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190327\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190339\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9720\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9720|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/21/1364?source=related_link\">",
"      Loteprednol and tobramycin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_30_24036="Multiple vitamins: Patient drug information";
var content_f23_30_24036=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Multiple vitamins: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/10/19619?source=see_link\">",
"     see \"Multiple vitamins: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Androvite&reg; [OTC];",
"     </li>",
"     <li>",
"      CalciFolic-D&trade;;",
"     </li>",
"     <li>",
"      Centamin [OTC];",
"     </li>",
"     <li>",
"      Centrum Cardio&reg; [OTC];",
"     </li>",
"     <li>",
"      Centrum Performance&reg; [OTC];",
"     </li>",
"     <li>",
"      Centrum&reg; Silver&reg; Ultra Men's [OTC];",
"     </li>",
"     <li>",
"      Centrum&reg; Silver&reg; Ultra Women's [OTC];",
"     </li>",
"     <li>",
"      Centrum&reg; Silver&reg; [OTC];",
"     </li>",
"     <li>",
"      Centrum&reg; Ultra Men's [OTC];",
"     </li>",
"     <li>",
"      Centrum&reg; Ultra Women's [OTC];",
"     </li>",
"     <li>",
"      Centrum&reg; [OTC];",
"     </li>",
"     <li>",
"      Diatx&reg;Zn;",
"     </li>",
"     <li>",
"      Drinkables&reg; Fruits and Vegetables [OTC];",
"     </li>",
"     <li>",
"      Drinkables&reg; MultiVitamins [OTC];",
"     </li>",
"     <li>",
"      Encora&reg;;",
"     </li>",
"     <li>",
"      Foltrin&reg;;",
"     </li>",
"     <li>",
"      Freedavite [OTC];",
"     </li>",
"     <li>",
"      Geri-Freeda [OTC];",
"     </li>",
"     <li>",
"      Geriation [OTC];",
"     </li>",
"     <li>",
"      Geritol Complete&reg; [OTC];",
"     </li>",
"     <li>",
"      Geritol Extend&reg; [OTC];",
"     </li>",
"     <li>",
"      Geritol&reg; Tonic [OTC];",
"     </li>",
"     <li>",
"      Glutofac&reg;-MX;",
"     </li>",
"     <li>",
"      Gynovite&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      Hemocyte Plus&reg;;",
"     </li>",
"     <li>",
"      Hi-Kovite [OTC];",
"     </li>",
"     <li>",
"      Iberet&reg;-500 [OTC] [DSC];",
"     </li>",
"     <li>",
"      Monocaps [OTC];",
"     </li>",
"     <li>",
"      Myadec&reg; [OTC];",
"     </li>",
"     <li>",
"      Nutrimin-Plus [OTC];",
"     </li>",
"     <li>",
"      Ocuvite&reg; Adult 50+ [OTC];",
"     </li>",
"     <li>",
"      Ocuvite&reg; Extra&reg; [OTC];",
"     </li>",
"     <li>",
"      Ocuvite&reg; Lutein [OTC];",
"     </li>",
"     <li>",
"      Ocuvite&reg; [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Cholesterol Plus [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Energy [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Essential [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Maximum [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Men's 50+ Advantage [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Men's Health Formula [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Teen Advantage for Her [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Teen Advantage for Him [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Weight Smart&reg; Advanced [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Women's 50+ Advantage  [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Women&rsquo;s Active Mind &amp; Body [OTC];",
"     </li>",
"     <li>",
"      One A Day&reg; Women&rsquo;s [OTC];",
"     </li>",
"     <li>",
"      Optivite&reg; P.M.T. [OTC];",
"     </li>",
"     <li>",
"      PreserVision&reg; AREDS [OTC];",
"     </li>",
"     <li>",
"      PreserVision&reg; Lutein [OTC];",
"     </li>",
"     <li>",
"      Quintabs [OTC];",
"     </li>",
"     <li>",
"      Quintabs-M Iron-Free [OTC];",
"     </li>",
"     <li>",
"      Quintabs-M [OTC];",
"     </li>",
"     <li>",
"      Renax&reg;;",
"     </li>",
"     <li>",
"      Renax&reg; 5.5;",
"     </li>",
"     <li>",
"      Replace Without Iron [OTC];",
"     </li>",
"     <li>",
"      Replace [OTC];",
"     </li>",
"     <li>",
"      Repliva 21/7&reg;;",
"     </li>",
"     <li>",
"      SourceCF&reg;;",
"     </li>",
"     <li>",
"      Strovite&reg;;",
"     </li>",
"     <li>",
"      Strovite&reg; Advance;",
"     </li>",
"     <li>",
"      Strovite&reg; Forte;",
"     </li>",
"     <li>",
"      Strovite&reg; Plus;",
"     </li>",
"     <li>",
"      T-Vites [OTC];",
"     </li>",
"     <li>",
"      Ultra Freeda A-Free [OTC];",
"     </li>",
"     <li>",
"      Ultra Freeda Iron-Free [OTC];",
"     </li>",
"     <li>",
"      Ultra Freeda With Iron [OTC];",
"     </li>",
"     <li>",
"      Viactiv&reg; Calcium Flavor Glides&trade; [OTC];",
"     </li>",
"     <li>",
"      Viactiv&reg; Flavor Glides [OTC];",
"     </li>",
"     <li>",
"      Viactiv&reg; for Teens [OTC];",
"     </li>",
"     <li>",
"      Viactiv&reg; With Calcium [OTC];",
"     </li>",
"     <li>",
"      Viactiv&reg; [OTC];",
"     </li>",
"     <li>",
"      Vitafol&reg;;",
"     </li>",
"     <li>",
"      Xtramins [OTC];",
"     </li>",
"     <li>",
"      Yelets [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Accidental overdose of drugs that have iron in them is a leading cause of deadly poisoning in children younger than 6 years of age. Keep away from children. If this drug is taken by accident, call a doctor or poison control center right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692172",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vitamins are needed for growth and good health.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check with your pharmacist about how to throw out unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11655 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-7288C09AE7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24036=[""].join("\n");
var outline_f23_30_24036=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234725\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017245\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017247\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017246\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017251\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017252\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017254\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017249\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017250\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017255\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017256\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/10/19619?source=related_link\">",
"      Multiple vitamins: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_30_24037="Antiretroviral medications in pregnancy: Entry and integrase inhibitors";
var content_f23_30_24037=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiretroviral medications in pregnancy: Entry and integrase inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/30/24037/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24037/contributors\">",
"     Elaine J Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/30/24037/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24037/contributors\">",
"     Lynne M Mofenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/30/24037/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24037/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/30/24037/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding antiretroviral therapy in the pregnant female are complex and need to take into consideration various factors, such as possible changes in pharmacokinetics due to physiologic changes, potential toxicities that may be magnified during pregnancy, and potential toxicity to the fetus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    newborn.",
"   </p>",
"   <p>",
"    The entry inhibitors and the integrase inhibitors represent two classes of antiretroviral agents with potent anti-HIV activity. The entry inhibitors include fusion inhibitors and CCR5-inhibitors. However, there is minimal information regarding the role of these agents in pregnancy. This topic will address the scant data that are available [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24037/abstract/1\">",
"     1",
"    </a>",
"    ]; information about the use of other classes of drugs during pregnancy is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42841?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18825?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical outcomes in women who are treated with antiretroviral therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy should not preclude the use of an optimal antiretroviral therapy regimen for the control of HIV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24037/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. An additional goal is to decrease the risk of perinatal transmission of HIV infection. Thus, all pregnant women, regardless of immunologic or virologic parameters, are treated with antiretroviral therapy to prevent perinatal transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24037/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Discussion of ART selection and treatment considerations in the pregnant HIV-infected female is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians are advised to report instances of prenatal exposure to antiretroviral therapy drugs to the Antiretroviral Pregnancy Registry at",
"    <a class=\"external\" href=\"file://www.apregistry.com/\">",
"     www.APRegistry.com",
"    </a>",
"    ; Telephone 1-800-258-4263. The registry is a collaborative project of pharmaceutical manufacturers with an advisory committee of obstetric and pediatric practitioners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AVAILABLE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The entry inhibitors include fusion inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    (T-20; Fuzeon) and CCR5 receptor inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    (Selzentry). The integrase inhibitors include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    (Isentress).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INTEGRASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-1 integrase is essential for viral replication; integrase inserts viral DNA into the cellular genome through two catalytic reactions. Loss of integrase activity disrupts the viral life cycle. Inhibitors of the integrase function have potent in vitro and in vivo antiviral activity.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    (MK-0518; Isentress) is an integrase inhibitor with potent in vitro activity against both wild-type and multidrug-resistant HIV. The efficacy of this agent is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Raltegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    is classified as FDA pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Carcinogenicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term animal carcinogenicity studies are in progress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Reproduction/fertility animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    produced no adverse effects on fertility of male or female rats at exposures threefold higher than the exposure at the recommended adult human dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Teratogenicity/developmental toxicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence of teratogenicity in animal studies; extranumerary ribs were found in rats at dose exposure threefold higher than human.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placental passage has been documented in rats and rabbits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    is secreted in the milk of lactating rats. At drug exposures in the rats that were threefold higher than those achieved with standard human dosing, the milk of lactating rats had drug concentrations about threefold higher than in the plasma. However, there were no effects in rat offspring attributable to raltegravir exposure through breast milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Human studies in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    -based ART are currently being evaluated during the third trimester and during the postpartum period at the University of San Francisco [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24037/abstract/3\">",
"     3",
"    </a>",
"    ], and in the International Maternal Pediatrics Adolescent AIDS Trials (IMPAACT) Network P1026s protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24037/abstract/4\">",
"     4",
"    </a>",
"    ]. Preliminary data from a pharmacokinetic study of 10 pregnant women who took raltegravir at the standard dose of 400 mg twice daily as part of their antiretroviral regimen found that the target 12-hour drug concentration of &gt;35",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    was met, although there was great interindividual variability in serum levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24037/abstract/5\">",
"     5",
"    </a>",
"    ]. Furthermore, raltegravir concentrations in the third trimester did not differ substantially from levels after delivery, suggesting that the standard dose may be appropriate during pregnancy and the early postpartum period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FUSION INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusion inhibitors are antiretroviral drugs that interact with components of the HIV envelope to prevent fusion of the virus with the host cell membrane.",
"   </p>",
"   <p>",
"    The normal fusion process involves binding of the viral envelope glycoprotein gp120 to the CD4+ receptor, which induces conformational changes that enable gp120 to interact with a chemokine receptor on the host cell. Binding of gp120 to the coreceptor causes subsequent conformational changes in the viral transmembrane glycoprotein gp41, exposing the \"fusion peptide\" of gp41, which inserts into the cell membrane. A helical region of gp41, called HR1, then interacts with a similar helical region, HR2, on gp41, resulting in a \"zipping\" together of the two helices and mediating the fusion of cellular and viral membranes.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     Enfuvirtide",
"    </a>",
"    (T-20) is the first drug in this class to be approved, and is a synthetic peptide derived from a naturally occurring motif within the HR2 domain of viral gp41; as a molecular mimic of the HR2 region, the drug binds to the HR1 region, preventing the HR1-HR2 interaction and correct folding of gp41 into its secondary structure, thereby inhibiting virus-cell fusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Enfuvirtide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     Enfuvirtide",
"    </a>",
"    is classified as FDA pregnancy category B (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Carcinogenicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term animal carcinogenicity studies in rats and mice have not been conducted; in vitro screening tests have been negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Reproduction/fertility animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effect has been seen on reproductive performance or fertility in rats and rabbits at doses 1.6 times the maximum recommended adult human daily dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Teratogenicity/developmental toxicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence of teratogenicity in animal studies in doses up to 27 times (in rats) and 3.2 times (in rabbits) the adult human daily dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A published case report of two peripartum pregnant patients and their neonates, and data from an ex-vivo human placental cotyledon perfusion model, suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    may have limited or no placental passage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24037/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unknown if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    is excreted into human milk; in lactating rats, studies of radio-labeled enfuvirtide identified radioactivity in the milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Human studies in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very limited data exist on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24037/abstract/6,8-12\">",
"     6,8-12",
"    </a>",
"    ]; there are no data in neonates. Safety and pharmacokinetics in pregnancy data are insufficient to recommend use during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CCR5 RECEPTOR INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CCR5 antagonists exert their antiviral activity against HIV by blocking entry of CCR5-tropic viruses into the CD4 T cell. Only one agent in this class,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    , has been approved for use in treatment-experienced HIV-infected patients. The efficacy of this agent is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: CCR5 antagonists\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Maraviroc",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     Maraviroc",
"    </a>",
"    is classified as FDA pregnancy category B (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Carcinogenicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term animal carcinogenicity studies in rats and mice have been negative at exposures up to 11-fold higher than seen with human therapeutic exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Reproduction/fertility animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     Maraviroc",
"    </a>",
"    produced no adverse effects on fertility of male or female rats or sperm of male rats at exposures up to 20-fold higher than seen with human therapeutic exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Teratogenicity/developmental toxicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence of teratogenicity in animal studies at doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    up to 20-fold higher in rats and fivefold higher in rabbits than seen with human therapeutic exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unknown if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    crosses the placenta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unknown if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    is excreted into human milk; in lactating rats, studies of radio-labeled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    identified radioactivity in the milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Human studies in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    in pregnant women or neonates. Safety and pharmacokinetics in pregnancy data are insufficient to recommend use during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here is the patient education article that is relevant to this topic. We encourage you to print or e-mail this topic to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=see_link\">",
"       \"Patient information: HIV and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no data regarding the safety and pharmacokinetics of integrase and entry inhibitors to recommend their use during pregnancy in the HIV-infected woman.",
"     </li>",
"     <li>",
"      However, pregnancy should not preclude the use of an optimal antiretroviral therapy regimen for the control of HIV disease. Use of these agents may be necessary in the pregnant HIV-infected woman with extensive drug resistance and few treatment options.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Public Health Service Task Force Recommendations for use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. September 14, 2011. www.AIDSInfo.nih.gov (Accessed on March 16, 2012).",
"    </li>",
"    <li>",
"     Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for 1 Jan 1989 - 31 January 2008. Wilmington, NC: Registry Coordinating Center; 2007. file://www.APRegistry.com (Accessed on August 26, 2010).",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT00689910 (Accessed on September 28, 2009).",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT00042289 (Accessed on September 29, 2009).",
"    </li>",
"    <li>",
"     Best B, et al. Raltegravir pharmacokinetics during pregnancy. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 12-15, 2010. Boston. Abstract H-1668a.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24037/abstract/6\">",
"      Brennan-Benson P, Pakianathan M, Rice P, et al. Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. AIDS 2006; 20:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24037/abstract/7\">",
"      Ceccaldi PF, Ferreira C, Gavard L, et al. Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model. Am J Obstet Gynecol 2008; 198:433.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24037/abstract/8\">",
"      Madeddu G, Calia GM, Campus ML, et al. Successful prevention of multidrug resistant HIV mother-to-child transmission with enfuvirtide use in late pregnancy. Int J STD AIDS 2008; 19:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24037/abstract/9\">",
"      Sued O, Lattner J, Gun A, et al. Use of darunavir and enfuvirtide in a pregnant woman. Int J STD AIDS 2008; 19:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24037/abstract/10\">",
"      Wensing AM, Boucher CA, van Kasteren M, et al. Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir. AIDS 2006; 20:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24037/abstract/11\">",
"      Cohan D, Feakins C, Wara D, et al. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. AIDS 2005; 19:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24037/abstract/12\">",
"      Meyohas MC, Lacombe K, Carbonne B, et al. Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough. AIDS 2004; 18:1966.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3780 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24037=[""].join("\n");
var outline_f23_30_24037=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AVAILABLE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INTEGRASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Raltegravir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Carcinogenicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Reproduction/fertility animal studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Teratogenicity/developmental toxicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Placental passage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FUSION INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Enfuvirtide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Carcinogenicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Reproduction/fertility animal studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Teratogenicity/developmental toxicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Placental passage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CCR5 RECEPTOR INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Maraviroc",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Carcinogenicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Reproduction/fertility animal studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Teratogenicity/developmental toxicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Placental passage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3780\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3780|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42841?source=related_link\">",
"      Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18825?source=related_link\">",
"      Antiretroviral medications in pregnancy: Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=related_link\">",
"      Patient information: HIV and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_30_24038="Hegar dilators";
var content_f23_30_24038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hegar cervical dilators (uterine cervix)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These dilators are double-ended and of progressive sizes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24038=[""].join("\n");
var outline_f23_30_24038=null;
var title_f23_30_24039="Epidemiology and risk factors for Candida infection in neonates";
var content_f23_30_24039=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and risk factors for Candida infection in neonates",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/30/24039/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24039/contributors\">",
"     Mohan Pammi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/30/24039/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24039/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24039/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/30/24039/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24039/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/30/24039/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida is a cause of neonatal infection in premature infants with the increased advancements of care, especially for extremely low and very low birth weight infants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology and risk factors for neonatal candidal infections will be reviewed here. Clinical manifestations, prevention, and treatment of neonatal candidal infections are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9991?source=see_link\">",
"     \"Prevention of Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=see_link\">",
"     \"Treatment of Candida infection in neonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida species are important hospital-acquired pathogens in infants admitted to the neonatal intensive care unit (NICU). In very low birth weight (VLBW) infants (birth weight less than 1500 g), Candida albicans (C. albicans) is the third most common cause of neonatal late onset sepsis (LOS), which occurs after the first 72 hours of life. This was illustrated in a multicenter study from the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network that evaluated 6956 VLBW infants (range of birth weight from 401 to 1500 g) admitted over a two-year period from 1998 to 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/3\">",
"     3",
"    </a>",
"    ]. C. albicans was the causative agent in 6 percent of first episodes of LOS following Coagulase negative staphylococcus (48 percent) and Staphylococcus aureus (8 percent) in frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, Candida parapsilosis (C. parapsilosis) was isolated as the causative agent in 4 percent of the cases.",
"   </p>",
"   <p>",
"    The incidence of Candida infections is greatest in extremely low birth weight (ELBW) infants with birth weights below 1000 g, as demonstrated by a study from the National Nosocomial Infections Surveillance (NNIS) system that included 130,523 patients admitted to 128 NICUs between 1995 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/4\">",
"     4",
"    </a>",
"    ]. The overall attack rate of candidal blood stream infections was 1.53 per 1000 patient-days among the infants admitted to the NICU. The annual incidences of candidemia per 1000 patient days for infants varied based upon birth weight as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Greater than 2501 g &ndash; 0.5",
"     </li>",
"     <li>",
"      1501 to 2500 g &ndash; 0.42",
"     </li>",
"     <li>",
"      1001 to 1500 g &ndash; 0.9",
"     </li>",
"     <li>",
"      Less than 1000 g &ndash; The incidence of 3.51 between 1995 and 1999 decreased to 2.68 from 2000 to 2004. Of note, similar decreases did not occur in the incidence of candidal infections in infants of greater birth weights. The explanation for this decline is unknown. The overall attack rate for infants less than 1000 g between 2000 and 2004 was 5.1 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this study, C. albicans was the most commonly isolated Candida species (60 percent) followed by C. parapsilosis (34 percent) in the 1997 identified cases of candidal blood stream infections. Other Candida species included C. tropicalis, lusitaniae, glabrata, and krusei isolated in 4, 2, 2, and &lt;1 percent of cases, respectively. C. krusei and C. glabrata may be relatively resistant to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    , and C. lusitaniae completely resistant to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Susceptibility patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a subsequent report from NNIS, the overall incidence of candidal central line-associated bloodstream infections decreased over the study period from 1999 to 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/5\">",
"     5",
"    </a>",
"    ]. The rate of infection due to C. albicans, which remained the most common cause of infection (50 percent), decreased from 0.9 to 0.2 percent, and the incidence for other candidal species from 0.4 to 0.1 percent. A decrease in C. albicans infections was observed across all birth weight categories, and a similar decrease was seen for nonalbicans C. species in all infants except neonates with a birth weight between 1501 and 2500 g.",
"   </p>",
"   <p>",
"    In a prospective study of 19 NICUs, invasive candidiasis (defined as a positive culture from a normally sterile fluid, such as blood, urine, and cerebrospinal fluid) occurred in 9 percent of 1515 extremely low birth weight (ELBW) infants (birth weight &lt;1000 g) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A change in the distribution of Candida species causing candidemia has been noted in several institutions with increasing isolation of nonalbicans species in neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]. Neonatal infections caused by nonalbicans species occur at a later age and are more likely to be acquired from the hospital environment than is C. albicans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. C. parapsilosis is the second most commonly isolated Candida species, accounting for a quarter to a third of systemic neonatal candidal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/4,11\">",
"     4,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the use of prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    has not resulted in an increase in the incidence of C. glabrata in neonates, it is important to monitor the relative incidences of the different Candidal species as fluconazole use increases in the NICU patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/9,10,12\">",
"     9,10,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of candidemia varies among different NICUs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. In the previously mentioned NNIS study, the overall attack rate was 5.1 percent for ELBW infants with birth weights less than 1000 g; however, one-quarter of the participating NICUs reported rates that were greater than 13.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differences in clinical practice, such as the use of broad-spectrum antibiotics, possibly contribute to this wide range of incidence. This was examined by a study from the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network of 3702 infants from 12 NICUs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/13\">",
"     13",
"    </a>",
"    ]. For each center, the average number of days of administration of broad-spectrum antibiotics per patient was calculated. In this study, the incidence of candidiasis ranged from 2.4 to 20.4 percent among the 12 centers. The average number of days of antibiotic use correlated with the incidence of invasive candidal infections (correlation coefficient 0.7). These results suggest that increased use of broad-spectrum antibiotics raises the risk of candidal infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SITE OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive blood stream infections are the most common neonatal presentation of Candida infections. Other candidal infections include meningitis, endocarditis, abscesses in the kidneys, spleen and liver, endophthalmitis, skin infections, urinary tract infection, and osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Candidemia may be primary or secondary to other sites of primary infection. In the previously mentioned National Nosocomial Infections Surveillance (NNIS) study, 14 percent of the cases (n = 288 cases) were classified as secondary [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/4\">",
"     4",
"    </a>",
"    ]. The primary site of infections included the urinary tract (35 percent), gastrointestinal tract (18 percent), skin or soft tissue (15 percent), lung (13 percent), central nervous system (8 percent), cardiovascular (5 percent), and other sites (5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidal infections in the neonate are usually dependent upon transmission of the organism from a carrier, colonization of the infant by the organism, and penetration of the organism through the host epithelial barriers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission of the Candidal strains is either by vertical transmission from the mother or horizontal transmission from health care workers or the hospital environment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using molecular typing techniques, vertical transmission of C. albicans, C. parapsilosis, and C. glabrata has been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Heavy maternal candidal colonization or vaginitis increases the vertical transmission of the organism and neonatal colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/17\">",
"     17",
"    </a>",
"    ]. Breastfeeding can result in transmission of Candida from the maternal skin to the oral mucosa of the infant, especially in mothers with candidal mastitis.",
"   </p>",
"   <p>",
"    Although neonatal candidal colonization is most commonly the result of vertical transmission, both vertical and horizontal transmissions contribute to neonatal colonization. This was illustrated in a prospective study of 76 mothers who gave birth to very low birth weight (VLBW) infants (birth weight below 1500 g) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/18\">",
"     18",
"    </a>",
"    ]. Maternal cultures were obtained within 24 hours of delivery and infant cultures were obtained weekly for 12 weeks or until death or discharge. C. albicans was isolated from 46 mothers (61 percent) and 27 infants (36 percent). Eighteen of the 27 infants were born to a C. albicans colonized mother (67 percent). DNA fingerprinting performed on isolates from colonized",
"    <span class=\"nowrap\">",
"     mother/infant",
"    </span>",
"    pairs, in which the infants were colonized by C. albicans by one week of age, demonstrated identical banding patterns in 11 of the 13 pairs (85 percent) confirming vertical transmission.",
"   </p>",
"   <p>",
"    Several outbreaks of C. albicans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/19-24\">",
"     19-24",
"    </a>",
"    ], C. parapsilosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], C. tropicalis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/27\">",
"     27",
"    </a>",
"    ], and C. lusitaniae [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/28\">",
"     28",
"    </a>",
"    ] infection have been reported due to horizontal transmission from health care staff. In particular, the primary mode of transmission for C. parapsilosis is horizontal from health care workers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/15,29\">",
"     15,29",
"    </a>",
"    ]. In one multicenter study, C. parapsilosis was the most common species cultured from the hands of health care workers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/10\">",
"     10",
"    </a>",
"    ]. Of the 2989 cultures, C. parapsilosis was recovered in 19 percent of samples and C. albicans in 5 percent. However, the carriage rates did not correlate with the neonatal intensive care unit (NICU) specific rates for colonization.",
"   </p>",
"   <p>",
"    Exposure to surfaces that are contaminated by Candida species is also a potential source of horizontal transmission. Both C. albicans and C. parapsilosis can survive on glass (three days), stainless steel (14 days), and fabrics (14 days), for significant time periods [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, contamination of medications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/31\">",
"     31",
"    </a>",
"    ], retrograde medication administration using multiple-use syringes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/16\">",
"     16",
"    </a>",
"    ], and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/10/26787?source=see_link\">",
"     glycerin",
"    </a>",
"    suppository [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/32\">",
"     32",
"    </a>",
"    ] have been reported as sources of candidal infectious outbreaks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida species generally colonize the skin, gastrointestinal tract, lower female genital tract, intertriginous areas (eg, groin and armpits), and the foreskin of the uncircumcised male. Similar to adults and older children, colonization usually precedes invasive fungal infection. Neonates are generally infected with a clone with which they had previously been colonized [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/16,33\">",
"     16,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In infants admitted to the NICU, colonization occurs in 30 to 60 percent of patients. The rate of colonization is dependent upon the birth weight of the infant, as illustrated by the following two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of weekly surveillance fungal cultures of the skin, gastrointestinal tract, respiratory tract, and umbilicus performed in 50 extremely low birth weight (ELBW) infants (birth weight below 1000 g) from birth to six weeks of age demonstrated colonization by a Candidal species in 62 percent of infants by six weeks of age [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/34\">",
"       34",
"      </a>",
"      ]. Approximately 85 percent of the colonization occurred in the first two weeks of life. The skin and gastrointestinal tract were the first sites colonized, followed by the respiratory tract. Colonization was inversely related to gestational age.",
"     </li>",
"     <li>",
"      In a study of VLBW (birth weight below 1500 g) infants, approximately 27 percent of patients were colonized with a candidal species, of which one-third developed mucocutaneous candidiasis and 8 percent invasive candidal infection [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The level of colonization is an important factor in developing invasive disease. The greater the density of organisms, the more likely it is that the organism will penetrate the host epithelial barriers, spread to the underlying tissue, and be disseminated through the blood stream. In a study of 40 VLBW infants, infants with heavy candidal colonization (defined as a colony count of 8 X 10",
"    <sup>",
"     6",
"    </sup>",
"    Candida colony-forming",
"    <span class=\"nowrap\">",
"     units/g",
"    </span>",
"    of stool) were more likely to have feeding intolerance, bloody stools, and candidemia compared with those with lower counts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/35\">",
"     35",
"    </a>",
"    ]. Factors that promote gastrointestinal overgrowth, such as the use of broad-spectrum antimicrobial agents, are associated with an increased risk of candidal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/1,9,12,34,36-38\">",
"     1,9,12,34,36-38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Risk factors for invasive candidiasis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients who are intubated can have colonization of their upper respiratory tract and are at increased risk of invasive candidal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Penetration of host defense",
"    </span>",
"    &nbsp;&mdash;&nbsp;The penetration of the organism through the epithelial barriers from the sites of colonization results in locally invasive or disseminated infection. The balance between benign colonization and invasive infection is primarily dependent on host factors, which is discussed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR INVASIVE CANDIDIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants admitted to the neonatal intensive care unit (NICU) are at increased risk for developing invasive candidal infection (defined as a positive culture from blood, urine, or cerebrospinal fluid), especially premature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/3,14\">",
"     3,14",
"    </a>",
"    ], for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunocompromised host &ndash; Neonates, especially premature infants, have immature immune systems. Preterm infants have low levels of circulating maternal IgG because of the loss of transplacental transfer that occurs during the third trimester of pregnancy. Even in the presence of adequate IgG concentrations, opsonization and complement functions are reduced in infants, especially in preterm infants. Neutropenia is also a common finding in premature infants with candidal infections [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/40\">",
"       40",
"      </a>",
"      ]. The epithelial barriers in preterm infants are immature. In these infants, the skin and mucosal barriers are thin and delicate, readily break down, and provide minimal protection.",
"     </li>",
"     <li>",
"      Compromise of epithelial barriers &ndash; Current neonatal intensive care therapy often requires invasive measures that compromise the host epithelial barrier, such as central venous and arterial catheters, intubation, and surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/36-39,41\">",
"       36-39,41",
"      </a>",
"      ]. These invasive procedures are more likely to be performed in infants who are seriously ill, such as those with shock, antenatal asphyxia, or respiratory distress, or who are premature. Clinical conditions, such as necrotizing enterocolitis or skin breakdown, that compromise the host epithelial barriers are also risk factors for candidiasis.",
"     </li>",
"     <li>",
"      Increased density of candidal colonization &ndash; Factors that promote candidal overgrowth, such as the use of broad-spectrum antimicrobial agents, increase the risk of candidiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/1,9,12,34,36-38\">",
"       1,9,12,34,36-38",
"      </a>",
"      ]. These interventions occur more frequently in the preterm infant. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Colonization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiplicity of colonization sites in infants [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These points were illustrated in a prospective multicenter study by the National Mycosis Survey study group that enrolled 2847 infants from six level three NICUs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/41\">",
"     41",
"    </a>",
"    ]. In this study, 1.2 percent of infants developed candidemia. The following risk factors were identified by multivariate logistic regression after adjusting for birth weight below 1000 g and abdominal surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endotracheal intubation (OR 10.7, 95% CI 1.7-450)",
"     </li>",
"     <li>",
"      Length of NICU stay greater than seven days (OR 5.3, 95% CI 1.2-48)",
"     </li>",
"     <li>",
"      Gestational age less than 32 weeks (OR 4, 95% CI 1.2-14.4)",
"     </li>",
"     <li>",
"      Central venous catheter (OR 3.9, 95% CI 1.5-12.3)",
"     </li>",
"     <li>",
"      Two or more parenteral antibiotics (OR 3.8, 95% CI 1.4-11.4)",
"     </li>",
"     <li>",
"      Shock (OR 3.6, 95% CI 1.6-7.7)",
"     </li>",
"     <li>",
"      Five-minute Apgar score less than 5 (OR 3.4, 95% CI 1.3-8.1)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       Total parenteral nutrition",
"      </a>",
"      for more than five days (OR 2.9, 95% CI 1.1-8.4)",
"     </li>",
"     <li>",
"      Intralipid infusion alone for more than seven days (OR 2.9, 95% CI 1.2-7.2)",
"     </li>",
"     <li>",
"      H2 blockers (OR 2.4, 95% CI 1.1-5.3)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the previously discussed prospective study of 1515 extremely low birth weight (ELBW) infants, identifiable risk factors for invasive candidiasis included previous antibiotic therapy and the presence of a central catheter or endotracheal tube [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, increased virulence of the candidal species is associated with a greater risk for invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar risk factors were reported in a retrospective study of larger infants with a birth weight &gt;1500 g. In this report, invasive candidal infections occurred in 330 of 530,162 infants (0.06 percent). In this cohort, the risk factors identified by multivariate logistic regression analysis included the use of broad-spectrum antibiotics and central venous catheter, and a day of life greater than seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/43\">",
"     43",
"    </a>",
"    ]. Additional risk factors not reported in the National Mycosis study were thrombocytopenia (platelet count",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL),",
"    </span>",
"    vaginal birth, and the use of prophylactic antifungal agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic candidiasis is a significant cause of neonatal mortality and morbidity. Reported mortality rates vary from 3 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/4,6,29,44\">",
"     4,6,29,44",
"    </a>",
"    ]. The mortality rates from large multicenter studies were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Nosocomial Infections Surveillance System [NNIS] study [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/4\">",
"       4",
"      </a>",
"      ] &ndash; 13 percent. In this study, candidemia was believed to be a contributing factor to the death of all of the 259 infants with candidemia who died.",
"     </li>",
"     <li>",
"      National Mycosis Survey study [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/41\">",
"       41",
"      </a>",
"      ] &ndash; 23 percent.",
"     </li>",
"     <li>",
"      In the prospective study of 1515 extremely low birth weight (ELBW) infants with invasive candidiasis, the mortality rate was about 27 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24039/abstract/6\">",
"       6",
"      </a>",
"      ]. The mortality was similar in patients who had positive blood cultures (28 percent) to those with only Candida isolated from urine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candida has emerged as a common cause of infections in infants admitted to the neonatal intensive care unit (NICU), particularly preterm infants. In very low birth weight infants (birth weight below 1500 g), Candida albicans (C. albicans) is the third most common cause of neonatal late onset sepsis, which occurs after the first 72 hours of life. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      C. albicans is the most commonly isolated candidal species (60 percent) followed by C. parapsilosis (34 percent). Other less common species include C. tropicalis, C. lusitaniae, C. glabrata, and C. krusei. Neonatal infections caused by nonalbicans species occur at a later age and are more likely to be acquired from the hospital staff or environment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Invasive blood stream infections are the most common neonatal presentation of Candida infections. Other candidal infections include meningitis, endocarditis, abscesses in the kidneys, spleen and liver, endophthalmitis, skin infections, urinary tract infection, and osteomyelitis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Site of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Candidal infections in the neonate are usually dependent upon transmission of the organism from a carrier, colonization of the infant by the organism, and penetration of the organism through the host epithelial barriers. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most candidal infections are due to vertical transmission from the mother. In some cases, infections, particularly those due to C. parapsilosis, are the result of horizontal transmission from health care staff or hospital environment. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Candida generally colonizes the skin, gastrointestinal tract, lower female genital tract, intertriginous areas, and the foreskin of uncircumcised males. In the neonate, colonization usually precedes invasive fungal infection. The rate of colonization increases with decreasing birth weight. Almost two-thirds of extremely low birth weight infants (birth weight less than 1000 g) are colonized by six weeks of age. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Colonization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants admitted to the NICU, especially premature infants, are at increased risk for candidal infections because of the immaturity of their immune and host epithelial protection, compromise of their epithelial protection with invasive procedures (eg, intubation, central venous catheters,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgery), and factors that promote increased density of candidal colonization (eg, administration of broad-spectrum antimicrobial agents). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Risk factors for invasive candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic candidiasis is a significant cause of neonatal mortality and morbidity with reported mortality rates of 13 to 50 percent. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/1\">",
"      Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998; 17:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/2\">",
"      Beck-Sague CM, Azimi P, Fonseca SN, et al. Bloodstream infections in neonatal intensive care unit patients: results of a multicenter study. Pediatr Infect Dis J 1994; 13:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/3\">",
"      Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/4\">",
"      Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006; 117:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/5\">",
"      Chitnis AS, Magill SS, Edwards JR, et al. Trends in Candida central line-associated bloodstream infections among NICUs, 1999-2009. Pediatrics 2012; 130:e46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/6\">",
"      Benjamin DK Jr, Stoll BJ, Gantz MG, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics 2010; 126:e865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/7\">",
"      Miranda LN, van der Heijden IM, Costa SF, et al. Candida colonisation as a source for candidaemia. J Hosp Infect 2009; 72:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/8\">",
"      Al-Sweih N, Khan Z, Khan S, Devarajan LV. Neonatal candidaemia in Kuwait: a 12-year study of risk factors, species spectrum and antifungal susceptibility. Mycoses 2009; 52:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/9\">",
"      Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001; 20:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/10\">",
"      Fairchild KD, Tomkoria S, Sharp EC, Mena FV. Neonatal Candida glabrata sepsis: clinical and laboratory features compared with other Candida species. Pediatr Infect Dis J 2002; 21:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/11\">",
"      Clerihew L, Lamagni TL, Brocklehurst P, McGuire W. Candida parapsilosis infection in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2007; 92:F127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/12\">",
"      Cotten CM, McDonald S, Stoll B, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 2006; 118:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/13\">",
"      Noyola DE, Fernandez M, Moylett EH, Baker CJ. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis 2001; 32:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/14\">",
"      L&oacute;pez Sastre JB, Coto Cotallo GD, Fern&aacute;ndez Colomer B, Grupo de Hospitales Castrillo. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol 2003; 20:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/15\">",
"      Waggoner-Fountain LA, Walker MW, Hollis RJ, et al. Vertical and horizontal transmission of unique Candida species to premature newborns. Clin Infect Dis 1996; 22:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/16\">",
"      Sherertz RJ, Gledhill KS, Hampton KD, et al. Outbreak of Candida bloodstream infections associated with retrograde medication administration in a neonatal intensive care unit. J Pediatr 1992; 120:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/17\">",
"      Baley JE, Kliegman RM, Boxerbaum B, Fanaroff AA. Fungal colonization in the very low birth weight infant. Pediatrics 1986; 78:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/18\">",
"      Bliss JM, Basavegowda KP, Watson WJ, et al. Vertical and horizontal transmission of Candida albicans in very low birth weight infants using DNA fingerprinting techniques. Pediatr Infect Dis J 2008; 27:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/19\">",
"      Bendel CM. Colonization and epithelial adhesion in the pathogenesis of neonatal candidiasis. Semin Perinatol 2003; 27:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/20\">",
"      Betremieux P, Chevrier S, Quindos G, et al. Use of DNA fingerprinting and biotyping methods to study a Candida albicans outbreak in a neonatal intensive care unit. Pediatr Infect Dis J 1994; 13:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/21\">",
"      Burnie JP. Candida and hands. J Hosp Infect 1986; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/22\">",
"      Burnie JP, Lee W, Williams JD, et al. Control of an outbreak of systemic Candida albicans. Br Med J (Clin Res Ed) 1985; 291:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/23\">",
"      Burnie JP, Odds FC, Lee W, et al. Outbreak of systemic Candida albicans in intensive care unit caused by cross infection. Br Med J (Clin Res Ed) 1985; 290:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/24\">",
"      Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP. Evidence of nosocomial spread of Candida albicans causing bloodstream infection in a neonatal intensive care unit. Diagn Microbiol Infect Dis 1995; 21:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/25\">",
"      Reef SE, Lasker BA, Butcher DS, et al. Nonperinatal nosocomial transmission of Candida albicans in a neonatal intensive care unit: prospective study. J Clin Microbiol 1998; 36:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/26\">",
"      Huang YC, Lin TY, Leu HS, et al. Outbreak of Candida parapsilosis fungemia in neonatal intensive care units: clinical implications and genotyping analysis. Infection 1999; 27:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/27\">",
"      Saxen H, Virtanen M, Carlson P, et al. Neonatal Candida parapsilosis outbreak with a high case fatality rate. Pediatr Infect Dis J 1995; 14:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/28\">",
"      Finkelstein R, Reinhertz G, Hashman N, Merzbach D. Outbreak of Candida tropicalis fungemia in a neonatal intensive care unit. Infect Control Hosp Epidemiol 1993; 14:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/29\">",
"      Fowler SL, Rhoton B, Springer SC, et al. Evidence for person-to-person transmission of Candida lusitaniae in a neonatal intensive-care unit. Infect Control Hosp Epidemiol 1998; 19:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/30\">",
"      Lupetti A, Tavanti A, Davini P, et al. Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J Clin Microbiol 2002; 40:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/31\">",
"      Traor&eacute; O, Springthorpe VS, Sattar SA. A quantitative study of the survival of two species of Candida on porous and non-porous environmental surfaces and hands. J Appl Microbiol 2002; 92:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/32\">",
"      Welbel SF, McNeil MM, Kuykendall RJ, et al. Candida parapsilosis bloodstream infections in neonatal intensive care unit patients: epidemiologic and laboratory confirmation of a common source outbreak. Pediatr Infect Dis J 1996; 15:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/33\">",
"      Huang YC, Li CC, Lin TY, et al. Association of fungal colonization and invasive disease in very low birth weight infants. Pediatr Infect Dis J 1998; 17:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/34\">",
"      Kaufman DA, Gurka MJ, Hazen KC, et al. Patterns of fungal colonization in preterm infants weighing less than 1000 grams at birth. Pediatr Infect Dis J 2006; 25:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/35\">",
"      Pappu-Katikaneni LD, Rao KP, Banister E. Gastrointestinal colonization with yeast species and Candida septicemia in very low birth weight infants. Mycoses 1990; 33:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/36\">",
"      Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low-birth-weight infants: clinical manifestations and epidemiology. Pediatrics 1984; 73:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/37\">",
"      Faix RG, Kovarik SM, Shaw TR, Johnson RV. Mucocutaneous and invasive candidiasis among very low birth weight (less than 1,500 grams) infants in intensive care nurseries: a prospective study. Pediatrics 1989; 83:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/38\">",
"      Weese-Mayer DE, Fondriest DW, Brouillette RT, Shulman ST. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatr Infect Dis J 1987; 6:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/39\">",
"      Rowen JL, Rench MA, Kozinetz CA, et al. Endotracheal colonization with Candida enhances risk of systemic candidiasis in very low birth weight neonates. J Pediatr 1994; 124:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/40\">",
"      Mahieu LM, Van Gasse N, Wildemeersch D, et al. Number of sites of perinatal Candida colonization and neutropenia are associated with nosocomial candidemia in the neonatal intensive care unit patient. Pediatr Crit Care Med 2010; 11:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/41\">",
"      Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/42\">",
"      Bliss JM, Wong AY, Bhak G, et al. Candida virulence properties and adverse clinical outcomes in neonatal&nbsp;candidiasis. J Pediatr 2012; 161:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/43\">",
"      Lee JH, Hornik CP, Benjamin DK Jr, et al. Risk Factors for Invasive Candidiasis in Infants &gt;1500 g Birth Weight. Pediatr Infect Dis J 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24039/abstract/44\">",
"      Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24:1122.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5028 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24039=[""].join("\n");
var outline_f23_30_24039=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SITE OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Colonization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Penetration of host defense",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RISK FACTORS FOR INVASIVE CANDIDIASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=related_link\">",
"      Clinical manifestations and diagnosis of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9991?source=related_link\">",
"      Prevention of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=related_link\">",
"      Treatment of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_30_24040="Clinical presentation and diagnosis of ventilator-associated pneumonia";
var content_f23_30_24040=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and diagnosis of ventilator-associated pneumonia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/30/24040/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24040/contributors\">",
"     Marin H Kollef, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/30/24040/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24040/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24040/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/30/24040/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24040/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/30/24040/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilator-associated pneumonia (VAP) is a type of hospital-acquired (ie, nosocomial) pneumonia that develops after more than 48 hours of mechanical ventilation. It is a common and serious problem, with an estimated incidence of 10 to 25 percent and an all-cause mortality of 25 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Early diagnosis is important because prompt, appropriate treatment can be lifesaving.",
"   </p>",
"   <p>",
"    The clinical presentation and diagnosis of VAP are reviewed here. The risk factors for VAP and its prevention and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=see_link\">",
"     \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6695?source=see_link\">",
"     \"The ventilator circuit and ventilator-associated pneumonia\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2756487\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;VAP typically presents with a new or progressive pulmonary infiltrate and one or more of the following findings: fever, purulent tracheobronchial secretions, leukocytosis, increased respiratory rate, decreased tidal volume, increased minute ventilation, and decreased oxygenation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/3\">",
"     3",
"    </a>",
"    ]. These symptoms and signs may develop gradually or suddenly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2756708\">",
"    <span class=\"h2\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with VAP are typically unable to provide any history because they are either sedated or their ability to communicate is impaired by the endotracheal or tracheostomy tube. Those few patients who are able to convey symptoms are likely to report dyspnea or chest congestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2756716\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever and an increased volume of purulent tracheobronchial secretions are common among patients with VAP. On auscultation, patients typically have diffuse, asymmetric rhonchi due to the tracheobronchial secretions that the patient is unable to mobilize. The rhonchi are often accompanied by focal findings, such as crackles and decreased breath sounds. In addition, many patients are tachypneic with increased respiratory effort. Bronchospasm (wheezing and increased expiratory time) and hemoptysis are also common. These pulmonary signs may be accompanied by systemic abnormalities, such as encephalopathy or sepsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link&amp;anchor=H6#H6\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\", section on 'Sepsis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2756692\">",
"    <span class=\"h2\">",
"     Ventilator performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deterioration in the patient&rsquo;s respiratory performance, as identified during routine assessment of the mechanical ventilator, may be the initial sign of VAP. This includes an increased respiratory rate, decreased tidal volume, increased minute ventilation, or decreased oxygenation. Many patients will require more ventilatory support or inspired oxygen than they did previously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2756495\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic evaluation is required any time that VAP is suspected because clinical features alone are nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The goal is to confirm VAP and to identify the likely pathogen, so that the appropriate treatment can be initiated. The evaluation begins with a chest radiograph. Patients who have an abnormal chest radiograph should have their respiratory tract sampled and specimens sent for microscopic analysis and culture.",
"   </p>",
"   <p>",
"    These steps are ideally performed prior to the initiation of antibiotic therapy because antibiotic therapy reduces the sensitivity of both the microscopic analysis and culture [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] (similarly, these steps are ideally performed prior to changing the antibiotic regimen of patients suspected of developing VAP while receiving antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]). Once the respiratory specimens have been obtained, empiric antibiotic therapy is indicated for all cases of suspected VAP, unless the clinical suspicion is low and the microscopic analysis of lower respiratory tract samples is negative (ie, few neutrophils). Occasionally, the severity of illness or delays in sampling requires that empiric antibiotic therapy be initiated prior to diagnostic sampling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Empiric treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H322109\">",
"    <span class=\"h2\">",
"     Chest imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest radiograph should be performed on all patients with suspected VAP [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/1\">",
"     1",
"    </a>",
"    ]. A normal chest radiograph excludes VAP, while an abnormal radiograph should prompt the collection of respiratory tract secretions. Common radiographic abnormalities in VAP include alveolar infiltrates, air bronchograms, and silhouetting of adjacent solid organs.",
"   </p>",
"   <p>",
"    While an abnormal chest radiograph is required to diagnose VAP, it is not sufficient. The reason that radiographic abnormalities alone are insufficient to diagnose VAP is that they are nonspecific (ie, they frequently exist in the absence of VAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/1,4,11,12\">",
"     1,4,11,12",
"    </a>",
"    ]. This was illustrated by an observational study in which only 43 percent of patients who had clinical and radiographic evidence of VAP at the time of their death were subsequently confirmed to have VAP by postmortem examination [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional benefits of the chest radiograph are that it can help determine the severity of the disease (multilobar versus unilobar) and identify complications, such as pleural effusions or cavitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H322290\">",
"    <span class=\"h2\">",
"     Respiratory sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower respiratory tract sampling is indicated for all patients who are suspected of having VAP and have an abnormal chest radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/1\">",
"     1",
"    </a>",
"    ]. There are a variety of methods available to sample material from the airways and alveoli, including nonbronchoscopic (ie, blind) and bronchoscopic techniques.",
"   </p>",
"   <p>",
"    Nonbronchoscopic lower respiratory tract sampling includes tracheobronchial aspiration or mini-BAL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/13-21\">",
"     13-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tracheobronchial aspiration is performed by advancing a catheter through the endotracheal tube until resistance is met and then applying suction.",
"     </li>",
"     <li>",
"      Mini-BAL is performed by advancing a catheter through the endotracheal tube until resistance is met, infusing sterile saline through the catheter, and then aspirating.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A clinician is not necessary to perform or supervise nonbronchoscopic sampling. This reduces the cost, allows specimens to be obtained quickly, and facilitates serial sampling when necessary.",
"   </p>",
"   <p>",
"    Bronchoscopic sampling is performed using either bronchoalveolar lavage (BAL) or a protected specimen brush (PSB) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=see_link\">",
"     \"Flexible bronchoscopy: Indications and contraindications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=see_link\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BAL involves the infusion and aspiration of sterile saline through a flexible bronchoscope that is wedged in a bronchial segmental orifice. The technique of BAL is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=see_link\">",
"       \"Basic principles and technique of bronchoalveolar lavage\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A PSB is a brush that is contained within a protective sheath. It is designed to minimize the likelihood that the brush will be contaminated during bronchoscopy. The procedure involves placing the bronchoscope tip next to a bronchial segmental orifice, pushing the sheath through the bronchoscope, and then advancing the brush out of the sheath and into the airway. Specimens are collected by brushing the airway wall, withdrawing the brush into the sheath, and then removing the sheath from the bronchoscope.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bronchoscopic sampling and nonbronchoscopic sampling have been compared in the setting of suspected VAP [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. The evidence indicates that bronchoscopic sampling does not improve mortality, length of hospital stay, duration of mechanical ventilation, or length of intensive care unit stay [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/22,24,26,27\">",
"     22,24,26,27",
"    </a>",
"    ]. However, it minimizes airway contamination of the alveolar samples and provides an accurate assessment of the alveolar cell population. Bronchoscopic sampling may lead to a narrower antimicrobial regimen and more rapid de-escalation of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/22,23,25,28\">",
"     22,23,25,28",
"    </a>",
"    ], which presumably reduces antibiotic resistance.",
"   </p>",
"   <p>",
"    The decision about whether to perform nonbronchoscopic or bronchoscopic sampling ultimately depends upon a case-by-case determination of the benefits of a narrow antibiotic regimen versus the risks of bronchoscopy. In patients for whom the risk of bronchoscopy is low, we frequently perform bronchoscopic BAL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Microscopic analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lower respiratory specimens should be sent for microscopic analysis. The most common microscopic analysis is the Gram stain. It can be used to semi-quantitate polymorphonuclear leukocytes and other cell types, as well as to characterize the morphology of bacteria. The presence of abundant neutrophils is consistent with VAP and the bacterial morphology may suggest a likely pathogen. Gram stain analysis may decrease the incidence of inappropriate antimicrobial therapy and improve diagnostic accuracy when correlated with culture results [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A differential cell count can also be performed by microscopic analysis following a BAL. It determines the proportion of total nucleated cells in the spun sediment of BAL fluid that are neutrophils, lymphocytes, macrophages, eosinophils, basophils, or other nucleated cells. In a prospective cohort study of 39 patients, VAP was correctly excluded in all patients in whom neutrophils were fewer than 50 percent of the total nucleated cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H322748\">",
"    <span class=\"h2\">",
"     Respiratory culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lower respiratory specimens should also be sent for culture. Quantitative or semiquantitative cultures are both acceptable, with the choice depending largely upon availability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Quantitative culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative cultures can be performed on bronchoscopic or nonbronchoscopic specimens. VAP is supported when an established threshold of bacterial growth is exceeded. Only bacteria that are pulmonary pathogens should be counted. As examples, Staphylococcus epidermidis, enterococci, and most gram positive bacilli (except actinomycosis and nocardia) should not be counted.",
"   </p>",
"   <p>",
"    Thresholds of 1,000,000 colony forming units",
"    <span class=\"nowrap\">",
"     (cfu)/mL",
"    </span>",
"    for samples obtained by tracheobronchial aspiration, 10,000",
"    <span class=\"nowrap\">",
"     cfu/mL",
"    </span>",
"    for samples obtained by BAL, or 1000",
"    <span class=\"nowrap\">",
"     cfu/mL",
"    </span>",
"    for samples obtained by PSB are most accurate because they are sufficiently high that patients with tracheobronchial colonization are unlikely to be mistaken for patients with VAP [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/1,9,31\">",
"     1,9,31",
"    </a>",
"    ]. Lower thresholds are reasonable if the risk of a missing a VAP (ie, a false-negative result) exceeds the risk of unnecessary treatment (ie, a false-positive result) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/32\">",
"     32",
"    </a>",
"    ]. According to a prospective cohort study of 122 patients, thresholds between 1000 and 10,000",
"    <span class=\"nowrap\">",
"     cfu/mL",
"    </span>",
"    for BAL specimens and between 100 and 1000",
"    <span class=\"nowrap\">",
"     cfu/mL",
"    </span>",
"    for PSB specimens decrease the likelihood of a false-negative result to a greater degree than they increase the likelihood of a false-positive result [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generally speaking, quantitative cultures derived from nonbronchoscopic specimens tend to have a lower specificity than quantitative cultures derived from bronchoscopic specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. However, this is balanced by a higher sensitivity, resulting in comparable diagnostic accuracy. In a prospective cohort study of 38 patients, the accuracy of quantitative cultures was greatest when the sample was obtained by tracheobronchial aspiration, followed (in order of decreasing accuracy) by BAL, mini-BAL, and PSB [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Quantitative cultures do not appear to improve clinical outcomes, compared with semiquantitative cultures. This was illustrated by a meta-analysis of three randomized trials (1240 patients), which found that quantitative cultures did not alter mortality, days of mechanical ventilation, or length of ICU stay, compared with semiquantitative cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/27\">",
"     27",
"    </a>",
"    ]. Despite the lack of improvement in clinical outcomes, many clinicians believe that quantitative cultures are advantageous because they may lead to more judicious use of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Semiquantitative culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Semiquantitative cultures can also be performed on bronchoscopic or nonbronchoscopic samples. They are typically reported as showing heavy, moderate, light, or no growth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/1\">",
"     1",
"    </a>",
"    ]. The amount of growth that suggests VAP has not been firmly established, but it is reasonable to consider a semiquantitative culture with moderate or heavy growth to be positive. Compared with quantitative cultures, semiquantitative cultures are less likely to distinguish patients whose airways are colonized from those who have VAP [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, false-positive results are more likely, which can lead to inappropriate therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H322876\">",
"    <span class=\"h2\">",
"     Other diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procalcitonin, the clinical pulmonary infection score, and lung biopsy are additional diagnostic tests that are often discussed; however, they have little role in the evaluation of suspected VAP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biological markers &ndash; Biologic markers are sometimes used to try to distinguish between bacterial and non-bacterial causes of pneumonia.",
"      <br/>",
"      <br/>",
"      Procalcitonin is a promising biologic marker. The use of serum procalcitonin to facilitate the decision about whether or not to initiate antibiotics in patients admitted with suspected community-acquired pneumonia was evaluated in several randomized trials that found that serum procalcitonin decreased antibiotic exposure without affecting clinical outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. In suspected VAP, however, it is unknown if serum procalcitonin levels are a useful guide for the decision about whether to initiate antibiotics because the evidence is conflicting [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. Until higher quality studies resolve the uncertainty, we believe that serum procalcitonin levels should not be used for this purpose. However, there are two situations in which procalcitonin may be useful in patients with confirmed VAP. First, procalcitonin may be helpful in the decision of whether to discontinue antibiotic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/39\">",
"       39",
"      </a>",
"      ]. Second, procalcitonin may be a useful prognostic marker, since progressive increases in serum procalcitonin have been associated with septic shock and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/40-42\">",
"       40-42",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other biomarkers, such as C-reactive protein (CRP) and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), were initially considered promising markers for improving diagnostic strategies for VAP. However, more recent studies suggest that the measurement of such biomarkers in BAL fluid has minimal diagnostic value for VAP [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/43-45\">",
"       43-45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical Pulmonary Infection Score (CPIS) &ndash; The CPIS combines clinical, radiographic, physiologic, and microbiologic data into a numerical result (",
"      <a class=\"graphic graphic_table graphicRef77054 \" href=\"UTD.htm?25/31/26108\">",
"       table 1",
"      </a>",
"      ). Initial validation of the CPIS found that a score greater than six correlated with VAP [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/46\">",
"       46",
"      </a>",
"      ]. However, subsequent studies failed to confirm this. In one prospective cohort study, the CPIS identified VAP with a sensitivity and specificity of only 60 and 59 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lung biopsy &ndash; Histologic examination of lung tissue obtained by biopsy is an imperfect and seldom used method of diagnosing VAP. In addition to requiring an invasive procedure, its reliability and reproducibility are uncertain. This is probably due to a lack of standardized histologic criteria to define VAP. In a prospective cohort study, 39 patients who died while receiving mechanical ventilation underwent post mortem open lung biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24040/abstract/48\">",
"       48",
"      </a>",
"      ]. The histology was reviewed separately by four pathologists who reported a prevalence of VAP ranging from 18 to 38 percent. One pathologist reinterpreted the histology six months later and reclassified the VAP status of two patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Laboratory tests &ndash; Patients with VAP usually develop leukocytosis with a neutrophil predominance. &nbsp;However, there are no laboratory findings that are specific for VAP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2756663\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of VAP is made when a patient who has been mechanically ventilated for &ge;48 hours develops a new or progressive infiltrate and the respiratory specimens are positive (ie, increased neutrophils are seen in the microscopic analysis and growth of a pathogen in culture exceeds a predefined threshold).",
"   </p>",
"   <p>",
"    VAP cannot be confirmed or excluded until the culture results are complete, which generally takes two to three days. At that time, the patient should be reevaluated to determine if additional diagnostic evaluation or changes in management are warranted. These decisions are based upon the culture results and response to empiric therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef76508 \" href=\"UTD.htm?26/43/27312\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with negative cultures who have",
"      <strong>",
"      </strong>",
"      not improved may not have VAP; therefore, other diagnoses or sites of infection should be sought.",
"     </li>",
"     <li>",
"      Patients with negative cultures who have improved may not have VAP; antimicrobial therapy should be discontinued.",
"     </li>",
"     <li>",
"      Patients with positive cultures who have&nbsp;not improved probably have VAP, but they may be receiving inappropriate antimicrobial therapy, have a complication of the VAP (eg, abscess, empyema), have a second source of infection, or have a second diagnosis. The antimicrobial regimen should be adjusted and then potential causes for failing to improve clinically should be sought.",
"     </li>",
"     <li>",
"      Patients with positive cultures who have improved probably have VAP, which has responded to antimicrobial therapy; the antimicrobial therapy should be narrowed according to the culture results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antimicrobial therapy for VAP is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2756455\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many causes of pulmonary infiltrates, fever, respiratory abnormalities, and leukocytosis other than VAP. The following conditions can present with this constellation of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aspiration pneumonitis &ndash; Aspiration pneumonitis refers to chemical aspiration without infection; it is distinguished from VAP by history (ie, witnessed aspiration), microscopic analysis and culture of respiratory secretions (ie, negative), and clinical course (ie, self-limited). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link\">",
"       \"Aspiration pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulmonary embolism with infarction &ndash; Pulmonary embolism can mimic VAP if it causes pulmonary infarction; it is distinguished from VAP when computed tomography pulmonary angiography (CT-PA), ventilation-perfusion",
"      <span class=\"nowrap\">",
"       (V/Q)",
"      </span>",
"      scanning, or conventional pulmonary angiography reveals pulmonary embolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute respiratory distress syndrome &ndash; Acute respiratory distress syndrome (ARDS) is characterized by an acute onset of bilateral pulmonary infiltrates and severe hypoxemia in the absence of an elevated left atrial pressure; it is distinguished from VAP by history (ie, risk factors for ARDS may be present) and the microscopic analysis and culture of respiratory secretions (ie, negative). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"       \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulmonary hemorrhage &ndash; Both pulmonary hemorrhage and VAP may cause hemoptysis in addition to the constellation of findings described above. Pulmonary hemorrhage tends to present with frank bleeding while VAP often appears as blood mixed with purulent secretions, but this distinction is imperfect. Definitively distinguishing pulmonary hemorrhage from VAP requires that the cause of the hemoptysis be identified. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14727?source=see_link\">",
"       \"Etiology and evaluation of hemoptysis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lung contusion &ndash; Pulmonary contusion is due to trauma, but it may be difficult to distinguish from VAP because the clinical and radiographic manifestations are similar and often delayed following the trauma. Pulmonary contusion is distinguished from VAP by history (ie, recent trauma) and the microscopic analysis and culture of respiratory secretions (ie, negative). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of inpatient management in the adult trauma patient\", section on 'Pulmonary contusion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infiltrative tumor &ndash; The lung is a common site of primary or metastatic cancer and the manifestations of a diffuse infiltrative cancer are similar to VAP. Diffuse infiltrative cancer is distinguished from VAP by history (ie, history of malignancy), as well as both culture (ie, negative) and microscopic analysis (ie, negative for neutrophils and bacteria, but positive for malignant cells) of respiratory secretions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Radiation pneumonitis &ndash; Radiation-induced lung injury may cause acute pneumonitis or chronic fibrosis. The former develops approximately four to twelve weeks after irradiation, with symptoms and signs that mimic VAP; it is distinguished from VAP by history (ie, prior irradiation) and the microscopic analysis and culture of respiratory secretions (ie, negative). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link\">",
"       \"Radiation-induced lung injury\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Drug reaction &ndash; Pulmonary drug toxicity can result from many different drugs, most notably antineoplastic agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ). The clinical manifestations of pulmonary drug toxicity can be identical to VAP and the timing of the onset of symptoms and signs is highly variable (ie, days to months after receiving the medication). Pulmonary drug toxicity is distinguished from VAP by history (ie, received a potentially toxic agent within the past months) and the microscopic analysis and culture of respiratory secretions (ie, negative). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link\">",
"       \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cryptogenic organizing pneumonia &ndash; Cryptogenic organizing pneumonia (COP) is an idiopathic form of organizing pneumonia. Its clinical features may be identical to VAP; it is distinguished from VAP by history (ie, risk factors for COP may be present, such as a recent viral infection) and the microscopic analysis and culture of respiratory secretions (ie, negative). Definitive diagnosis of COP requires lung biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link\">",
"       \"Cryptogenic organizing pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ventilator-associated pneumonia (VAP) is a type of hospital-acquired (ie, nosocomial) pneumonia that develops after more than 48 hours of mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      VAP typically presents with the gradual or sudden onset of a new or progressive pulmonary infiltrate and one or more of the following findings: fever, purulent tracheobronchial secretions, leukocytosis, increased respiratory rate, decreased tidal volume, increased minute ventilation, and decreased oxygenation. (See",
"      <a class=\"local\" href=\"#H2756487\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      A diagnostic evaluation is required whenever VAP is suspected because clinical features alone are nonspecific. The goal of the diagnostic evaluation is to confirm VAP and identify the likely pathogen. A typical evaluation begins with a chest radiograph. For patients with an abnormal chest radiograph, the respiratory tract is sampled and the specimens are sent for microscopic analysis and culture. (See",
"      <a class=\"local\" href=\"#H2756495\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      These steps are ideally performed prior to the initiation of antibiotic therapy because antibiotic therapy reduces the sensitivity of both the microscopic analysis and culture (similarly, these steps are ideally performed prior to changing the antibiotic regimen of patients suspected of developing VAP while receiving antibiotics). Once the respiratory specimens have been obtained, empiric antibiotic therapy is indicated for all cases of suspected VAP, unless the clinical suspicion is low and the microscopic analysis of lower respiratory tract samples is negative (ie, few neutrophils). Occasionally, the severity of illness or delays in sampling requires that empiric antibiotic therapy be initiated prior to diagnostic sampling. (See",
"      <a class=\"local\" href=\"#H2756495\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      The diagnosis of VAP is made when a patient who has been mechanically ventilated for at least 48 hours develops a new or progressive pulmonary infiltrate and cultures of the respiratory specimens are positive (ie, increased neutrophils are seen in the microscopic analysis and growth of a pathogen in culture exceeds a predefined threshold). (See",
"      <a class=\"local\" href=\"#H2756663\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      There are many causes of pulmonary infiltrates, fever, respiratory abnormalities, and leukocytosis other than VAP. These include aspiration pneumonitis, pulmonary embolism with infarction, acute respiratory distress syndrome, pulmonary hemorrhage, pulmonary contusion, infiltrative tumor, radiation pneumonitis, pulmonary drug toxicity, and cryptogenic organizing pneumonia. (See",
"      <a class=\"local\" href=\"#H2756455\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/1\">",
"      American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/2\">",
"      Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/3\">",
"      Meduri GU. Diagnosis and differential diagnosis of ventilator-associated pneumonia. Clin Chest Med 1995; 16:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/4\">",
"      Andrews CP, Coalson JJ, Smith JD, Johanson WG Jr. Diagnosis of nosocomial bacterial pneumonia in acute, diffuse lung injury. Chest 1981; 80:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/5\">",
"      Fagon JY, Chastre J, Hance AJ, et al. Detection of nosocomial lung infection in ventilated patients. Use of a protected specimen brush and quantitative culture techniques in 147 patients. Am Rev Respir Dis 1988; 138:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/6\">",
"      Fagon JY, Chastre J, Hance AJ, et al. Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients. Chest 1993; 103:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/7\">",
"      Torres A, el-Ebiary M, Padr&oacute; L, et al. Validation of different techniques for the diagnosis of ventilator-associated pneumonia. Comparison with immediate postmortem pulmonary biopsy. Am J Respir Crit Care Med 1994; 149:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/8\">",
"      Dotson RG, Pingleton SK. The effect of antibiotic therapy on recovery of intracellular bacteria from bronchoalveolar lavage in suspected ventilator-associated nosocomial pneumonia. Chest 1993; 103:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/9\">",
"      Chastre J, Fagon JY, Bornet-Lecso M, et al. Evaluation of bronchoscopic techniques for the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med 1995; 152:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/10\">",
"      Timsit JF, Misset B, Renaud B, et al. Effect of previous antimicrobial therapy on the accuracy of the main procedures used to diagnose nosocomial pneumonia in patients who are using ventilation. Chest 1995; 108:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/11\">",
"      Rubin SA, Winer-Muram HT, Ellis JV. Diagnostic imaging of pneumonia and its complications in the critically ill patient. Clin Chest Med 1995; 16:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/12\">",
"      Wunderink RG, Woldenberg LS, Zeiss J, et al. The radiologic diagnosis of autopsy-proven ventilator-associated pneumonia. Chest 1992; 101:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/13\">",
"      Pham LH, Brun-Buisson C, Legrand P, et al. Diagnosis of nosocomial pneumonia in mechanically ventilated patients. Comparison of a plugged telescoping catheter with the protected specimen brush. Am Rev Respir Dis 1991; 143:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/14\">",
"      Marik PE, Brown WJ. A comparison of bronchoscopic vs blind protected specimen brush sampling in patients with suspected ventilator-associated pneumonia. Chest 1995; 108:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/15\">",
"      Papazian L, Thomas P, Garbe L, et al. Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia. Am J Respir Crit Care Med 1995; 152:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/16\">",
"      Rouby JJ, Martin De Lassale E, Poete P, et al. Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis 1992; 146:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/17\">",
"      Kollef MH, Bock KR, Richards RD, Hearns ML. The safety and diagnostic accuracy of minibronchoalveolar lavage in patients with suspected ventilator-associated pneumonia. Ann Intern Med 1995; 122:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/18\">",
"      Marquette CH, Georges H, Wallet F, et al. Diagnostic efficiency of endotracheal aspirates with quantitative bacterial cultures in intubated patients with suspected pneumonia. Comparison with the protected specimen brush. Am Rev Respir Dis 1993; 148:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/19\">",
"      el-Ebiary M, Torres A, Gonz&aacute;lez J, et al. Quantitative cultures of endotracheal aspirates for the diagnosis of ventilator-associated pneumonia. Am Rev Respir Dis 1993; 148:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/20\">",
"      Marquette CH, Copin MC, Wallet F, et al. Diagnostic tests for pneumonia in ventilated patients: prospective evaluation of diagnostic accuracy using histology as a diagnostic gold standard. Am J Respir Crit Care Med 1995; 151:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/21\">",
"      Jourdain B, Novara A, Joly-Guillou ML, et al. Role of quantitative cultures of endotracheal aspirates in the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med 1995; 152:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/22\">",
"      Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study. Am J Respir Crit Care Med 1998; 157:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/23\">",
"      Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000; 132:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/24\">",
"      Shorr AF, Sherner JH, Jackson WL, Kollef MH. Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis. Crit Care Med 2005; 33:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/25\">",
"      Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004; 32:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/26\">",
"      Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006; 355:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/27\">",
"      Berton DC, Kalil AC, Teixeira PJ. Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. Cochrane Database Syst Rev 2012; 1:CD006482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/28\">",
"      Kollef MH. Diagnosis of ventilator-associated pneumonia. N Engl J Med 2006; 355:2691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/29\">",
"      Estella A, Alvarez-Lerma F. [Should the diagnosis of ventilator associated pneumonia be improved?]. Med Intensiva 2011; 35:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/30\">",
"      Kirtland SH, Corley DE, Winterbauer RH, et al. The diagnosis of ventilator-associated pneumonia: a comparison of histologic, microbiologic, and clinical criteria. Chest 1997; 112:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/31\">",
"      Baselski VS, el-Torky M, Coalson JJ, Griffin JP. The standardization of criteria for processing and interpreting laboratory specimens in patients with suspected ventilator-associated pneumonia. Chest 1992; 102:571S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/32\">",
"      Baker AM, Bowton DL, Haponik EF. Decision making in nosocomial pneumonia. An analytic approach to the interpretation of quantitative bronchoscopic cultures. Chest 1995; 107:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/33\">",
"      Timsit JF, Misset B, Goldstein FW, et al. Reappraisal of distal diagnostic testing in the diagnosis of ICU-acquired pneumonia. Chest 1995; 108:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/34\">",
"      Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/35\">",
"      Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302:1059.",
"     </a>",
"    </li>",
"    <li>",
"     Bouadma L, Luyt CE, Tubach F, et al. The use of procalcitonin to reduce ICU patients' exposure to antibiotics: The randomized controlled PRORATA trial. Lancet [In press].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/37\">",
"      Ramirez P, Garcia MA, Ferrer M, et al. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. Eur Respir J 2008; 31:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/38\">",
"      Luyt CE, Combes A, Reynaud C, et al. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med 2008; 34:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/39\">",
"      Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009; 34:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/40\">",
"      Luyt CE, Gu&eacute;rin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005; 171:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/41\">",
"      Seligman R, Meisner M, Lisboa TC, et al. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care 2006; 10:R125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/42\">",
"      Hillas G, Vassilakopoulos T, Plantza P, et al. C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia. Eur Respir J 2010; 35:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/43\">",
"      Linssen CF, Bekers O, Drent M, Jacobs JA. C-reactive protein and procalcitonin concentrations in bronchoalveolar lavage fluid as a predictor of ventilator-associated pneumonia. Ann Clin Biochem 2008; 45:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/44\">",
"      Anand NJ, Zuick S, Klesney-Tait J, Kollef MH. Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in BAL fluid of patients with pulmonary infiltrates in the ICU. Chest 2009; 135:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/45\">",
"      Fagon JY. Biological markers and diagnosis of ventilator-associated pneumonia. Crit Care 2011; 15:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/46\">",
"      Pugin J, Auckenthaler R, Mili N, et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic \"blind\" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991; 143:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/47\">",
"      Fartoukh M, Maitre B, Honor&eacute; S, et al. Diagnosing pneumonia during mechanical ventilation: the clinical pulmonary infection score revisited. Am J Respir Crit Care Med 2003; 168:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24040/abstract/48\">",
"      Corley DE, Kirtland SH, Winterbauer RH, et al. Reproducibility of the histologic diagnosis of pneumonia among a panel of four pathologists: analysis of a gold standard. Chest 1997; 112:458.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1635 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-425BDFC11D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24040=[""].join("\n");
var outline_f23_30_24040=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2756487\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2756708\">",
"      Medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2756716\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2756692\">",
"      Ventilator performance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2756495\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H322109\">",
"      Chest imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H322290\">",
"      Respiratory sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Microscopic analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H322748\">",
"      Respiratory culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Quantitative culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Semiquantitative culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H322876\">",
"      Other diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2756663\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2756455\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1635\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1635|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/43/27312\" title=\"algorithm 1\">",
"      Diagnostic algorithm HAP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1635|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/31/26108\" title=\"table 1\">",
"      Clin pulm infect score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14727?source=related_link\">",
"      Etiology and evaluation of hemoptysis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=related_link\">",
"      Flexible bronchoscopy: Equipment, procedure, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=related_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=related_link\">",
"      Overview of inpatient management in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=related_link\">",
"      Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6695?source=related_link\">",
"      The ventilator circuit and ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_30_24041="Celiac disease Light";
var content_f23_30_24041=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1107px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Celiac disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a small bowel biopsy from a patient with celiac disease. The mucosa is flat with complete loss of the normal villous architecture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Normal small intestine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 168px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACoAgUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDph1HGfapE+mfrzTFGRjjk1Ko6buc9MjvXuMwJIgcdfr71MvX0piDg5xnv9akUc1NriHKDnjn2qRAQeeaQcEdf8mpByQaBiipAMY/n601evIqRRx1ppDHqePSnDpnqKTnH+elOXpzQFhwx0FPHXgmmCpMY4YEd8UxigYI4GMZzn+lPA9Sc0gIxzwKd060WAUc47e1GM0daKAF70o7+lJ796dj6UDEIAzQcHrSgfnQB0oGIentSdelO+tBGBQIYR68Uc5pfekNFgGHrnt7VGe2STjvUrDPao269frRYCNutRsDg469qlYY7YpjY4zSYERGD/KmHrzUrAc9MfWo34ppisV3BAAznjqep/Cos1O/PJ6CoW6mi4rHWaKT/AMIFqR7/AGgf+06wdwIzg1oNqMOkfC/Wb6cHy4rhSQOpJaID9SK8B8V+PNS1JJIrD/Q7XuFPzt+P9KMNDm5n0v8A5HTQwFXFNci07nrGr+I9M0mMNeXUalmCqgOWJ+lMTxLpUjYivUfHG1Qc14Vd2kixvLIxeRcAyF878/3f60tm9xbz+ZEGPGFzXoLDx2dzvpZRSnC6k7nvVnr+m3X+quow552udprWV1YBlO4Edq+d1ubiM7dxUtzuxz+HpXZeAdYuDqsFrfXUjQtkIAerdg3t/hU1MPG14mWJyj2cXOErpHq+4Eeo9fWl4IznimlscnGMZ/GnA5XIHWuSx4oeuWwKRiMjGaN6CQx+Ynmbc7dwzj1x6Upz746CiwBxgDP096AeeM5oB55/KjOeueaLALnHp6UmckcnrS9enHpRnt3osAmfpTs5PUZ/rTcHIzt4/nThxjNAwznqePrSg5xyfakIbB2YBxwSM0uRznOP50rALu9M/lQSckGkON1L9adgFBzS+1JjnB+tL1wBRYBD0z3pelJnHXrXL+IfGenaNObeQtNMBnZGQcH0J9auEHJ2RpSpTqy5aauzqM896buGcV5dfeP9TEDTxQ20UZHyZ+Y/j71zk/jbX5gA16sauTyigEfjXR9Wa3PSp5NiJrWy+f8Ake5M+CvDEMcDAzjjPPpRn/8AXXz3fa3qj/Z76TUb4zphVHmnYf8AgP8APPrXTXfxE1NdNiiiaBrp1Ba5ReEJP3QOhOO9N4e2zJeUV72jZnr2QKBz9a8PtfG2sXUKW9xf7I8kNJsw5+prJk8R6pC9wf7QuUQMfmMpIYevt/8AWprD2V2y1klV7yX4/wCR9BOwUbnIUe/FNDqxO1g3rg5r5zvtZn1SxhKXN1Kp+bMkhGD0zjv0qfRdXudLjWaC5lR4z9485z2p+xV7XNFkcnDmU1f0Pob8aKw/Bmup4g0ZLk7fPQ7JQOgaisXTs7M8SpB05uEt0MjGBnpx61KgC+w6HNJGvyjjpzkdqkVRgYz06n/6/wDniuRo0Y5fYjk8VKuD7D3qMKB0HNSKByc8D1pWBEq+v4U9cZxTUwwBUhgeQRT15HFAx68VIoHp+FY2oa9p1jlHvbUTjA8tpgMeuT2rVs54LuES2ssUsRP3o3DDPpxVuDWrRbhJLma0LAoZ1ijaSRgiICzMeigdSaco6YrnviBK0Hg/UmjzllVDjrhmAP6U4R5mkVSh7ScYd3Y4PxF491PUZprfQIpooCfLjdQFZsj7xY9D3AHbrWPpPifX9GuFgnmnyxby1kfem8jndknPNZOk3kVjqL21zsRZDuTaOMHP9RVjVHt2uNPhtJUZIssCrZyQc8d8/MevYeteoqUUrWPoVSpwXJGOh79oup2+rabDe2jZjkHIPVG7qR6iryKFAVQcdu9cd8M7lJdEuQjxKBcEiFCSYgQODnnkgnvWN8WPFCWduNNtLmaOUMPtJhO07SOEyOc85OO3FcHsbz5UeM8K3XdKOiX4I9GE8bNtjdJG3bdqMCR696n/AM/SvnjQmC6rA+qu1jYsyBJrdCWLkZ9eOg7d69h0jxnpGpNKonMJDHaZRww/vAjgD61dTDOO2pVfByp/Bd99Dpu44FHSl+v/AOujtXPynFcPr36ijr2zQvP/ANevHfHvjq+j1GRdFvpY7RAIyI12HeCd3OMnoParhRdR2R04ehKvJqOlt2exnrz1pDzx3/nXz4ni3xPJaHbqFwifdDCXIyTwCeuc/Wuo+Ffiq+vfEUthql5PL5ysFWUkgSjBGCfbPHFaywzim7nRUy6pCDldaep61wOlJwScU/PH9abgYrmsecMJ/I0wkYHOag1XUbPSrQ3WoTpBACF3NnknoAByTXKXnxE0a3voYAs8scsbP5sagkMDjaVPOT9e4q405S2RtToVKqvCLZ15HGaYR61X0nUbTVrJbvT5hJCxweMFSOoYdjVk+9S420Zk007MYRkEGonAycetTHvmo3B64qbCIHA96rOG3DAXZzuPOR6D/GrTcjAqBx9KLAP8YjPwO8RA97mH/wBGw184yWx2jzGAHQg8V9IeL8j4IeIsEAi4iOT/ANdYa+WNPnupUu7W/cuJAWjlJzg9SM+nFdGAimpX7/oj3MvrOnSt3b/JG9ZX0f2S5t9ygI4LRhMMxGcEnv8AlWZa+IIjfvaGNoyvzb2IxnqQao/YJ00qS4h5YOqnac4Xkjj61m3cEl7qU7In71mUEKPYV3SbSVjSVWcLOPr+Z1nh03WqGRbkFi0rbCRjC/4dq9D8NeFLmK4ivRKP3DK+wqct7fyrlrPX7eC8sNM2F7jKlnHBHHT9P1r1bTPEmmRxRwCXDBfnYjGD706qkl7uplicRVhT5Kav0Z0MDSTW4e4Qwuy5KEglOPUcVJCx2AZDKOjetebeIfHMm+S1htgFDAqzH05B4q/4T8YNf3SW1xGU3jd5h6ADrXG6Mkjy55dXjTdRx0O++XcWwAw4zjn6UiqqltoOW685zVVL63c7fMUHOMMcc1Z3AkgdRWDi1ucLTW44ckH+dKT39uM9RTe/uaKEhDwRyCTQfXBpoJAwQcUuemfzpWGDM2SFUg56kcf/AF6eAM5FM7gelOHB5PtzQFhR+B9KcPY0mM5HbrkUA5/Ac4o6gKeCMYoBz6imucFAMdeadzTsAAjPXmkd1QEuQAB6cAU4A8d6YWAbbk5PPHtSGVb+9S32J1kk+6Bya8R8e2clv4hmjlIDuglbaMD5jmu98R+JIdK1p5J8SSRjCIOp/oB+fWvMvE+t3Guak966qjkBFVc/KK66ULWZ9HlGGqU5e0a91rf/ACMS7vks0jW4uNu/KoDkBvqe31qvJdubcJH5cFwxDKjsDkDuKk1WeDdDbsqSS43LCY9wdu2SOlYku7LT3EYJyUjRo8CPHbIrd3O6riHGTinoaL61c5jRYkns8fPIjDCHvj/69PtNSmvJZxa24+zoCUlLfeYdAP8AOaZZafF9jKXAIaXkgHjHbp+dTy6VIFgTTrgoYpPMy3Rjxkmnae7EvbJKS23t+gBLqWGE3UbJcOSSi9AT2P6Vm3a3KafdnUbhljdwwC9SvdQPf+lauk6ffx393PdXYaJ1PGcknsMY4qKLTliW6eUkrJzk/wA/rRyuSBxlOK5l3W/lu+5TfUJ7m2gisU+ys5C73OfLUcfyrTbZ5W0b3I6t6+9ZGqjBWG1GEjGZJDxjuc+n/wBaktb+6e5WARmS3Gd0w6H3qJuzswo1uSdpXeyPYvhHfx2+k3scjfN5wOeueKK8803VJbDzBG2N2Ont/wDroqlCnJXbOXFZXKrVlNdT0TxpHry+IbOexe8FnFGTF9kUnbJnBDqOD688YrsNHuLj+xLefVh5NwI982/C7cdzjgCruSkW4AtgdFxzXJ+P7ib+xIFeMwh5wDlgxKhWzwO/T2rginOyPFg/bqNGyWu/Uj17xtBAnk6S6SXDZ/eyKQoA7qDgt/KsDRviHqQu9tyEnDciKVBGSP8AZKjr7c1lwK0cdrOsTu0+S4KFmVcYyvHHPP6Cq+piI/ZYZC4keQKhKhSpGCXz34yMd/wrqjSha1j1YYajGPLa/rv/AMD5Hrvhxl1CyNyhQ2pm86BY227TzlWUcDBPTv1rlPijr08LnTLUuqRostwUbBkB6L9Mc1zl5dXNrpsK2xYSLP8AbF2NtJYYC/yP51t/E2CG51KO4hyPtForyEcDb/CVP4YNRGnapqRTwqpYhSe2tvJo4i3s726himjkjgik5XePTIYj1/H05rZ8Nazc+GfEO0tO6H5ZImXCyKOT+IzkH19qv6e4v9O0428YtkD8sx2jaqkZ29lYjJPfI4rN1J08zT5iwmVnKLvTDZwQMAHsc8HNdKipXTOx1FU92Sv+p75bTR3NvHPAweKVQ6MO4PIrC8VeINA06P7Hrk8T+aObcrvJHqQOg5o8A3U114ZgEyEeQxhR9uA6jof6Z9q8x+JdhJdavqXlTq7SShlZJQ24YwVz2Yeh9K46dK83HseTQwqdaUG/h7GP4jsrKXXkh0G/kks5JA0K+UDIvqVyQcDHHrnFUr7T5LmSL7OkSXTZTax2hQpwWz9eMY/nU2i6dc6cz3VnG15YmMbDMAHXDcqoBycHt3PHcVV1HVNPuzDH5trGsZ8zzI4zvdicnA/h57Gu2Foqz0PYbcuu+mrPVPhvdLZ/2ndT7I7aG3Ek2JATIwPBC9u4/EVw2tPBdalBcZdC935gSYgtubOV3Dr9eK2/h1pz6w+q+X9oULZNGkkwCq7MeM/lmse/tWgukvoUjmeEESRsAQ6j0I6kduelFLlc20JqMalRrfT5G8bD7VqSR/aC6QRNLCGY8sAMhs+h7Hk/TFc5pckenXt5ZPAHMjB3V2Kh0z6L0B59Ov0rp5JEZILthF9pRlVI9+zbF5eMYyOSPQHkdOa5myjE9zcXUgCCYbYy7EHGTyew4x15rSK7kUvedn3PY38T2Nn4XsdWnQB7lAscMf8AE4GCvPQDHXtXB23xB1eXVgfOjiWQjFs0RMRHJyGPI6HJ9ulReL4GuNPs7G1uraO4sLJU2bsKXf52Kt06Ec5AzmsIafbBIoYBGt80ZcBAFIYDr1xyO2M85rGlRha7W5lSw1GN3a9+/bpb5dT3Hw1rlvr+n/arfKlJDHIndWHXHqPQ14p4os49L1DUYbyd55Y5SXcLhW3c9+SefpXX/DvxPNHcWWm3Lo1pLmJSDny5TyAD6Hp+NSfE7SI7e9XU45fmuz5ckBHUhcFgfTpxx9azhH2VXlfUWFi8NiJU1tJadf66nE+Hm+z6QJjN5cbbFkV9uOW5VT1XA788DrUVzLLpeqxy6c5jMreZFMnDYwO/cd/XnFGk7otVeyw8dnMN42ZyTjBIPbJxkelW9Wxc2luliUlurcFlMmDnb8pA6d+oHPOe9dNlfU7U3B2PW/CPiRNf0ZrjaY723IS4ixn5vUezYP61txCccSgSEnIKjG0eh968O8CeIr+x1pkgjAIkWGeF5QEfPp/tDOQTXujOwTKqHJb5dp6j1rz69L2b8meHjaMaU/c+F7HjvxH1yTVry5tokMlpbS/Z4VjZQ3mchnOeo6j8BXKx6XbLaLumnLMEYmYH5fQnA/A9skUviS9fUL931ArKskhBlji8v5QeGO3Hp3qtexXkivaRahdm1k2QhYEEjE7gQA2c9QMr7V2RXJBaHtez9jFRj0/pl3wf4pTwn4ja2mkaWGSRY7nJ6J6ntkE5+nFfQAIZVZCGRgCrA5BHqD6Yr5A/sO4W7E1xO6rJK0eyRSr88FiDznOeT619C/Ca+lbSrrTJpGlWyKlHYEYVv4OfQj8M4rimpzvNqyPPx1H2kPbbNfiuj/Q7gjr6+lMccVIep7UwisTxyuwwahdODip3461FIM0AU/iS7R/s/wDil4m2MLiHBzj/AJbQV8oWq3EpRNjMhyw+XoCOtfV3xNXf+z74oG0Nm4g4I/6bwV89aUss9gFnQfMv3wMEj3rbAK/P6/oj08HTdSNix4XtCkcCXBaPzGHmluiDPJq5pVvG2rXsksEcEgOMO2VbBz94dQR3960tNurJ7N7RVDXoQMXP+8KvT6mllpd4LSO3e6YBB5yDOOhIz6YHHvXfJ8q9D0LtrlXp/wAG5w2qRiKV9RIK3K7tuffp/OrfhO/ae2S2vTJulDNHIvIwvUsT78VFr092tj5d/ZJmQqTJGQHUjkEDoQQe2elaOjpbT6FEbaRo4oXWFQSCwUkmRie/PSiMle6Kqc3tLLT+l95kwazFc3fkGOSOJckSvyOO/wBOK07TUoprgNo8jHyQFJP05Ncvq8V2NQkjtmaSJmIjQcYXPGferFhNdpdppOnosUMbD7VOy/ePUnPoOgFHOr2JjWqRdp7HomjtdS3AG4yFuiE8NWuniW40jVrP7UqrAMo+G3DYT2Pt65NZEl7pFmiRQzCVkCsyhS3nOQQR+Gf61gz2815dFIYZ9z/LFGyncB24/HtUzd1qEKSxM3zxtHz0PoNWDorKcqwyCO4NL6VmaNb3FrodlBMxM0UQV8HOT6ZqZYLl8OLyRQeQvlrkD0Jrz7LufMOCTauXwM0oNV4fPX5ZjG/+2oxn8KmJCjJIwP0pCtYcpHQcjtxTgRjqMdKruxRgVHBGTz0rkda8eafot6trexS5JGWjXKp9TVRg5bFQpyl8J22cdxz1pcDNU7G+tb61W5tbiOWBgCHVgatK4YZUgipcWtybDsHnP6U7p1Hemg+1AOcHvRYQ7j/PrTScj2o4569KRuF7UhnhfxBt7iHxBcGZs723A+1c5EC7/Mqr6Y610Pje8fUPEFwzt+7jO1BWDHhZQGADHk+n0r0Ka0Vz7uhdUIKW9jP1GxkMkf2J1gCHmQL859s/nWXqtiLYxSrFK6A4bEgVVPrjHeugEpBLMBv9PSob22jvrcpcBTGD3ODnseKqWuiM6uFUk5df69TJsFSbV44tkNuZSrN+8LArnJOPXvgVvwx3b38iLbGbTerPGOUbPBz6Edq5+5ZNGu7KbakaZ+7t3lfXnr34rVbW2ZLuzt1lhMoVxMfuyoWGCMVpG219Tg51SUot66f5nV3VsJrd23llZmELPwQSOAAOD2z9Kx9N8PvaWsFtqNwXcuWnY+p6bQf85rrPDGoaanhGebUpYIb2BP3E0wyd/svc8dvXtWc2pSavGtykLXQKlbm7xjaw6DGeOMfUmm5JTsy6U3UfNayWn3/h/wAHocprcOxZJYkjQhSoD4KxqfX1NYOlo8Fyjh5pt/G1U2Ig9QP/ANVdhqNoWT/SI/mYApD3x1yfT+dVNE/09mt5ZYzLu52kYT2odPmkbTjFTUm7WM7yWYk7DnPTniiti6nn0qVoba4BQk8tEMnH50VjyRW53Ko5axV1/XkdR8Q7If2okoYyC5hEuwtgBlOMjnGOlZOrytd6ZaCWdJCtmiL5g+Xqfl688Yye/pWn8ULyFHtLGMqqW0J3cZxnHy/98r+tZ9rZr/wihu9iiO2ADxqTwrcqRjk8k5/Ssab0i2eDQd6Ub/10X3omnl+yy28hdYYEhDmJZCFzgYyuenDcfjVSVUW9gWR4XkEbOBCWweduRknI4NN0u4j1iGR7XbFJGiwvHdZxx91ifvHqeeuO3amXlxK0VvfFXC73PylcNnORkduM7hjryK1iy1ZSuXNeEK6TvfzGnWOLy0DcZ3emcnkk+x4rd8ZXJjmiEZxYQWySQIgABJHPP14PpWFqcmNMkQM+8yCNcE8ludpPXr3963PFySCK1kuXfnTo2zu244OcY/yalfEi5K1RN+Zkac8IsIBNacSTCIKH4jZhkHHdQTzz06Hiq/iC3meyt5QsqXdrywdQ53Be2OcEdPr361qRTQPosSXUZ8slFViM7WDEYIP+9+PQ1TCPbaHcBXZvNcqAei4wg2nOdvbk8Y6Vsr8xF25HV/C29lae5jYPia1MgjD8B16gE9+cZ9q47V4byw0n7ZAqLG7bWfHmbQfX39667wPFb2+qmVYggtbR2RQ2WLBe2eT3+lcrqyTwWhdBIkgcO+1fmA9QO4qYfxH8i7vnm1u0r/ib+kWCWulqBKrXMsPyO6ZZcuDIf9njofWuSmtLSPWJJNSUJOsuYImjCqAO4xwx5710/wBumOnQXlgyvIWG1SgJwM/dB5O44GOnesXUbgN43jWaYfuS/kZA4b1Hfpxn2q1u7kwbT+Z23g55TpviCBXEN00AIkYY9QAT2yT+ue1cT4gilt7NdnmRqpHmoE5K57gjkV23hlRJo/iWVmb7QLf/AFhPJBBJ/l1965R7q5Bj02NY/s9yuHZgGK/7oI/+tU0378v66FfaqfL8kSyMjXZukMYtkj8oSBgSh2gkBSOmTjdnrxiqGjWBaG5uFmVYWYiNC3Lf7X1P4fStqRLNBJaQBFjjt/MiUL/Cwwx65Kkgn696ytEu45YY5VRD9mkAKBNowDnG09BVptq5VO7ldMveOLFBcz2zEbobeBWA4xIEUHPPPv8AWoUVUEIlkjlt548eTgfKuACScAgDg5JyelWvF6xTfblEk5kklZ1umlCxsh5+cYzgg44HX8qR1awtbcxli+VjXaVAjBABkx1IPA2nkkZ6cUou0UiXdpeiMW1UR3t1BHIGCjzEY53dc59ue9eo+LfJ1XwTb6oVlkmjjWQhTlgBw5A7nn+vavPrGV4tY1ORoFDeYIsyLjC7eDzXoHnJH8NAlvcBpEKqdmeGZ8lQfocZ+tZ173i13JrNp05LdS/M8ka7tjrtrIskqMg/dxOpVs4weM4P4V1d5erdzl0IaBwyxxSHcYsK3zKcZC9AcnPPpWJflpWg0x4bcqzL5M2T5q7Tkgn/AOt9DW8Y4Ht7hEuX3efunhlQERoAOAv91uOc4OOnFavZX3N6kkpbbnHC0kg1IRq0rrOu942OBET1/wD1c17f4H1Ca78KwSSDDWQaEqg4cIMj9MD615Dp4kk1S+iaOOZhiVvnIHUDG7+Q9vU16t4SvYtK8GrdahOoiWVwip8xXJ4Qepzn/Gs8UvdSOTGvnpJbu587a/FqN9cz3TM8LXc7EAcEljnA9qt6F4dvIIJZ7i/kt0HHlxKZJS/YhQRtIAJz610mr2Jv1uo4FM0shLfvUxu5ycgdD39Kl0wwXNvGZ5QTbwEtKqhnDHA5PoCO/THApRw0VqdmJbUrrsZVzDDNInkX7NdpH5yahICZJwT06ZJwO/tzXdfDM3tzq1/btfutu9sGfZPmRWyMMvXB9frzXBeI5oo4ooGiWS4353oMkAkkbW4ODngYx9MV3vwjtnbXb26K4WO1CMT/AHmIwP8Ax0/lTrRSgzKo19XnfeyPTI45IYURH84qMEueT+NQ3N7bWu5bmeGFlQuwkkAwvr9Oao+KPEtlodvKHkEt7sBW3TBfnoxHp3/DivBpr25utZuTc+ZcTyqXmkJBI464PGO2OPauKnRc9XseZhsE60eeo7Lppue5x+JdFnLhNStA6KXZWkwQB1PP/wCuobnxHo0ECTzalbiOUbk+bJYfTGfzrwuPTr2YtJM6W+Rujtih3svY4I5yR0qWfTVgMCTaiFErfNIpVwvr9P51r9Xjvc6v7Oo81rv8D3Hxlqlpqv7PviqbT5xLEl5BGXwQM+bbk/owrwvwyiCJm4cMcspOR+Fen6NFs/Zo8YJHuuh/akZB2kbxvtTkfh/KvLPCsSyb4UZ48fN5bjGD7HvRgklzr+8/yQYeEacmo7HS2mn28Lw3TuYSzFdzHKg8dfQnA59qxtNuI7i1u4vEAgt5tzLFC2VD9tw7D2JruNPsLabRLi6uJB5UYKrt5ZWGP5nHFcbrFnJdXk8rsY47WA/apE6qvUDHOfpj1roi1K6Y5VPebi7NMzvC2li/DLdzqq2UBk8llOWG4gqeeDkfiK3dcZNIsZfs1nNOs0axbIwAI9x65+grU0BLOfRoIo848ogXOwEsMnBP8qdqsCtGEjlJiJCSepAPGBmpUVGWhpGrOSUZPY851pXt4Ij55jSbJJXl2/DsK0NAjKQfcaCBuTJJ80kn+0fQDsKm8QzR2zyNbKsaLwm/D7foccmudg1G8RAsPlxq/JaTlpPXmtNDWb5Z8zPQtP12xsY7ia2is5FCjy96t5zHGCM5xnPpjitPw5r8mnwkhmYyHIikbcI8+hPNcbBayTQrcTRvGrY+YrgtU5V4jhScY657UOKe6FDBwkm5u9z2rw7r0eqvJEAFljAJx3Fbgb16ivJfhpdrF4hMUj8yxEJnuc16yT74rgqwUZaHh5hh1h63LHayY4HAGRVXUtQttPs5Lm9lWKBB8zH9APU+1Q6tqdvpdlJdXT7UXoM8sfQe9eUeKfEs3iHbG8QitlfKqDkk+9TTpOb8isFgZ4mV9o9WaeuePri5k8vTI1SA9Hk+8fXHp+tcpq95JqJ3StsC9FXhfes55o5XkSAqbiPjaOlU9M1geRN9rjHmxMFz6df8K7owS0PfpU6GHtyL5l+1S6MjLbyuCvJ2k4rrPDfiXUdFcvL/AKRbMcyKeufXPrXOPf2dq9sUlAlchQG6hiK0NOsjeJcXFxcBBGygcZJLZwf0GafKkrM1rypVIP2qVvxPaNG1i01OyS5tZlaM9cnlT3B9OtaY5/8A1V4ReXf/AAirpNpNw0gnc74i4ZdnTII7nnmvX/CusQa5o0N3bybjgBgSNyn0NcdSCT0PnMXgnSj7WGsHsbOPekYZU+hpRmk47dKxucB4X450ySw1u5YpmN2LKayLK0vb1v3ELsvALEYUD3J4r3fXoLM6fPcXltHOsKF9pHoK8N1fVbjUZRJOQqj7kKfLGg7ACu2lNyR9fl+MniaduX4dL/8AANG/0iy03SJGe8gnv2IAjibdt/HvXPXA2WTsu08cZOAfXn/9VTxqZAWIw3T5ayNTYh5obm5tDBt/1Lfe/Ic1ulY6ak3CFpSu36L+kUbW0tzqEcAkM9ux+6WDgH0yK7qJLaSFbdbIQqkQWVWOSdvQr6DpXBeGvOFzIIY0EIGGYbgce3vXWRKJtNSHZdPibdKIV3uI8cbe/wB7Gc1VNqxwwVqbqWL0uhC5WBZpZESM/dGM4PJCg/nmp/D1yY/EV5ZDy4NHJcPDgEDAwrHjJbpz9egrW0g3NtpsCamQJxETliC3B7+hrB8O2kkOq3dxcL51qivMxX7zDJYkfpUulFzcr2/UUq8pU7SWn5enmaJRY9HurcxSfa7sFVccgJjB57f/AF64b+yodIEkkDSSTqMAbgAPb3rtrS8ttRs3udNZ2ZDznnZ1/L0//VXP6rY7tpHmKh+ZmfrI3oPxrRxTfmaQ5ZpySuzAto5b95ZZ5SWBx04HtRVfWFjtrhY5RukA5SN8Kg7D3NFYS5b6i9soe6/1Ov18vd+KPOkR44byU+W5GCgB+bn6AZzW3HqY0rXltbkE2rM0UsO75SgGOR7ZH51ka/E8PiRZbdg9uZ5VMpABYg5I657ntzjNafi6ymWaK/idmLKX2oM7yg2spOeCV2nPrWHkcys0ovZ/8Apa5E+na8LuJI0WNvIaJEI/dfw89T1B3Y+prVlt1u9MKIHVmyAsqjepHPBBwR+nNZVreC7sbdbmUqyHyWlZCf3RGQSvXj+Rx2qDS9Qjs4Ykfy3lhykUgQg4J9OvGOa0iimrJEN9cS3tlGrOVgt3yEH3i4OSB68jn6V6N42tAItMFwUMzW/ktHGDtwMdD+OMVwtqqyTwwuoVICFd2HGck5kXk5wQfWvQ9dRLvRdIu553dUYpIYgGYAjgHnqMAc+tKWk4sipO1SD9fyON8N3i2WmOXnIAnJWVMMQ2cjBxg4x0/Cm3cZl06+F6kcYjb97x5b9iPl7K2MnP8W4VDGrmWTTZYwIrhsQSfe28ggkdcAgZxUWoJIYtWhv0FxdQuPMuZWG2QLgABeuDgnJHPPU10faE21I2PCdxNZX2nT3YIjDgFSuCIz8p46Hg+1aPiO1aO/v4pkPDshLISrccfMeo/I1V8MtD/a2myzxkxSSJgDKlc8D8jgirmsS3dvrl0zKiXHUqRuUkdGP4AfXFZt/vNOxpK/tFbt+pyq+dHb2cEyOs4k+UKPkcDqoG7nAycZ6gcGjR44FluIHWE3kLlSS4LSLn7ynrxipYD9vheUx2yzI8qvGHO0ycfNkg44BGPemW8Tz+KEFpHCAkeWVeiKV5y3GTnoPatX1uCbi1I7XSAIPDOrXUK7m2+VKrt/CcDGfT5s9jx1rmdUOnJNZyQ3o+1hxsjEWdo/jV+/ToRmulsZPJ8IarE64FxIqqV7EFc5/PpXJLGf7Ymknkdre1iEhUDhVIAOSeg56isqe7YJv3nfr+iNFFb7DqquUijZlAAbDwjaQFUkfd4B6/hUOmRwlLcReW8e5VJXue+e9MtJ5F0meTzW2W67Y3QBwRgbgSWyT6cnFGhMkcFt5skkryyZw24k5PQE1payZdLsix4kuJIrXU41EjRnKEYzhfU9wMfzqjp8iys8DX0UF0FiyshJRgF2jLE9CDwevpVzxD5cixjJVJ7pUG18Egk4Gf8QelLi3a5muHtYGiaLfLK8ICsUJClgTnduHUDkgYxT+yZys9ijPPPL4ikUNcMscGDHN8odumR/CM/WurcvN4FsonYosV66l8cH5SQfwJNc1o0s1/ZxKNwlnlIAMpl7+/Kj27Yrb8Z6uy3BsrZgbHTwsSKBtXeF5YgAnrx+BpS1aii9fdXz/r7zEYlNXisbm4E1u2wq1vEQ7ndk4J/px+tXI75La3ubmSG5MhSXPnKmVG4hgGUjK7jkAAjv3rNguJb26huEtpTBESEIXcdxHULxgAdD1NLrNxP/ZsgJWa7uI0gYFASwHue2DyMcH3q+W9kKUdboq2FtGI5bx2dp7oBnH8KDsAe/19a7LxKFttE0bSYf8AWQRefOpPzLK4zhvQ8n86yvCWl25vFjn3LaWEf2m4bOdwXkAE+pwKz9e1l5Li5up4DLLcP5+VOQmTgAj04AzUtc8lboaOyav9nV+r/p/gUNMNxe6nM11PPZC2YEmP5QB1yR1HHfn861Yo7adoZrK4tpY4eFZ8gTLtOPfOCSFwCcZPaqOlwTyXMF85AuNhdIwRGRGDgtk8NjPT24rUH2aO4kaO6mldYd0eY22iMhTwWH3vxFVJ62Mm7ySuc7afabhZESzimjidibxFw5J6hj3PsDXpngae30LwNPqlxGQJJWkbaeZMHaoH+fevKNKZJ5bwPcIAHDxxLkgg5JIwePpXf6zqKweDdJ0m824lhWXzEGREqk4PHUnp7YJ5rLER5rLzKqRdSnGn0b19OpyPiLdqA1HULZxFK/8ApJzICV55XJHP0/Dmm6LZ28VlIyILi7uImkZixGAejle/JC468k1mXPlXupWxg2So8LCWO2Jwce38JOe1bdvLNb3Ai06GBSB5OSxbzFA5bOOuMDPTI5qrWViqkm9umhgarcXbXm0PM0kKoyzkh88DKnPToB7Yrd8I+Fhrsou7RoPJDKbgzOS6nJJXaeSffoc9cisOcvb6jKzIVtpDhlzgg5wGx6HtjrmvQPhVE0Oraihhx+5UeZux/F3Hv6+1ZVbxXMmVVn7OhKUPiR1euadP4a/Z38VRwzm5f7ZE8fmLjaplt12++AOteFeEL19QnkW6mKSHIyW+Vz2+lfSHj2F7j4GeJIogGdriHjOP+WsJr510fTmRi5tnt5AMEq4AJ/n+tc+Acmpu/V/kjzsK5VPfb6nSQXl1pVrqckoNxblCTA78hWxjJ9jT/tMtx4da40qWWxvpE5KfM0kePmUn37EZPNaHhGz1S71zzpfKuNM2eXM0nzFhjpz71kXk1xqes6pb6dOkAtXIhkVP9Xg46duc9q6U7y3NXKDbpta/1oR/D6/eDS7e5kS5MgkceVOuRImcYUnqPT6V1fiCZrpkSOAQwgAkBQFb6kV5nFqurWfiGG21KSK5aTEcsn8US9hxgdcnp+tdjdXi+RiMtO7/ACFTgY5/hBocbu73FTim0+qMrUrVb2ZvMSEYOQijaAfRR0xXEeIryVrn7NFFHDHEcDyxljj1bv8AQcV2GqzGKCVAu0rwWU5JUcYHt71xN9LA0rNIZJXJzgDrTkvdOmr8NrlzSo7i7gZVuWRB94KxLfn2roVPlW8ab2bbxuP9fWsrw7G3lNIq+XGeApXAPvWpLJzzjjt6VS2OmhFKKZNYTm3vbeVMh0kBBHWvf0ffErdNwDY6dRXiHhrS59W1O2jjQhFYM7HoAK9Z8U3v9naDdyrjcIyi5OOTxXLW1aSPNzdKpUp04/F/meZeP9bfVdXeOBz9ntwUQdNx7tXLwMQdrfd659KcQWlJZSD1/rVTVr6K02oR5jHG7YeVHrW8Vyo9dRhQgoLZDXeyXxAv2W4H2g5MiDkHHXB6Z9RVXxFBaB5Bp8rPNJhypXqe49Cfap7TSYzDe3llMrTzDETGMFcd8DPXtziiHQJ7WXy5WCN5gyG6rjkE9q1tdWZ53vu6a3KWraf5X2O4lDbFGWyed2OldfZXKPp8cpJV51y0eOCDWDc6DNDJPLPcNPJcASqGyMDPA/mPxq5b39usbRzPsZRhj2HbA/z2oirXOmnG0rzVkyR7J7gRpEwZV+6o5wPSvQPhPpepWuoSTsjLYbSj7jgFu2BXI6RLJa3wlESEd1foR25/rXqXh3xNBcRCK5iNoy9CclcfWsKsHq0hZjUqKg6dON0/w+R1w69uKO/0pkciyRq0bKyHkEHINP79q4D5QpaxbfatLuoCceZGVz9RXz5KmGkjOd0ZK19GXEfmRPHxyCDXgWs2rWeq3NvLuUhyQcda6cM9Wj6DI56Th6Mz5bUSRZk7dBk1z2pacTeS3JDsq4OHQKMdMbj/AFrooLuSxiYkpvLYLSYYjnIwCPpUs1099p0cGpRRTPvZi+wKWT+FTjjjrmu1pM76l6suRR26nJ2d3OoMzSyCNTxGzgqfb/Irr/Dd5LeW7SwslsQxG1nw31BHasq40y3lt3WKAqADtWLALVU0WfUdPXbDaxvDu5SYYIqk7aMyUKlJ8r1R22sajINKuo7WNJmuAsRZc5UDqQO5PH0zWBe+H7qyhtBDJM9wELzWoO2RFJOAPz/I1uRT5gEximRTjOw8oezKfr2rNmm12TUbubV53SyeFkmbaDmPgDHqcnHXvWEv3U+c0cOeDppf5t9P69BfD0Eltdo9wkcZaLFzjhWOOOnByefwrR1iIiJX5by8mLaMjJ6+2O9Zvg+4eSG7tbqOOSEgGMFuQc847jnGB+A610Fm5u7O6QoF2jYvy45z0FbtqS5o7GML0pe8mn5nl+oxRW9y7T26ylyTvll25PfGPrRXWaxp0V3cjzLdD5a7MMcAHuB6/Wio5H/SKnh3KTlG2o2C3jkmtbuS6+9yUOPkUnk5HfHYHH8666aVrrQvtthM0bpMJcKcNGB8p78cEE+v51541ilsm61bzgXaAowUmNieGH4DgH1r0TRYEm8GXcSIM4mkWUfecKFx+HUVyydkrnJUdlF+f5nG6dayXMMgnSbyUmkj8yKUh1GRtUkAjkk4z0GeMVsSaciaounW1svn/dDO+8FduDu5IDDoARg9RUPhuUHVr213YhYxyujRE+YMH5fcMeCa0JLe0fUreSITrqBZnmnZyEAkbAC8YPXufU54qru453TsR6TNHda6WS1ENtJcoixEDAC8vu5PJbP5V1OvL5Wh2ckY8o3Mr+Y2cFwDlRxzt7/WuI8H5U2fnONonkTcygBSSwGefU8n3ruvGBLWekAqEwjlE/upgDn3/SpfxpEyf7yC+f5nJ6XczzTXUrlpkjbYsSFd4B65Y8dAevFMvTCWfS7QCMTnzZlWQSLHGSdpDYznGBs5Ax2ptioaxhSK5ErzzmLcBuVUGWPyngngDPoRilt7hIrzTreC1iK+R5bK+cbf72B3z9a6OuhV7yOp0K0t/wC0bSG2md7ZAJcbCHKrzgL3PuKj8Q3SPPdTP5izbFRMAEbexJJHPINT6BDZx6vFgPdpDGztgfKXHIx3AHXnnisvxfdwTLqbsI0gkx8pUEgEDHzZz+FZRu5if8TTt+pgWJEenSxxCSSYI80sSMVZwSQc465A6d8kU5p7S1vrqRx81wAVK5I4HK568H/JqxDLMLCwMcXmyjcxnCjHB2j5s56Z65xmq81uLhEjtEja1RFbeyFUyBg4ycqcDJz7Zro6ml2mrG+LnbpcXmyJHY5yqoMjJ78ckj1//VWXaWsrQFZGaAzy4mcRks8hB2qOQOVz1zzjjPRlpawwXbtLIs3kxMz7W3gADJOc8dQQD1xW1a2Pm2Wk3JuTNeW8hjjLkqhZ8sGPAJOD1GOB61LtFaEyncyfEsc8Wnixhg8i1kkijiEZxuAUbgOcg5GOfT3rX07/AEZomiluD5IAEchBUsOgH5fpWdaQPczW3ntdTNaIS0u3IaRgPlGecADrnJz1pl3JcwXke3DJMdoQ4wARzgg54AB59RTtpyji01ZjdQhdr2yjZ42YO0oZ/wCEjpn1Gfrn0pLSBZXCXMyXEBYTXEe8sN2Tt+brzkk+/HFWA0Y1OOS5eNYorZ2cSsOmcDHvj+XrUMsBi05oTcxmSWVdxDEltzDABx0AFWuxTu5XZpHULfRdt7FFtl3jDtxznnCjqay5bW11I3EQmZ1PzvjhlJJ5JI5P1qxKlmlz9qhSaF95kVpAGaIA8KFBwNxBA5OOuOaSxikVJLm5WMPIxZwOFz6D2ApJLcuMubYqaXZmC3mhDR/a0H2WMO4QMWOVbPfOV+mMY5zUUTI2uyw3USLNCuQuTtD8En0696msr6Bmv5ivmX0xEdnGwH7ojgMSegwd3069atW9lDplgFmEXzAiSRzneO+e+OapOxC1l6Ek+qLaW8lrExaW42xtEgwZDu9egAOOaoto0kcj3Mx88hCgLrtTaCeAT15GfoPQ1Wt7bddCOJiPO3TrtIBQDOw5OcZ79/Qda1BYecsQvJ5X+Q5ROEBPXHcg5p2S2Gpu+xKJw00C6ncwfZYiDGu47mnzu3YHHHXAIz7mqKqL3TLwzXn+jQTFpJJAcM6gAGPpt4yT6VXsFure4vI4Jm2QruU+WJCQTjGD347dKgSIzTC0hnMlkpaaZOeGY52HHpnJ55z7UctnoSk+bYg0i1kNqd0SqGdlhC53MOgPPc9ffNb/AIqkWTUpVTYI7WFLcIGOF2ryoz1G7PP41d021NrCt25UvsY2sHJOQMbz6AdR6kelc94hRotOdn3ZP94nJPbn1qN5HUpcvyM/Rmii0sumHk80ttjmCOUIOSCfbJH0zWjqaS21h5qtGJUURRSmMtnIy5Xk9evXBzSaUk0UULQPEjxwbt0smEUl/mDjrngDHv060uqa69xps0aLc3KEfuyYOnpgjA5yTyvGQAaTTucqeqM+0sYp5BJEz3MkhwmH6kZAAx169K9Q8BaFcWCS39/vWeVfLjifgomcnPuT2/xry/RoriGyZXBhMYBAUkEK3Jznqfp0r3q2YvawO2/5o0OX6nIHX3rmxUmlZGOOquNJRirX3E+IMzW3wI8SyoHJW4hwF5P+ugFeG+HtWs5oFjcRvMQcI3BOa9x+IdrLd/AbxPb28gjkknhAY9MebDn9Mivl62aXTo47VGV2TIHmKAR/9asMA9J9r/ojDCX5fI9LstTurGzlgtZCm75W7n/eA7HFZ+kyQRX6R6TBdiSaYGS4+8zH0K+nNVbB5rnTjGCIpZV2gryqt2NbHhOK8sbaZ7qwSa85VZvMIzH+HAOfp0rrso3OqqkrtLVjfHVzYaJbILaJE1SePcWkX5lBOAe+Oh59jTtK1C2u/DsTS2rwX4j8s9CHX+97knvTddvLPSjZpr6RXt3cQGS38yLf5GW7n04rntOvtTldpb7SZbNJCUifBAbk5Iz1HTkcUtLJGNHV2kyTVpgkWGWMSYOOeW+vtXNuXsIluLl7a2Q9Hcbnb2XrVvxJqBt5EitUdbhSSZNoOMdgTVK3tHvooZtXDzSOzCJZB/XrWj7R3OqpNt2j0Oi064S50+OSOV7lHOfMPyr9ABS3CZcfIAemelSw2UFlp6vBNCU4Kwx8Aev4Z796NvmgGNJWB9FJH0ofmdOHlzrTU6L4e6jLYarFZ5Bt7k4IPBBxxXQ/FGcrpdpACR5smT9Bx/WsjwLo00+qpeyRMtvAMgsuMt7VY8W3cGp+IVs5g/k2q7mKEAs3Ugf57VzNJ1NDiq8jxqmvsq7/AK+44KMHzAeR/SuR1S5eTUy+dwDcA8EDuK9hj0LTLyE8tbA5KN5mSy/T19q4PxT4afTb4lXMkDAFZFXII/2v88GtrqWiNqldVlaO5FoULQ7yGzBINwB6Bv8A64/lW/dXCW3lm5dyHxsym48fX0zVDToTBaYgUTPsLBc8E9eK3o9ZtW8KSxz6cl7dJMphZUKgZXcScc8cgj161dSTjG66G0WoOEOVu/YpaNcW93fiDVFMCLG0SSFflLfw8+vPHrmuev8ARotwdAwcsdy9ycdAK1vE2swQpHqcenSNJLJDFJFGx29M4IAwcY4/CrPiOxlmt5ktjIskq5Mm37q8c/XsafMn6mVOTk5Qnq+iMrRZnnaZTLA8EbbFWM5KEdAT9BW8L6VYmiZjt6YPTHtXMafoRs1hiRnS3U7i2fvt3rcYq2VVhlew7VavbU3pXatPc6n4feJWsNU/s68lJtLg/u3J4jbt/hXq/wCFfPBRkAKk+Yp3Aj1r23wbqo1jQoJ2bMyfJJn+8K4cRC3vHmZvhkmq8Ouj9e5tn0rifHfhV9Xxd2AAvE4Kk43iu1YMCOnTpSkenT3rnjJxd0eVh8RPDzVSG54Bq2l3WmuialD5cr8pEMFmA6n0Aqu0wEZRIkiVsBmHzMfx/wAK9G+I0OnXzxb7lYb+IEID/Evof6V5o6hJMAsRjgsu0/lXfTk5K7Pr8JXeIpKbVmSJ8iMZCFBGR61yniC4Rr5I4JAz42l1k245966aaCK4typhjdwMgyDv+dYWqWDJE88txBCiDHl+SMD6E8/rW072MsRzOLSRLDd6iLG2g0i6CuHPnJOobzV+vTj04r0WG2F14dNy7lLqBgjxsNyMpHTafcV5no2qY/dpDJJyMnIxjPoO9dzZ6i1tJbwRRMUmPzyMMrHjucDpT5bq6OSylHmi3fQn0+zhcuI0CRBcrFEM7fUnnPX61cSezudK3ad57iKTckgwcnHzBh+o9qxrye10m5kjeRJDKCsioSysrejD8qS5ntdF0d4ra9jt455RLH5hJLkDkA4IHBxUXbfLHY0qpJKpJ+n6lHxLa3dzJBLZXgjUhsho93pzz+NFC+H73X40mt9ZgMMYwIV+cRE8nkevFFDhG+rMJYpX6/fYXxBBLPbYtfIjv93ki2lkCtLtOBICOpGOhI47VseB7iTTmis71I0mYOjW5HMUgxjKnnDgY96y9TW2t7nTbO3OcGSRjnqcc+hPXgnPvW94rQS6fpF3O+28RRHPIjcup+4Sf4sHH4kiuSWrsZSjeyl10/UoalaNaeJp7GBUKSKWV1cgqm5ZFYegXH5Z96pyrKuoyypcGOZw0UTu6fwuuNgbjaM9/Wlup3kvXm3AMIQpkZuRxk8npnCj2DYrSsvNF9Hbyx3EUbxq5cgSxvLkFlXPQYYjp/KrWi1HJNWvuZ0GJbvUjgB3u5JFZfXPp9efxrrfEbC8stJIGPkkkG3qqEgAfmDgelc34eWA2DNIB+8mkkYICxC7m4B6H0qTWru6Fm/2NZDKRtGP4AT0H50+W8lboWl8Mu3+RS0uKcQQYuLlR5rbZEYhtpdVwq9Tn6459Kt6Xtk1G8vPPLEMbdQUBJAGAcdx71JLE2mwpK8UgW0jPlgSbtjGMnLc527jgDueO1U4HS2s/KhYGdvVwGVj1Y9gBnPpxWq1uxRdzo7G4j0qFrucyG4kBWIZChemSTnqTxj0rC1vzb9o40mUTX0g5X+71Yj2xVBjb3sE0NsZZ7pm2xyyq3YnMhye+eB1wKNPWWG/uC85dojsSQt8y9CcDHpx+Ofamope8Ny15u5sTwtaadcviSG5eHyGKHEcQTaASATyfXk888VJc3kdtEs90jSu7Yt2XaEfCjJAGNu7gEdBjgVLYTz2Fz9kuJI44pS805HOwsARsYAAHOTjnn0qjLY/2jbzljKWhfzFYhizqxIxk8HpyRxz6Dk7XEm9xsi7pYjZo0cs+07C4kUDqSynooJIweTilijmgu7qQSS3MaJukY/vOfvADPAPy/hU/h63Eiy3GwW8bRjdGjddq5+YdTz36ccUxbkQJrSruBcxhZCMnkAZwPqe+RmqXZDRBd6v5Wr38qgNEzBmVW43459mzRZySz3DtJEFkHzyAR7PnYDAA64Cjr3qB9OhW40+OESM5kYkDnIHJ4OPr2qWNmltmaZv9Jv5ypcdWXONw54yBxz1NXp0Gvdepbtl+13ksih2hfiTorFEPHzdOWbOMZIpLwpe3MtpHLHGYUBZXG3cDweTwOpJ571StpTHe3IEUolUlEJK7YlDZ9jn/DHNN02aU3ESOfNj+dyzJ1Y4BHI6dOtHK9w5tCzqxgbUY7eLEMUkYuJy7hQSuQAMdfXGT2qWORdSulsLdwkDE+e+MZCjO0Z5+pHQGs54LO42Sf6NcysfLWOIbB5h9c9Rzyc8nvg1fVLi3Mv2WNJI5XkRXhk/dDCbVzkgKB05zjr70PRAm7DdP8kTTXMJZBt2hWbcI17jJ9T+mKnnMWp+Y0zTpYW+fOwAWZwMhR2AGRj9RWYILJIZJJZ3DxRrJhoyyySE4xt6FeOOQe9PtrtYntmZFJjXlNm6R3wRuY9+OmemRTtfVBfoadri1AOYvtUwLIu0EFsEhR9B+uTRZXDSNNLNIWhUlRMOFZgAW+g3evOOaoO7S3zSSxGSXy8KkX/LPIztYkY9z1zjFS6ekcySYkmW2dXmlt0wsbMGUE4HRe5APGPpRYfNqPmuMu93Yli7KIY2Tg/KwJOO+eQAOtU9MeSCC4lvcQRs+8kgIW65+XnHp+FbMS+fJ9rQyANnyg2AAp6MAAMcAfhWPfTvIryGCKSL7kEkn3V/vMR/EeRgdcHIpjTa1NGG/F8HwXEaqFORnYoztGfTgVjTGfVNXhhEks9pbuoIQE+Y5OQpH8+fWrdr9gvZXF1cNbpFEokkUlBcEE5GOwHqSc8VO8DRQXe6N5pY4A8NvEN+xi33hsPAwoyeef0ltIUql9CtqkZvEnhWdTcOfOEWxRwBt5YDaxxnnnpjtUFjdw7Y471zbyjhgwGDjjuefpWg9qZ0likuGWR0DSXCSER3D7sbOcckZ6Z9RSXV3bPYH7XCYIRAXa2kwx3ZGNrfhjHvUpu1hxkov3TX0W00S71aOO7vZOXCpEIdiO3pnJxzx712uqX8WmbLy+v0FuGYJBbRA+Y3cZyTx+AFeI6TGyTNLbRTRwSEFEUn5efrhasPq11HBLaSQl4Y3MzhSAEIHUDtx+YrnqUXNptkVaMa0k5N2/rb/hj2i1vX1H4H+Lbh5WlV9TXZv4Krut8L6DHtXgPiaxFxco0U53AcRGXaDz1U9M17P4alKfs6+KpL5hGv9pIcls4GbbGfT6V4xrf2yYwz6PHbXduoJkgPzFsdh+HpzWOG932n+L9EReCjL1/yNrwzZzDTLiZjIHiYYjc/Nt67sjg4rVt73Wkv7iBcPbyRNIQ+DuQDjA9f61maLautobmKTbbyxB/KlOxlB7A+oqTVd/75XcqJohKSSCcKvIB9Mfyrpe5ooqS1dy5rGqaXfWkD6rbCaSBCqtISCo9QR79VNQajqa6rBE1pN+5ih2o+Mk8ck+/QfhXK6VaQ6hZpHDPKtv5od0kJDZGSCD16H9a62WzisIYo4Y/Kh8sIADu6DtTaSsKjFKV7HD2kUct95k/mzsCCAv8AUmumjmYPvGx2U5UtyQenBrntVe4tZ5RsMSsTgSHr7/59abo115e97i7JQL8yldqr75q2zSm4wfLI3II1hIPPy9M8gY6DHpWrFrWqhh5N66KOdqIFX8ulZemXltfwNJbyGVFO0nBAz171ZZ+QEGT61LSkdcXCSskmvkekeC9eur/TryO9IkubYbt2MbhjjNeb3Msksr3DE+azF92ec5P+fwrsPhkc6pfqTgPEOnbkCvMNVlbX9RutP0t9mkwyss92jbvNGfuIehHqen4Y3crmqcmktXsjkhyUK9SEVvay+X5HT/bXZD55cjjgMV5GehqW98SJp2lQxXziZGcbIV5ATHJ9c8/0rE1D7TaWNtDpUamOIbChOSFAwMZ+nXNcyLiZ5j9pR2YnHzjIH+FdNu5NWEY7bnoOnTQNMtxasz7dsik8BkOec+n/AOqq/wDwkVpfQOmms8kkSFk3LgbvT175qj4VuJYbGZZD5dtvy2TlR6+341urcaXpqJGqwRtMcq8a4U5HXIq2tSuaTs2clpU95pMr392hcs25reVuWJ+bJA7cfrXZR3kU+myXFwFt1lVWWA5ySTwB7dz60ljbWMOoXMt+9o8k0eIUkwzD1YA/zrP8daLqd1FshZFdJY3g2EASqB3P5H86y95Su9hqpGMOWK1X4mHq95Nb3zASlnIG2MLwnt/n1qxotyhkWCRJfNYbix5x7E1X1q6uBdtsgjEi8GRV3Fx3bPYdffrT4roxWyw2kBe4c58w8KP92urWwRmlM1p1KN8vTrjPSus+FWtJa6lcaXdEr9oO6Inpu54/GuQ0+O6+zM13tZs8difrTvLJlWRAY5VOUYHBBrCpDmVjsnTjiKTpS0v+DPoXHHNMmdYYmd87VGTjk/kKw/A2rXGraJ5l6Q08TeWzgcP7/WtPWWuEsm+xqWnPCgdq81xcZcrPkalKVOo6ct0eW/EWJG1eOZc7JBg89/f/AD3rl9rouA25B2YbsV2vjzTriHT7Wa4meWTJZyUA2k9cY7Vx0rx/cjyzdSRyBXoUbcp9dgZuWHjbpp9xDEMOBjv6U27iWSLbKFKkZwwyrH3qZY2clVIB+9zn+dZespfEyJFLDFBgEvvIYfj0xWz0RrUlYyomXTNScQzCAZ/ihByO2CO1dtou2+txLCDcbMb1iPP1x1rzKYE7Fe9+1DJPc7fxrvfCRSLTjCt0JInPEjKQycdM9aINtNHnxk22o/1+Jf1LRdS1m5IstOhlaCJdscTBSVJ4zzz+dWrLRL06WYtesFhQLIsImh+Uvj5c545P51v2Fhew6R9uimNlIqNsnjcZf/ZIPGOO9czd+NdWg0u8sbqTz5pBvE7Kp2gkcY6e/tXNN8spSX9f8EuMqtePsqdmk7dbr80cumm6hpO/yo2t/NYnagJyB0yfxortbPUXttIsLo2k12txHt3QzFcMvUH35FFKVOcneMml6/8ABKjiY01yezTt1sjBurIw3FpqDskkcsP+sR2bYxI3ZGTxnjjpRrGsGfSU02080mNGV3jUDbk7uSeQc9B6c4otZ54y9zBp+2CVWNuyMoKngBiMc9BjPPXOaLQpBcNYajCiThB5e04DjAy446g1Ohxr3lysXSYI7u2iju1knt7mFpXcM2JJNyhhgY7Lz0xznrW6t0LjVLIC83zeav7xoBGqISCuQ2BhSuMjuOlcrp0ksLTz7mjtJW+Q+YeASqkgdBzjB77hxWjdi6e/LWzsJ2QxOWJ/cupzuB9SrdB65p8t9BSj1NL+xZY4Z4YruMQ+aTCknysH5OxgOVOR0z0x61DePHc6Q7LvjmmXgA44PH1BJqtY3t+nnQTzyTXMbC4jkdC29V69OSMHJ69OhpdQaCOeR4gkrbmQNApjWQnACrg4GAeQCMfrWkb31FFtbsj1TVQtrFawW0MJjIyxJZm2k7Sx7+v41BG8vlSNcgrdTqMIw3CQNwu4546E4AxxV86WY7aNtoEzDK/KSpweRgc47celWYknutVuXuXExh/dxsgwoz6ZHbgc81at0C1nYglkFrAkNu6B5H5JPcfeb3PQD3Iq3pAhRYrWSBE8qQIY1z5hBJ+dvbkg/n6Cqd3a7L5Jh5UbJbvKc4O4gjgjv0FTWmlR31kJhEwQ7ZJZQx4yeN3t2qmlbUp6szr63kl1L7CHaOIrkBByeSeT0z3JHerMkj2RWCaWYxBWeBgxC7c8xkKMnj09cVJpim3uFZ12RFjDMiDJRskhiOwOcjH0xWrf20UltIZmZdgLBsYYHGQQR3FU3tcFFvQXwmiQ6bcPMqb545MHodxPJ+vBwKozwSHUhHI4RXeMyxxKN2B0yPqO/bmkgkkSx8yOSKKN5FLbkYCN2zwo5O1hyPoeRiqtrbm6kuxIkE8UuWhuJF27iOpyfu7cfNkd8cg1OzbHolctX2yS/Vbbc5jTaAhBBZsgj8M1BpsZWRI3ldLjO6P92WVUUbipyMbj69RkECk0+W1unnsIrpo4JYSn7lSJHVAdrISByO/TOe9WtN0+5axsHhJliucSRJGVcK+CPmLH5SuM8Zz0HrRzaWYpNEdtB9suLezd3Zj++lbG49OhJ6E9fxqSNDb3k7W26Jzsgj/u4bOfr16euKTTpvs97cIYZZ5BNsACbQr+hPp9etEUMsV1HeSBJLjzSnldH3YyygHGSoxx26jrVplSQzVbCO102NCAXiYMJCcEncOp+tN1CWZ5p4rmNShILoOULDGOvbp1rXkuJtWthYrDLI0TbVkK7BEpO7JPr/gKrNC073CvJFO74NtCPla4TAAwSMEZ4+oJzQpfzDatoY2pMki2TMFHl5Q4A/eH5SWPc85HtmltoJvtKtsikmu90cZJw0Q4ySv0/wD1GtC4iIiR0YxCfKxJ8rKOQV3EZ6gY9evYZqfQlj01i1zb+UAxjQs4YMqnB3EE89MjqOBRz6WQkuxYuIhpNlvYGL5C+VUhmY5AOPc1lC0n/s5wSySlAjENjduIYoUHTOMhhgEZ/GfxFfPqGsCYOdnLt5p2hiAVzz2x8qn16ViKoupIgYBsDBvLiQ4b5doHc4x1PHT6U4p2uxPXcuWpa7hEM8wQTAqLfJQoQQNzjHTGec1qi1Fpbm4kYPcBd7MCMnHdfT0HeorYJY2z3F3GI5GJVjkZAH3VAHGO+PeqxM1zqAE8MjRod6xbhhQRwWPdu/HSnqykrbjtOvks47h7y0l3XYCogAIidgSoOe5UZJxgVoaTNHYGMSXqTRHHlrG6MHkPLIAPunHYHBz2Nc+I7izvdnmnAG+Up8i7QDjcR94dufWrFmscsc9xPAkVoZWk8jHyRjHU9icdOw+uaiUbkqN9x2ovYyWTGytXa5X975Qk+XJLbl2q3UZJ46Fu/Sm71a5OnhFSKJVfaWzlyBwp44HpUWoTWz2/2aCNFiB3oxJXPGfkAGScd+BxUDWdxegTPEcSgOHlVVCHnHQZPHQnFNKwbPQ0bq4SOM8NJLx+7jGW/So7ewY+ZJqD+U8hLyRlsDaBkKT3HqPaq0MKWMcnmSwwkhwwiyTJu7kZ69e1UZZJGut8cxJQDfLMApGM8L39ePc9qlopvqz1aaGK4/Zu8XCFkljm1CJgc7Af3lt3+o4/CvnTTLmW2lNta3E0LB8lGXOT+NfRFpIw/Zu8WlLdjt1GMKqrgMN9tyB2H/168FGpGC4ilYBFztzIufLJ4BPoPeuDDpKVR/3v0RypLmb8zvbCHfbWyS3ELM2FZ0zjPfcDyKz9VPn+I4bdCS8q+UoHGcrgdPrV/TZjvjMyKrodxdeuR6+tYfiFbi88S3kGmkm9jGI9vcleP8K6G9Ts1jdeT/r7ie+0fVdCvpLHRtq2SCItcFlODjkluT1zx05rUm1SW71R4oY5xBCqo0+B8rBRnHH6e9cbpcWtaHHKdUWeNrsbFSY8k7sZ/A/zruLq8itobDSTBN9rlzJJKi5Dt0575wP85oUm1exzUUkovucjZ6RPo8F5JqF7DdRzE+UkrbsDOQ59GPoPf2rNuNVEts+nN9mktZmDOqIFG7tg4zx65rd8Si0hdmvpWWRf+WQG4/THQfnVLw3N9vvRbabogKjrKTll9zxgVWkUolOMY2h0+809CtTa2QiaBYEQnaqvuJ9znvRql5Hp9jc3kwO2Nchc43HoB36nA/GujTR5IgSZYRJjGBk/rXH+MtB1TVbq0s1VIbRP3kk7sG3NnGAOuQMnsDmorVHGm/Zq76HT7aMY2pavocVoXiK9W5axvdUuLXSdQmVNQaFRu8pnBkwQpI4ycDryMHJB9Wv7OxsL6e20hY105Npt/KbcpQqCCG53A5znJznOa1vg94G0iya5vp7VLy7hdVimnXdsYYYlF6KcgEH7w9aXxwFPii8xjO1Mkeu0frXDgKNSlN+0d2cuBco4icJ72/yOet2Eu5H+U9vmGDzWBrdpdaVqCzZFxGx34I5Q+gPb6V0kcYEgbd83Y96zb+5kknFvF5FynImh3DzQe3+R+Nera51VVZavQv6K8OpaacLlMfveMMoPXIHasq40nWFviktugtIphthkbYNmcAKT7c5HXNaug6WvmP8AYZW5BzEVCkk+/StDVtFvdX0YRB5J57IAgcgqncD3B/z3pt8rMqjbim3sYl3ZRT+Jy8JYR2ZX90q9SBjap6bff/GuqtJxLZqLadLlID++UHhCegyexzWY91Bob2trNby3VxLAnnSYBCE8ED1OapaZc+R4q1DRYLURaWxV5Jf4mKjhic9OegpMSlGL93Zj9Vik8hZIoYzkkbzxj/d9awopTZPJdZjMmQC7NkD2xXdXMkqNvaPe0fyKzDIUDkACuA1h1mvHdYSwDfdbgZPfGBitIu6NarfxG5pOpm/kkCq+O7suBn6VbJ5I+Y474pulRTLYx72iL5+5EMBfpViZSH6npkgUrHVSlomzvfhPcKIdQszjzFkEoP8AeU8fpXe3EsNvbyz3UqRQRoXkkkYKqKBkkk8AYGc183654vu/B6291pToL6VwoDrlWRSCwYeh4XGQfmyCMV03h/Wbv41X0lpdp/ZfhnTfLlvLKKcvJeyMWKKzhVxGNmSBzkdzgp4+KqxjVcI6yPBzOCWIck97HR6PrWoeNtZk1K2jFv4GslkQGaEGTVHwQWXIyiKRweDkYPUhOQu5xcTO6xmGGRiVhj4UL2HvXt5tYo7VbO3WKCBYvKSONQAi4wAq9AAO1eD+JZ9S8J3zWUtsnmfM8cpO4OueCP8ACtcNNUk3NnZk8k+aK36ItG26so2+mT1Ncz4gN/HcoYpXELL8wKpt/HNEPim7DB5YYj1yF4qS8120vos3Np+9XOFB6+2e31rsjiacup606NSUdTCht7drouJrl5RhiIVUqD9K7GwfECFGIyCMsuD+Nc/DNJeQBY4U0+JWx+7Ybm+pAyatHVpLWRYTa3c0S8F2Ay3uOK6IuNtDlgvZatbno9pfWMWk/wBm6mBh4TJDKucjB5U471z/AIgg0ifR7q4tblZv3yrkAb3G04b257VVa4jvNMAZwroQyEjDAH1pFd9Lt7C6sokOfMaR1hV1BwQFK9Oe5PSspU73QlH2Mvaxb31Xfrp6lbQ/Feo6DpqW32QyQsxaNmbZn17c0VveOtRS2OmLZvHDvt/MYx7WRs4+77A5FFcbhK/xfgjrpUKWJj7Z07X82v0MKOXZLLPIGiRSZIj5WXkOBkvnvjj6e4qsLQaxDCsUk9rtRvLaVSzIG+by0OeVIDc9cnrxVZVaLUN17KVKQPMCuVCYBx0GABxzya1LW+uZIVa4uzJC5GEOdx+b5RuxnB5HPXtWrR5S1diG0igayeOeCSd4WUrDJIAqlWGAjDls8EjgDb3NWobmG7lgd4VtblmZTErZVe5UY78d6ZPNaWVyTIkaGe3V1IJfI9QfUHjpSS6XcafFaz3dsIY7lWmjl2hvLdTu8tk755PGetNWWo213LeqwmAxTeW5hRT5sY5IDAA7T+AqrPcxyrBNB5UYjlTckZcoeApI3dTjAzntVo3twvy3EBMhxtkQ70bIyGI6j+ntRY6fPdaWfJnO15gpiQEiHcfmZvcYwB/tZq721ZMn1NDV2lexxgBEUhM4IA3ZIwPX+tN8PssNzLLfIYoxIryI42nB6kAnpVAWF7Nc3VvIk8jwxKNsmFVScgfXjkZIHc1INNvLhIElW3IXIZvPAXaByoGGByemMYzmndJWFe5f1JYrjVkWIrHFOXQk4K4PIyOyjqTxVjTtVm0nT/s1xaXSGRFWT9zuDZB6Efw4/PiqGn6NPH5VyWlSRWLBYdvOWyyYx8uMAbue9bENnDdz/bZkupYyN3l3BbYxVsD92MDI2/8A1uaTkrW6DeuljAdftMtw8IIQ7AGYZCjcoLEggDggjPJAyKvPpTpK0ohllQsT5WQ0qggYBYttIyOo5J46VtwpHEfPKhHmbC7F49uAMDj16CrNlG6kRLvZWblyOi9h7nP8qcqjK5bamVZ2d0wxeT5nK/LDbqWRCw5chuM9emABwOKll0o3cskmoREyFNhmEqoSSMHChcHg/TgcVqWl4lu0gkl824UYZ2gaMAZ4GefXrnvUUscksTCC2eVQRlRlup55PRcdvbioTYKOl7aGdcRzS3U6iZ47TBKrtUq6j+HIAbjbx65IqW2sYbZI2t55LXftXcY1YMcYDcjryc7cZzng81vR2EksqLE4QjBxJDghSOcc/wCe9Vb7Rp0SMTyHMh8sKpwQ2eoJOcdyOT+VJSi9Lk80L2MmRJjEu6NEIfzlVRtDsOkoIB2k5AAPI75q09xYHQ7mCazcPIrNK8GSFw3Rdv8AESST6/pWwuk3KxKkkkcx2bcDkHse54/Wq8ekPC5LzmKOPGG8wnp0GCffv1NHNF9RpwfU519KtUvpZVt7y8uHzFLK105JznAz7Y6npwKvvBaW5DrbSD7OAiszeYe+cDvyefWnaWvm6jcK7sgnLII927y5VOSvHqO1SnMsgMDSTRbcs1uVZUOe5PTPp6dqt6aF+6noYFvpVlGbjzld4N3nn5wojmxtD5QD8skZOeM1dtFjaJ7iCdYCI5I2EsRZcjjJYEgsORuAyfbBrVijjVY0Nskby5VlRMJux0J649+nGKS8tYZYyXY+UELlUHKsO6t6j+tHMtgcYswLtLe5lmuriCOBYWSJHRTJujJyjADA+7uLZyR1OSaykWAShrIXFveRLtwse4TEndsDDkNjjnjgjJwa62KF7PYllHK0rOC2SAD3ZmyPT8zVC6sRA7XseBPLKYmZfkd13Dac84P6H2qoy6JhqupiXFpcERm4uYfLACtHKcrHJ157EDI6E56VqXH2XTNJj2MJ7iY7xvYcgn731OMnPQU99J067s0/0LbE0rOWt1IbDEn5mPzYBOevtg4FU7vTbmDS57iZIjLC5XbHLneuQCQMZBwAQcnqw4ziq572TE21qznJGeZZ4j5Q81t0s+9svg5HB6DHQdalsrH7W2EcsYvkMsnKsvUFF7++Txir72cf2Z4pb2N7y6Y7BGQAFB/1ZBxtfkcdfp0qX+3Le1keyWDbLvERSZgm7Hp3Az/jV83YE1uVrs2+mZEMRluivyM5yDznk/wj9Kr3Ul0iPM8qsC4Ecayj5iDhs4ycDn+tSwWE184kuFDRHKSu3G9hxsI6Bcj6VPf2kNojQwRRTTyfKpX36sWIz+JpXKMe2USBp7uCbep2oIAcHrnOPpnr3/Cra3NnvI8iRSCFZjFgrjpnvn6881X08yDzrWGYJAGDSurBS2M8qewGT+fatGO1tApMpTbGMAcHHc5JPXnP45pNij3PSNKLXX7PXihbUhJBqCAFuoO63Jz71883ml3iXPyzGcnqhbLH8+v/ANevo/wdDb33wK8SQ2m3Y2ornyzxuH2c8fkK8V8TaLlC0sTOEyC4GGT0IPcVwYdXdRf3v0RjFqTkutxdK1b7JBaveq0bs3lfMuMNgdR6c1b8Lxo/jXU5ZiS28vnOCmOev0A/LiuQDag0EmmKj3ZlX9xJINxQ+x9Pr0ru/D1pYR2GpNeNIZhAIldRnBYEbj+WPxrbmUro1nGTjzNf1sO8Rrb6xNo1yk5aOyYNIeoODkgevzcVn6xr2fEH2CBZhcXCCTzY+kYIPHt07VXtrC48P2GnWUp8xppi5bGCy/481c1lJIfMkgVUIUKbluC2Rnaox0BJq1G9rCgkkrb9TlrgwR3m+4KTNn+MttJ+nU112iXmIwA0UUbgghIioA+nU/WuT0mwnkvBMbtsI24hYxg+1dU82MDOSe+OTWl9DSFPnvdGoZlXIMyeYDv3o2QfTA/nSXl2psssEJXIBixknjk/41ki2lnV3iiLBThiq+tXLHTp7yeKzCBGmYLywHHepbSKjhYRfNKWx6d4OtVsPDNtn/lopmkJ755z+WK8t1S6a91G7ujn95IW+gz/AIV6b4q1GLTNClgjYeb5YhRc8rkYH6V5eqDGGO1ugOaxoRu3I58uTfPXl9p/8H/ISEIW5DZ6g46VkatDaRX8Nxc2rSwn708HDKecZ7H8a2JCYAWLKFOPvHANc1rF5buTGBdWUxPL9UkH0z0rq0Oms042ZpxLqF/q1pfaLqayQxhFuLebJXYDy230x175HWu1g1iSLWzHpsLIsxOwo+RG3oR9RXn/AIYsr2PUI5LYrNHnBkhbJGe/sTXV2a6fpOqXa3U0w1K/kGxiMCNgepOeDn+VRPlWr6nMqV1prfoc691r76xYtb2rKTcGO5VlzuyRnOei4yPbH0rY1p9Y0fUdN/sqwS60yVgJiYty9R8ue3B60viCJ7XXFml1FIYkZUlV1J69ACPvZrW0/VLW+vprW0jl2wAhlB+VsH7yj3ocdLoLyd1d62MPWfKuNWspFe5MsCuwjSX5Dk8HZjJ/PtWHqtyLO0cyYjuGwUWXoOcZ29/xrtlJikd12b4xlXY9c+/9K4PWrbbcvLkTSu2f3h2qv1rSO1kbSjZNpD/CyXd20jT3cpjXAKgdPYHoPpXUzLtXahB9eP61W8L6DczeXNPOXDDcI4ThSPp/WurnsbR0ZVhLMAfmjk3Dj+E/nScuXQcK8aaSZ4VqVjqPizWZrqzh22K/u4ppflQoM4IOMnJB7HGcGvoL4TfDXS/DFtb6wtxdXWqTw8yFzHGqnOVCKcEfdzuLcqCNprkZUO90UAFSV6V654GuRceFrFsglFKH8DXmTwUKf72Wsm9/+AcOYUFCkqid23qSajNNb6mZVEphVFH3R5YBY5OfWuJ+K2iLqE1jqBSRohEY2ZBkKc5GfzNensMghgCPQ15X431FV1gw6eWU2/DlmJG7rgL0A9a0pJTaTWxlljn7dSprb8jz2TR7QvsWUo5/vVTuNBmi3Yli3dMH19K1LlvtXiOC4v7dEtMBXWEEDGOSD1z3rq7SK21fTkjtLrybmE4a3mC8j+8Djnt1rdQpz3Vj6SvXnRSlJafgjxjULDV7e/Zj5oQn5dvI/A/5610uiG5eALczEH+HzDjn25ruI/COopK6XEP+jlW2gNkk9cccfjXl2tw28GuvBtZgrYYFcDHtj/CrpQjT1i7/ADPMjVjGTnB3+Z2baespeeMSJdRwEfM3U5HT1+lX/Dun32sW99aLvD7d0mG4VueTn2zVrRIwiQKsjzKU8tHY52dxz6fhXD2+uXUM2oPGAjfaGAcZwFHOCR3OP8K1nq+U3nWUE+j+/UvXlnqM0ixS2ssy248pC6klQCTj8yaK7K61DS44bJvt9xCZLaN2jEZYhiPmySDzmislQvqaLMVba33nKi0mvdSi82dLKIr87lgxdQQSPQnofTjHrXT6Bp9vPGbtTLeyWYz+9YtuJ6D6ccnnOAKkttIDzZjgmcQ/LtKmQzZ65JHH4Dt1rbs9PvothaEhepjRTtwOmQf5VzzkjzZyjFPXUhh1C3t7iK3uxEs0qHyXEeSnTGSACQOB7E+lTah4jaDTIlSzM5yd00ihVVs/eBz15z1FRXNhqv2l7mOJmm2BYGPylB3BIBzknPNYd7qF1DKBqVvLG/Me2Il4nYYwwH8Lex4pJRkyYQhNp2v8xlrZvayNO8ix3D/u2lngRnGem1gMMMd+mOKvR2cg3G3+1TyOGAlPzmNgMHB7HPYZP5VG88i2CXR1Z0bByZwcBAeMqOwq9amb7J9ms7tIrgL54dbbKyDqc4xnPtjrxWu2pq5WV7E9tY3JsozJHNKvXbJ95vwPXpmrBs2jAd4Igu3JMgC7R7ZPHX61Wt7653WtvFA96zK0nnvhSRy20kfKmRgDr055qxaW8s+oW5lumeKMZMDxgtL2IIHHXnI698VOvUhya3LGiW0d0iqzu4YthXTyse4Azke9ZN3qpk2R6dp9xOjyLED5mDg5ywycqB6+9dXc206xyw29rN5jIDtibBIPBXJwAB1xkdO1ctqN/aeH7uS18uWC5lcBrry9yjPBAJ4BzjkjvmlGSbHSqczfX+tzUlSVTZzQ+bNPEDuie4ZVKcZPozAnqePSs86zY/8ACQTx22r2pmRt4iV/mVQMMnp7+orI8SafY2x/0S9ub3UHQJvlvAJPuk5Cn5WHqM5B6CuEubO9kglneMOc48xlDkMe/rnge9KUuXo/uOuhhvbRck16Pqe03uoNJG0mnFmhRjgomSmF5UnkZB7Hrn2rQa0kgsLOWa1lk3/feKNztPXp1GemcY4+leZ+C9YlluYLaWXyjE/mlgWBLZ+8GzwAeoORXvlnMtxaQTR52ugYbjzyO9ROaUU4HHjIzwjUWjn7Oy1WeK3NxELcPnfHvwYz0xxySR/OtGLQbZLzzUx5ZBGwjPXryT3/AArGuPFh07UPL1CEyWZYR/aokIVXPRSM8Z7E+lWdD8Zafq1n5yxXVswOCkiZI9MEcYPrUS572X4HNUjibcyjp5eZjXktrqGqy3GkQzxmwPk3DxqyhOSu0r/EeMdOMZzzVM3mqQhjfaeIk3tEcgncA2FBBHJJwM8c9K0NZ8RWuk6t9vguZI45U2mHZw755cgDt0z7msPVtdlughuCGW4LCR92VRFAJIX+8OAO5BPfFdFOMrbaHXC+l1p+Jp2UJtJvt2oTol3vXcjyBY0baTh2JGT1Iz6elVbfW9OEUrS3Nu0j3LEJBOFd+w4zhjjGR9PUVyukrbS2slzFZSvGUk/dTq4kfODtAORz8vJBP4VNp+ibL+e7uotyQjzYY3Unecn5uT7Yyc5xkYFOUZHRCnSablL+ux2cUQRNiXUu8MzDzYRgknkHjr7+1MjnkMeLmKC4UNtVwwR14z1Hbtn6daxotSlmvYAyIA2doyMovYk55B49+fTpHfvd312He03WlrKPutsZn6H8s4545quV7MlUtUmanmW0129os1yZ0XlljGxMHBwSBk9/pSx2oAP2cBnjcDDAAso4259z/nmmxJHDaiS6neRZcIo8orEo5wMjOGPXOcHp0xSy29myRw295FHFDmF1QBhwPU88Ck3Yi/QoWdrLearKlx9oWzlYSRMJGXZzghsHBAx06c57mqOpwf2fqv33i34WOVI1aKUnu3cD0wa1byH7LaMFxP5yr+9gXJIwcDI7bTxmmS7VVbJLoxTON0Tyx+cuQBnIPTj6Von1RMW1r0MrUUsHmigvY9hG2RLjzFQPtPGSeTz3PHasyWwgs455jp5eQGVzdWx2lWxn50J6feHX69cV0dzbpcR2kjeReKUMD7Ygm47gc5IyBkZxUUaLAiiyEIABJRs4wc4U9uv9cU76FLXWxwdt9ojlVnuSFm2liRsKqeQCSOp456cdKe9lcXVxcwWjCeYxbnyxTy8OfmBPzMeRxjjrirb6VDJc3NxHDcz3sspEjtKVWILwShOeATxuAPBA9nafM/26+hlubeKATEsrygjftycDuMdxV36MF72hRfTzAEnuwxC7V3RuGI+oIwRzz0rQSC1sZUlvHe8YDesKJt3k4A2jkAAd+fwpmoPJPc/Zbb50jYiR0AKNx90N689e3vVK2lRroy3TP52zyl3pyVHoR3x+eaLXCx7N4bvJYPgP4jnlt0V479UKBhzloBnIGAee1eK63rgu43hK3NtJkMDIucY7YznFeqzyiX9mfxULcNhL6JV2Ng/6y2PB/GvI/DQ1AL/pTmS37rMuSOnQmuHDaSqf4v0RjBc0pW7m94YtYpdAhke6SW983KxJ96ROOBx1Bz+FJL5NtcTeZBGgbcJBkgEZzzitvw8rJKb1vkgAaJWAwdxX/IrKu47cKf7Qn27slVgG4ydetap6s3hK143LEt7ZeJLmzuLFUjWAeW6sOFbBOfpxVTVJIhaRtLaoyKmcfeYj2Hqas+DZbO4hMdjHYxvHNuFuiFCxIOM5+vc9qju1kYyQErGpJHynIxn+E9xVxdnYiilbl7HN2+s3d8VgtrVIbUZG0jAz2/GtOKeF4AH2qynBGetY2oaDbIRJeavHGB0OCDin6ZcWe9ks2lnYHJkcZz9K0NIK7s2axZmHyOygnpu4qfTpxZXtrc7SHjlV9x9M801VDxgsrZ9BSEbuMfL0HUiho7FK/uvY674gW6x6hFexgmG5iVsg8F149ePlb9KytO0uOdi9xIBGQNvl4LfU10emv/aXw8nSRBLJBG6Lu6jHI+lcRaXclsU8luoHy9s1lTbaceqPNw8ans5UovWLsbGt+CrHVIIt124dclMgAZ9PavONU0I6bNHCNSRULcJK3PH+zXTX3jOa3mns/Na1kbH7zyySvP8ACT2qhc6MmtlXN7DM6ZKsD0B6hs85z3rSMW9xJTV+fUq6Cl/ZX4aIh4ncAtEe3rkV0d3oF3qYbVrdoj9lAU5c5zyQfcc+tL4a0n7HG6zsXkVdwMLYZsduR+NSadfarNra6dayOLKZsyxFAQfc/oKK1tEdlHnUW4WVt79iz4VtBq1lLHrTmJAwczSgBhgcDrzyT7YrP8TXBsJJ7HQLRDLcOyi4jySxxyyn6ccetX/GJVkt7CwjcrbuYHOP9WMD5m9TnP4CuN8Lalq17qbp5Hl29u37u55AXB28HOMn2o5tU+5yRV3Zu19v69DsFaZLFFu18y8AUfOQo4+9k9sDn8K4WVYp9ae302JrnL4Xz5B8xz/dHJ/Wu6122efSpzLOiFm8tmXsABk49/XpXnUDQWrTx2s8cU7cLOGJdMnqMdPw5q+bqaS0Xkd1pgvoUCOwhkT5NsWQFHXGK0mv7lh99FbPOzgn+mawr2CW8trdZL68lEcYUFm+Z+OrVasoZ1t47W3WWXav3idxP41T7s6IUudLmiTzllB3ZBxjnrXsHhSyGn+H7aLq7L5jfU815LZaRql1MsRtZdw6buMAH37V7bahUt4kBB2oBwc9BXJiZXSODNqi5I04td9B6/cGQQe4NeMa/G8XiDU0YfN55OfryK9pboc814/42uYLjxJcyQI67QI5GAyGI74/z0rPDP3zLJ2/aSXRr9TCeNVBlkYqFBJA5OAOtYUurWjDfp7meUf8sw4jb9a2z8vAdW9DjqPeqGp6XHd2jmOOGKduRIIxn8a79WtD3J88fhYReLbuWH7LNJqUYH8D5IP0I61Rj+0i8FyunC6Dtu3yIEJ+p61lywGzBjvLu2KA42gncB24FbmgadG1wjpK2xz8pEvy498/54qo2Ryxi3pt9x0uni4v7do4ZVgEMbOAxCkZ6jPrUmh6DAL/ABqEUdzBeMu9FJQIfUd++c1GJpLSzk+xwtNdFtqrkAMCcYqz4F1hPEF5dadq5EdzY5JtrfrgHH1454FZzla7RjiZKOj2NHXrbTYLoRwDzrcfdEb8ocAEH8gfxopNZUWl0Egt4oUK5zMxQt+A4oqIyaQqduVbv5naA+XtBDE8DPAp4YEAjqRkZoorx7HgBgBvvcnt61TvdJtb1i0iFZCMFkOMj3HQ/jRRVQbWwKcoO8WUrTwrFbs3lzhFJOCq5bnr1OKnk0CV2xFqO0BgV3whiAOoPOMH6UUVp7SXc2eJqt7kEvhi8VB9m1MF2YmRWiCgr/dGOevfrWhYaFPDukbUGEzKV+RPlXP90cfnRRQ6kgeKqNWb/BGzYW/2WExl/MO7O8jBP+96/WuY8V+Grm+1P+0bFkctEIZYS2Ny7skjPGccYNFFKM3F3RNOtKnLnW55Xq0d3ELm11O2WE+ZvW3DHax6BSTgqe/GKpQy3QJiLXEYdCYzbDgYIycE89P1zxRRXqQd4pn0rjeKfdG54ZWS+1m4W1WGCNoTM04faWi4B+XGPvADHv1547e88W3OladDY2VuN9rEFld5FCwR4wp29WOASPfrRRWbipOzOeolUmlPU4y41g6pc2wsbiU3Fq5EbAjcEKElmcn5iO3XHrjpf029Fxp8N6TGkxbzfKXEgfAOUyD0wCAcnniiitIao2nHlfKuwywhtri6AuXSXg3KyFiWXcBu+9yCCeCccL05q1sDJbzpFLdyJukLkgu8ik7c4BG7LHoOAPaiiqsc9jNuI1jv7SyaSdIhuYASkyCYgSfe+8yZzkgdcDjNawWWyilPC3U+Zdh/eMW/i2jjcc4wM9PpRRQ90hRerQsUhhikla4kEr7GjaN93lH0QdDghsjH16VaupLifU5POu4po2wYYN3zLj7znPOcnA7Ac0UVEktzVO/vdS59qntjFGAIkI8tU3ZBJ7HsKiMhjX53jlcybiu1d0hHGSOMgA9fQZoopW6i0avYk1GSSBreGEPbxN8jNbbZAjAcLtI6fiMHFVZP32ZrozJEQrNtcJsxyCcHcPQjocUUUktLmHNZK3Ua/lXVubiznc2RaNl8sEl/vBixxwM9SPSpXj2qzqqB8AN0HIPA57c579aKKX9fkWm7f15GfeWoQxNCinJ2tsPIQnkAYxyeuK5jxhZ2cH2e7S5MdxG5jDPy0nGdn1yAM46UUVV9Ab0uYumtKTvgZElMWHE+fu9ADjr9R6dav22nz3enK0WCgIAYg445DDnAB7r14ooq27K4R1R6bpdqw/Zq8UwtKCTqMZBwQF+e24A/z1rzHw+J7RD5chZVOdrjOM/56UUVyYfep/i/RBTiuaXqaj6tEl+bVh5UlwS0ceDtHrg+vHSq2tk2m6SO0YuEym9iA3p2oorVFJ62/rYq+H78X9kBHZrHfmf5mVsnaAM9O365rZ1JpFVkYksihUZjkoOe317UUU1uh0tGkeb6lp8kl4XnvPNDc+YwIz9B3qXw9dJbTgW6CTPyv5UbM2O3eiim0ozVupEnySuju0ybVTsbnoSOKgBzxtP1JyKKK1Z203zanSeGNXbT45IZ0MmnzOyS46xlhw309f8A61ZctobK7mtps5iYjg5yOx+lFFZpJSuupzw/jzXf9Lf5lW6ihuGHmRJIB0LLmszUr2LS4HlhMduEwZBHGCQO2e+OaKKqUuWLZVT3U2jV8M3txqCpcK6zxyZ2uFC8e3b8Otb0Ms1va28ln5qTo5G8RgjAH+eKKKT1SZgpOUdf63MXUdSXyZLm9nKRzMd5Ck5bPXA+v6VVvpbn+2NN06ztPtiXIMiRQ/KuD/EB+JJooqlGyuh1qjg2kaiaXBqNg1vdMVB2lo/u5bkdfQYriJ9KutM1NY4zEvzkr5a7+D+H60UVcFcqes7HXxAtGocnJGR61GGMLFoWeJiMHaxyR6UUUSOumxJLqadAjzyuO25zgfSuu8F2t+1zbX+m3EkkMUhhuLWdiQoI+8p/pRRWVZ8sG0c2ZJfV3O2qPS52CREk7QeMntXiV4CLycp++JkYsV+YHk0UVy4bds48n3mvQrF45B0K468d6rmQsG8oFsfwg8n8KKK7ou57VVcl7HMa3bPdXQzmBj0WWPG4fWtnQpP7JggW/eFVd/LjIBKkn1OCB9TgUUVotFc4pvlUpdTqL6WLTNDlujE7zW8/76D/AGee/wBc1yXijw/Fc6Wmu+E0uor29lY3Vokh37s8FSB90HJPPXFFFYSgpJt9P1Ry1rys36l7RNVk1G2FrPNPLfWQEdxOPmWQnOMfTBBPeiiitYQTjdmlKvOMUkf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low (left) and high (right) power views of the normal villous architecture of the small intestine. The high power view shows the enterocytes and interspersed goblet cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24041=[""].join("\n");
var outline_f23_30_24041=null;
var title_f23_30_24042="Atrial fibrillation in patients with heart failure";
var content_f23_30_24042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atrial fibrillation in patients with heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/30/24042/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24042/contributors\">",
"     Alan Cheng, MD, FACC, FAHA, FHRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24042/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/30/24042/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24042/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24042/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/30/24042/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/30/24042/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/30/24042/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general population of patients with atrial fibrillation (AF), the main goals of therapy are the control of symptoms and the prevention of arterial thromboembolism, particularly stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H31#H31\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Summary and recommendations'",
"    </a>",
"    .). These goals are also true for the relatively large subset of AF patients with heart failure (HF). In such patients, the adverse hemodynamic consequences of AF can quickly lead to a decrease in exercise capacity and a worsening of symptoms, both of which may be difficult to manage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Similar to the general population, no survival advantage has conclusively been demonstrated with either a rate- or a rhythm-control strategy to manage the abnormal rhythm. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Effect on cardiac function'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic will discuss the epidemiology, prognosis, and management of AF in patients with HF. This discussion will focus mainly on the ways in which the control of rate and rhythm may differ from the general population of patients with AF. An overview of the evaluation and management of AF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the purposes of this topic, HF refers to patients with symptomatic systolic left ventricular dysfunction, unless otherwise stated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE AND PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of AF in patients with HF was examined in an analysis from the Framingham Heart Study in which 1470 participants developed AF, HF, or both over a 47 year interval [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/3\">",
"     3",
"    </a>",
"    ]. Among the 708 who developed HF without prior AF, 159 (22 percent) subsequently developed AF over a mean follow-up of 4.2 years (incidence rate 5.4 percent per year) (",
"    <a class=\"graphic graphic_figure graphicRef56154 \" href=\"UTD.htm?19/36/20045\">",
"     figure 1",
"    </a>",
"    ). Somewhat similar findings were noted for patients who developed AF first; the subsequent incidence of HF was 3.3 percent per year. In another report from the Framingham Heart Study, the odds ratio for developing AF over a two-year interval among patients with heart failure was 4.5 for men and 4.9 for women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of AF in patients with HF varies from &lt;10 to 50 percent, depending in part upon the severity of HF and New York Heart Association class [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]. In the V-HeFT trials of patients with mild to moderate HF, AF was present in 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/5\">",
"     5",
"    </a>",
"    ]. In three cohorts of patients with more advanced HF referred for heart transplant evaluation, AF was present in 20 to 27 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. African Americans in general have lower incidences of AF and this is also true for AF in HF (20 versus 38 percent in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/11\">",
"     11",
"    </a>",
"    ]. The reasons for this are unclear.",
"   </p>",
"   <p>",
"    There is a direct relationship between NYHA functional class and the presence of AF. The prevalence of AF increases from 4 to 40 percent as the NYHA functional class increases from I to IV [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/12-19\">",
"     12-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also an association between left ventricular diastolic dysfunction and AF. In a study of 840 patients &ge;65 years of age, 80 developed AF over a mean follow-up of four years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients with abnormal diastolic function had an increased risk of AF compared to those with normal diastolic function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=see_link\">",
"     \"Pathophysiology of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It should also be kept in mind that each (AF and HF) may predispose or promote the other&rsquo;s persistent nature [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFECT ON CARDIAC FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;AF can impair myocardial function by four mechanisms: (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link\">",
"     \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heart rate changes. In cases where the ventricular response is fast and maintained, a chronic tachycardia can lead to a rate-related cardiomyopathy. In cases where the ventricular response is exceptionally slow, patients can develop symptomatic bradycardia and possibly syncope.",
"     </li>",
"     <li>",
"      The irregular rhythm.",
"     </li>",
"     <li>",
"      Loss of atrial systole (also called the atrial \"kick\") required for optimal ventricular filling.",
"     </li>",
"     <li>",
"      Activation of neurohumoral vasoconstrictors such as angiotensin II and norepinephrine, as well as other maladaptive and procoagulant biochemical mechanisms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some patients with a dilated cardiomyopathy, the left ventricular dysfunction may be primarily due to the rapid ventricular response to AF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. This phenomenon is called a tachycardia-mediated cardiomyopathy. In one study of 213 consecutive patients with heart failure associated with AF, tachycardia-mediated cardiomyopathy was the presumed cause in 29 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/26\">",
"     26",
"    </a>",
"    ]. Improvement in left ventricular function is seen with both rhythm and rate control, although it may be more likely with rhythm control [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/24\">",
"     24",
"    </a>",
"    ]. This process can occur even with moderately fast rates at rest over time. If the ventricular response is corrected, ventricular function may improve or normalize, whereas if the rate is uncontrolled, there can be a precipitous decline in ventricular function, leading to increased heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations illustrate the potential magnitude of this effect:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, the left ventricular ejection fraction (LVEF) was measured before and at a mean of 4.7 months after cardioversion in 12 patients with chronic AF and presumed idiopathic dilated cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/24\">",
"       24",
"      </a>",
"      ]. There was an improvement in mean LVEF from 32 percent at baseline to 53 percent at follow-up; the LVEF returned to normal in six of the patients. This improvement persisted at one year in the 10 patients who remained in sinus rhythm, while there was a marked deterioration in left ventricular function in the two patients with recurrent AF.",
"     </li>",
"     <li>",
"      In a study of 63 patients with left ventricular dysfunction and AF who underwent atrioventricular nodal ablation and pacemaker implantation, 16 (25 percent) displayed a marked improvement in LVEF to over 45 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/2\">",
"       2",
"      </a>",
"      ]. The mean increase in LVEF in these patients was 27 percentage points.",
"      <br/>",
"      <br/>",
"      More recent data have shown that in patients with preexisting cardiomyopathy or HF who undergo atrioventricular nodal ablation and pacemaker implantation, biventricular pacing reduces in the likelihood of worsening HF when compared to a standard right ventricular pacing system [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who develop tachycardia mediated cardiomyopathy may be at risk for sudden death even if the ventricular function improves.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hemodynamic deterioration also occurs in patients with underlying heart failure. This issue was examined in a prospective observational study of 344 patients with heart failure who were initially in sinus rhythm; 28 developed AF over 19 months, 18 of whom developed permanent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/28\">",
"     28",
"    </a>",
"    ]. Permanent AF was associated with significant worsening of New York Heart Association functional class (mean 2.4 to 2.9).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data as to whether AF is an independent predictor of mortality in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/3,5-7,29-31\">",
"     3,5-7,29-31",
"    </a>",
"    ]. The largest experience has come from subset analyses of the SOLVD, CHARM, and V-HeFT trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A three-year follow-up of 6517 patients in the SOLVD trials (patients with asymptomatic left ventricular dysfunction or NYHA class II to III HF) found that AF (present in 6.4 percent) was a significant predictor of all-cause mortality (34 versus 23 percent in those without AF), even after multivariate analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The CHARM series of trials enrolled 7599 patients with symptomatic HF, both with reduced and preserved left ventricular ejection fraction (LVEF) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/30\">",
"       30",
"      </a>",
"      ]. Approximately 18 percent of the patients had AF at baseline. At a median follow-up of 38 months, AF was independently associated with an increase in all-cause mortality in patients with either a low LVEF (37 versus 28 percent in patients without AF) or a preserved LVEF (24 versus 14 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The V-HeFT I and II trials included 1427 patients with NYHA class II to III HF, 206 of whom (14 percent) had AF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/5\">",
"     5",
"    </a>",
"    ]. There was no significant difference in mortality at two years in either trial (34 versus 30 percent and 20 versus 21 percent, respectively) or in hospitalization for HF.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other data does not support a relationship between AF and mortality in HF patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2667459\">",
"    <span class=\"h1\">",
"     GENERAL MANAGEMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;AF may worsen symptoms in patients with HF and uncontrolled HF can precipitate or speed the ventricular response of AF or precipitate AF in patients in sinus rhythm. In addition to the management issues discussed below, all correctable causes of both AF and HF should be identified and corrected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link\">",
"     \"Management of new onset atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with heart failure and atrial fibrillation will require a beta blocker to slow the ventricular rate, as part of the treatment of hypertension, or, as part of the pharmacologic therapy of heart failure with left ventricular systolic dysfunction. (See",
"    <a class=\"local\" href=\"#H2666291\">",
"     'Rate control'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis of four randomized trials (8680 patients) of beta blocker therapy in patients with heart failure evaluated outcomes in individuals with (1677) and without AF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/32\">",
"     32",
"    </a>",
"    ]. In AF patients, beta blockers did not reduce mortality (odds ratio 0.86, 95% CI 0.66-1.13); in patients with sinus rhythm, a reduction in mortality was seen (odds ratio 0.63, 95% CI 0.54-0.73). Although the lack of benefit from beta blockers in the AF subgroup is surprising, it does not change our recommendations for its use, in part due to the small number of events in the meta-analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RHYTHM VERSUS RATE CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with AF will have unacceptable symptoms attributable in part to a rapid ventricular rate. These patients require a slowing of the ventricular rate prior to a decision about rhythm or rate control as a long-term strategy to control symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the general population of patients with AF, we prefer a rate-control strategy for many, especially if they are not symptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link&amp;anchor=H5421057#H5421057\">",
"     \"Rhythm control versus rate control in atrial fibrillation\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The restoration and maintenance of sinus rhythm has long been felt to be important in AF patients with symptomatic HF. This is based upon the expectation that HF symptoms are more easily controlled in such patients if they are in sinus rhythm. However, evidence from one observational study and from subsets of patients in the AFFIRM, RACE, and DIAMOND trials with HF is conflicting regarding improvement in outcomes such as survival, thromboembolic complications, or hospitalization for HF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/28-30,33-36\">",
"     28-30,33-36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link&amp;anchor=H8#H8\">",
"     \"Rhythm control versus rate control in atrial fibrillation\", section on 'Comparative studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The AF-CHF trial was the first large, randomized trial to test the hypothesis that long-term rhythm control is better than rate control in patients with HF and paroxysmal AF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In this trial, 1376 patients with a left ventricular ejection fraction &lt;35 percent, HF symptoms, and a history of paroxysmal (or persistent) AF were assigned to a strategy of either rhythm control (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    ), or rate control (with beta blockers). At a mean follow-up of 37 months, there was no significant difference in the primary outcome of death from cardiovascular causes between the rhythm- and rate-control groups (27 versus 25 percent, respectively) or the outcome of the event-free survival. Improvements in quality of life and functional capacity were similar in treatment arms, as were assessments of the six-minute walk distance and New York Heart Association functional class [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We believe that for many patients with AF and chronic HF, a rate-control is preferred to a rhythm-control strategy given the burdens of cost, a more complicated medical regimen, and the potential for adverse side effects of antiarrhythmic therapy. In particular a rate-control strategy is an acceptable initial approach to patients who can easily be rate controlled, are very unlikely to maintain sinus rhythm in the long term, and who are not bothered by symptoms such as palpitations that are attributable to AF. Nevertheless, certain circumstances may warrant attempts at rhythm control depending on a patient&rsquo;s hemodynamic status, severity of symptoms, and ability to adequately control the ventricular response rate. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Rhythm control'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For those patients who have heart failure precipitated by new onset atrial fibrillation, the acute management may include rate control, but ultimately these patients may benefit from cardioversion as opposed to the group of patients with chronic heart failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic atrial for relation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2666291\">",
"    <span class=\"h1\">",
"     RATE CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rate control to prevent rapid AF often leads to an improvement in symptoms in patients with HF. In addition, slowing of the ventricular rate often leads to a moderate or, in some cases, marked improvement in left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/8,24,25\">",
"     8,24,25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Effect on cardiac function'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The potential benefit of rate control was demonstrated in a post hoc analysis from the randomized US",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    Heart Failure Trials in which 136 of 1094 patients with HF due to systolic dysfunction had AF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients treated with carvedilol had a significant increase in the left ventricular ejection fraction (from 23 to 33 percent compared with 24 to 27 percent with placebo); there was also an almost significant trend toward a reduction in the combined endpoint of death and heart failure hospitalization (7 versus 19 percent). This study does not prove that the improved outcomes are due to rate control, but rather a beneficial effect of the use of one beta blocker in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with HF due to systolic dysfunction and AF requiring rate control, we recommend the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers as initial therapy, since they are recommended in such patients for general HF treatment.",
"     </li>",
"     <li>",
"      If a second agent is necessary to achieve adequate rate control,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      should be added. However, the efficacy of digoxin wanes with physical activity. Care should be exercised in HF patients with decreased renal excretion, as the rate of digoxin toxicity increases significantly as renal function declines. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"       \"Use of digoxin in heart failure due to systolic dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=see_link\">",
"       \"Basic approach to arrhythmias due to digoxin toxicity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=see_link\">",
"       \"Digitalis (cardiac glycoside) poisoning\"",
"      </a>",
"      .) While the combination of digoxin in a beta blocker may be more effective at controlling rate, digoxin may also have other adverse effects in the heart failure population.",
"     </li>",
"     <li>",
"      For patients with decompensated HF, the initiation or increase of beta blockers is contraindicated. If such a patient also has rapid AF requiring rate control, use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      is suggested. However, digoxin is often ineffective when used alone, especially in patients in whom sympathetic tone is elevated. The adequacy of rate control in AF should be assessed both at rest and with exertion [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The nondihydropyridine calcium channel blockers (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      ) should be used rarely and with extreme caution, due to the risk of exacerbating HF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30438?source=see_link\">",
"       \"Calcium channel blockers in heart failure due to systolic dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=see_link\">",
"       \"Drugs that should be avoided or used with caution in patients with heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the event that rate control with either beta blockers or a combination of beta blockers and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      has not been achieved,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      may be useful either alone or in combination with other rate-slowing agents. Also, for patients with acute AF with rapid ventricular response and associated with heart failure, amiodarone may be helpful to slow the ventricular rate. Although usually used for rhythm control, amiodarone can also provide a degree of rate control while it is being loaded and thereafter. Amiodarone is not recommended as a chronic rate-control medication, but in the acute setting can assist with rate control as it is being loaded, or can be used as a temporary rate-control agent in a patient who is unable to tolerate other therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/39\">",
"       39",
"      </a>",
"      ]. The use of amiodarone may prove helpful for rate control in this setting, but care must be exercised when using these agents, especially in those without adequate anticoagulation since there is the possibility of pharmacologically restoring sinus rhythm. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Amiodarone'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       Dronedarone",
"      </a>",
"      should be avoided in patients with heart failure or left ventricular systolic dysfunction. (See",
"      <a class=\"local\" href=\"#H19977042\">",
"       'Dronedarone'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107635149\">",
"    <span class=\"h2\">",
"     Rate-control goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In stable patients, the adequacy of rate control in AF should be assessed both at rest and with exertion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the RACE II trial of strict (resting heart rate &lt;80 beats per minute and heart rate during moderate exercise &lt;110 beats per minute) versus lenient rate (resting heart rate &lt;110 beats per minute) compared to strict control strategies in patients with AF, approximately 10 percent of patients with permanent AF had a history of HF, there was no significant difference in the primary composite outcome, which included death from cardiovascular causes, hospitalization for HF, stroke, embolism, bleeding, and life threatening arrhythmic events [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link&amp;anchor=H4#H4\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\", section on 'Rate control goals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limitations to applying RACE II to patients with HF include a primary end point comprised of many components, uncertainty as to whether these are a reasonable way to measure rate control, few patients with HF or ventricular dysfunction, and lack of measurement of key quality-of-life parameters.",
"   </p>",
"   <p>",
"    Although the evidence to support one rate-control goal or another is limited, we believe that a lenient approach is a reasonable starting point. For patients who remain symptomatic with lenient rate control, a trial of more strict rate control would then be a reasonable approach. For those whose ventricular rate varies markedly with minimal changes in activity, especially if associated with symptoms, a rhythm control strategy may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2667550\">",
"    <span class=\"h2\">",
"     Patients with preserved left ventricular systolic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with preserved left ventricular systolic function and heart failure (diastolic heart failure), either nondihydropyridine calcium channel blockers or beta blockers may be chosen for rate control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2666305\">",
"    <span class=\"h2\">",
"     AV node ablation with pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rate control can also be achieved with radiofrequency ablation of the atrioventricular node (AV) node and permanent pacemaker placement. This strategy may be useful in patients (usually with permanent AF) in whom rate control has failed or been contraindicated.",
"   </p>",
"   <p>",
"    The type of pacemaker may be important. Studies such as the DAVID trial and an analysis from the MOST trial have demonstrated that isolated right ventricular pacing (at rates &gt;40 percent of ventricular beats) may actually worsen HF and increase the frequency of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In HF patients with AF who undergo AV node ablation, if the left ventricular ejection fraction is or below 40 percent and there is an expectation that ventricular pacing will occur more than 40 percent, strong consideration for a biventricular pacing system (also called cardiac resynchronization therapy) should be made as opposed to a standard right ventricular pacing system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11545?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Implantation and other considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=see_link\">",
"     \"Rationale for and mechanisms of benefit of cardiac resynchronization therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/983?source=see_link&amp;anchor=H2#H2\">",
"     \"Cardiac resynchronization therapy in atrial fibrillation\", section on 'Use of crt in af'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who can potentially benefit from cardiac resynchronization therapy but have atrial fibrillation, it may be necessary to ablate the AV node so that a high percentage of ventricular pacing can be insured since patients with atrial fibrillation may \"override\" the pacing and reduce the efficacy of the CRT device. Compelling data would suggest that AV junctional ablation in patients who are not pacing at rates of upwards of 90 percent with CRT pacing may benefit from radiofrequency catheter ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RHYTHM CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhythm control is a reasonable approach in patients with HF who are hemodynamically unstable or who are persistently symptomatic despite adequate rate control [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/22\">",
"     22",
"    </a>",
"    ]. It may be the treatment of choice in patients with recent onset atrial fibrillation in whom there is an exacerbation of heart failure even if rate control is achieved. In some instances, direct current cardioversion may be necessary, and this may even be necessary acutely for patients who have sudden precipitation of heart failure or the development of pulmonary edema. The trial of rate control even under these circumstances with attempted stabilization of the patient is recommended before acute cardioversion is anticipated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link&amp;anchor=H13#H13\">",
"     \"Cardioversion for specific arrhythmias\", section on 'Atrial fibrillation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link&amp;anchor=H8701654#H8701654\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'DC cardioversion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the efficacy of successful restoration and long-term maintenance of sinus rhythm is dependent in part on how long a patient has been in persistent AF, but several other predictors exist including left atrial size. Both antiarrhythmic drug therapy and radiofrequency catheter ablation are available to achieve this end in select patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107635608\">",
"    <span class=\"h2\">",
"     Cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the first episode of atrial fibrillation, electrical cardioversion may be performed without initiation of antiarrhythmic drug therapy. For those patients who have recurrent episodes of atrial fibrillation or who convert back to atrial fibrillation rapidly after cardioversion,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    make sense as first line antiarrhythmic therapy. In most cases, patients with persistent atrial fibrillation do not return to normal sinus rhythm with medical therapy alone. Electrical cardioversion can be performed in patients in whom it is not clear that the atrial fibrillation is specifically responsible for the symptoms but cardioversion can be useful to determine if atrial fibrillation is of importance in restoring functional capabilities, quality of life, and improving symptoms, such as dyspnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antiarrhythmic drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, many patients with AF and HF have been treated with long-term antiarrhythmic drugs based upon the assumption that the restoration and maintenance of sinus rhythm will lead to improved outcomes, such as fewer symptoms or admissions for heart failure. However, not only is there no high quality evidence of better outcomes, but also concerns have been raised about increased mortality with rhythm control with some of the antiarrhythmic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Rhythm versus rate control'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19977042\">",
"     'Dronedarone'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    All antiarrhythmic drugs are associated with significant side effects. Taking these into account, recommendations for their use in patients with heart failure are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2006 American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart",
"      <span class=\"nowrap\">",
"       Association/Heart",
"      </span>",
"      Rhythm Society",
"      <span class=\"nowrap\">",
"       (ACC/AHA/HRS)",
"      </span>",
"      guidelines recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      as first-line therapy to maintain sinus rhythm in patients with AF and HF; this recommendation was not changed in the 2011 update [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 2010 European Society of Cardiology guideline for the management of AF does not recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      for the maintenance of sinus rhythm in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/47\">",
"       47",
"      </a>",
"      ]. In addition",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      is contraindicated for patients with New York Heart Association (NYHA) class III or IV HF, and is not recommended for patients with NYHA class II HF with recent exacerbation.",
"     </li>",
"     <li>",
"      Our authors and reviewers generally prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      as the first antiarrhythmic drug in patients with AF and HF for the following reasons (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Amiodarone'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H11\">",
"       'Dofetilide'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H19977042\">",
"       'Dronedarone'",
"      </a>",
"      below):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is more effective in preventing recurrence of AF.",
"     </li>",
"     <li>",
"      Compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is easier to use as well as being more effective and possibly safe. In addition, the risk of torsades de pointes, which is a major concern with the use of antiarrhythmic drugs (particularly when used in patients with HF), is much lower with amiodarone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;When used for preventing recurrence of AF,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , particularly in lower doses (less than 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and occasionally less than 200",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    has the advantages of lack of a negative inotropic effect and little or no proarrhythmia, despite a low incidence of QT prolongation. The near absence of proarrhythmia was illustrated in a meta-analysis of four trials of low-dose amiodarone therapy for a minimum of one year in patients with underlying heart failure or myocardial infarction; there were no cases of torsades de pointes in the 738 patients treated with amiodarone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, since amiodarone has beta blocking and calcium channel blocking activity, the ventricular rate is usually slow and well tolerated if AF does recur. Its use in HF patients does not necessarily require hospitalization, but careful monitoring of the international normalized ratio is necessary as amiodarone can potentiate the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link&amp;anchor=H22#H22\">",
"     \"Major side effects of amiodarone\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    was illustrated in a subset analysis from the CHF-STAT trial in which 15 percent of patients had AF at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/39\">",
"     39",
"    </a>",
"    ]. Among these 103 patients, 51 were randomly assigned to amiodarone and 52 to placebo. The following significant benefits were noted with amiodarone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A greater likelihood of reverting to sinus rhythm (31 versus 8 percent) during the course of the study. Patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      who converted to sinus rhythm had a lower total mortality than those who did not convert. It is not clear if reductions in mortality were because patients who converted were less sick to begin with or if restoration of sinus rhythm was causative.",
"     </li>",
"     <li>",
"      During AF, a 16 to 20 percent reduction in the mean ventricular rate and a 14 to 22 percent reduction in the maximum ventricular rate.",
"      <br/>",
"      <br/>",
"      In addition, among 531 patients initially in sinus rhythm,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      was associated with a lesser likelihood of developing AF (4.1 versus 8.3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are, however, potential complications associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy in patients with HF, particularly during the loading phase. These were illustrated in a report of 37 patients with HF and an average left ventricular ejection fraction of 24 percent who presented with AF or atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/49\">",
"     49",
"    </a>",
"    ]. During the period of loading with amiodarone (1.2",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    32 percent developed a bradycardia requiring discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and 19 percent required a permanent pacemaker. After 9.5 months, 57 percent of patients remained in sinus rhythm and 14 percent developed complications, including hypothyroidism and neurotoxicity. Side effects with maintenance therapy are less likely with lower doses but still occur (",
"    <a class=\"graphic graphic_table graphicRef57845 \" href=\"UTD.htm?5/11/5309\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advantages to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    include the ability to start therapy as an outpatient, once a day dosing, lower cost, and a lower risk of torsades de pointes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Dofetilide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     Dofetilide",
"    </a>",
"    , a class III antiarrhythmic drug, is effective for preventing recurrent AF in patients with HF. This was illustrated in a review of 506 patients enrolled in the DIAMOND-CHF or DIAMOND-MI trials who had left ventricular dysfunction and were initially in AF or atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/36\">",
"     36",
"    </a>",
"    ]. Over the course of the study, patients treated with dofetilide were significantly more likely to convert to sinus rhythm (59 versus 34 percent with placebo). Among these 234 patients, the probability of maintaining sinus rhythm at one year was greater with dofetilide (79 versus 42 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=see_link\">",
"     \"Therapeutic use of dofetilide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     Dofetilide",
"    </a>",
"    is relatively safe in patients with HF. This was established by the DIAMOND-CHF trial, which enrolled 1518 patients with symptomatic HF, including 391 with AF at baseline; the patients were randomly assigned to dofetilide or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     Dofetilide",
"    </a>",
"    was more likely to be associated with reversion to sinus rhythm at one month (12 versus 1 percent) and one year (44 versus 13 percent) but, at a mean follow-up of 18 months, there was no overall difference in mortality between the dofetilide and placebo groups (41 versus 42 percent). Subgroup analysis revealed the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients who were cardioverted to sinus rhythm, either pharmacologically or electrically, those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      were significantly more likely to remain in sinus rhythm (57 versus 28 percent) (",
"      <a class=\"graphic graphic_figure graphicRef69648 \" href=\"UTD.htm?20/52/21325\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients in sinus rhythm at baseline, those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      were significantly less likely to develop AF (2.0 versus 6.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mortality was lower in patients in whom sinus rhythm was restored and then maintained (risk ratio 0.44), independent of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was a difference in mortality when analyzed by baseline corrected QT (QTc) interval [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/51\">",
"       51",
"      </a>",
"      ]. Among those with a normal QTc interval (&lt;429 msec),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      was associated with a significant reduction in mortality (risk ratio 0.4); the risk gradually rose at higher values and mortality was increased in those with a QTc interval &gt;479 ms (risk ratio 1.3).",
"     </li>",
"     <li>",
"      The most important side effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      was torsades de pointes, which was seen in 25 cases (3.3 percent); three-quarters of episodes occurred within the first three days while the patient was in the hospital. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommended dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    is 500 micrograms twice daily in the absence of renal insufficiency.",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (FDA) has approved the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm and for maintenance of normal sinus rhythm. Because of the risk of torsades de pointes, the FDA approval for dofetilide was contingent upon the following restrictions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       Dofetilide",
"      </a>",
"      is available only to hospitals and subscribers that have received dosing and treatment initiation education.",
"     </li>",
"     <li>",
"      Patients must be",
"      <strong>",
"       hospitalized",
"      </strong>",
"      for a minimum of three days for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      initiation (to give six pills, one every 12 hours) at a facility that can provide measurement of creatinine clearance, cardiac monitoring, and cardiac resuscitation. The majority of episodes of torsades de pointes occur within this three-day period, the time of peak increase in the QT interval [",
"      <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/50\">",
"       50",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Our authors and reviewers are more comfortable using dofetilide for HF patients with an implantable cardioverter defibrillator is in place or in younger patients with less severe impairment of left ventricular systolic function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19977042\">",
"    <span class=\"h3\">",
"     Dronedarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     Dronedarone",
"    </a>",
"    should not be used in patients with NYHA class III-IV heart failure or left ventricular systolic dysfunction (left ventricular ejection fraction &lt;0.40), as efficacy is poor and safety is a concern. This recommendation is consistent with that made by the European Medicines Agency in September of 2011 and that made by the United States Food and Drug Administration in December of 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. While the available data does not does not allow for firm recommendations regarding the use of dronedarone in patients with NYHA class I-II heart failure or mild left ventricular systolic dysfunction, we suggest that the drug be used with caution in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link&amp;anchor=H58992353#H58992353\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\", section on 'Concerns about dronedarone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the general population of patients with AF, a 2009 meta-analysis found a significantly lower rate of recurrent AF with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    (odds ratio 0.49; 95% CI 0.37 to 0.63) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link&amp;anchor=H17#H17\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\", section on 'Dronedarone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strong evidence for an adverse effect from its use in patients with HF comes from results of the ANDROMEDA trial, which evaluated the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    compared to placebo in patients with symptomatic heart failure and left ventricular systolic dysfunction (ejection fraction &le;35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/55\">",
"     55",
"    </a>",
"    ]. The trial was discontinued early due to a significant increase in the incidence of death in the patients assigned to dronedarone (8.1 versus 3.8 percent) during a median follow-up of two months. It should be noted that in the ATHENA trial, in which approximately 20 percent of patients with NYHA functional class I or II HF, dronedarone appeared safe, but not necessarily effective. The rationale to use dronedarone in symptomatic HF patients is extremely weak and analyses are post hoc from ATHENA. We believe that patients with severe HF, generally those with NYHA class III or IV HF, or those who have been hospitalized with HF in the past four weeks, should not receive dronedarone. Patients with lesser degrees of HF may receive the drug cautiously. Benefits are uncertain. Symptoms may not be reduced. It should never be used in patients with suspected permanent atrial fibrillation and HF.",
"   </p>",
"   <p>",
"    Concerns also have arisen with regard to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    in patients with permanent atrial fibrillation. The PALLAS trial has shown that there is an increased risk of the combined endpoint of CV death, MI, stroke, and systemic embolism, the endpoint of death, the endpoint of stroke, and the endpoint of heart failure hospitalization. Thus, dronedarone should not be used as an additional agent for rate control, especially in patients with a reduction in their left ventricular ejection fraction.",
"   </p>",
"   <p>",
"    There have been two case reports of severe hepatotoxicity with a need for liver transplantation in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1417883\">",
"    <span class=\"h3\">",
"     Sotalol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    <strong>",
"    </strong>",
"    should be used with extreme caution in HF patients based on a report of possible increased risk for torsades de pointe [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/58\">",
"     58",
"    </a>",
"    ]. This is especially true if there are marked fluctuations electrolyte levels, if there is a low left ventricular ejection fraction (&le;0.40), if there is acute onset of heart failure, if there is decompensated heart failure, or if there is evidence of renal dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=see_link&amp;anchor=H16#H16\">",
"     \"Drugs that should be avoided or used with caution in patients with heart failure\", section on 'Antiarrhythmic agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link&amp;anchor=H25#H25\">",
"     \"Therapeutic use and major side effects of sotalol\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1417890\">",
"    <span class=\"h3\">",
"     Class IC drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Class IC drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ) are also associated with an increased risk for proarrhythmias and risk for sudden cardiac death and should not be used in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6868902\">",
"    <span class=\"h2\">",
"     Beta blockers for rhythm control",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is also evidence that chronic beta blocker therapy may reduce the likelihood of the development of AF in patients with HF due to systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link&amp;anchor=H20#H20\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Possible role of angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) have not previously been considered a specific therapy in patients with AF, an increasing number of observations suggest that they may prevent both new onset AF and recurrent AF. Although the data are not definitive, these drugs might be given empirically in patients with recurrent AF, particularly if there are other indications for their use such as hypertension, heart failure, or diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20503?source=see_link\">",
"     \"ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pulmonary vein isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic approaches to rhythm control can also be effective in AF in patients with HF or cardiomyopathy. AF is often triggered by atrial ectopic beats originating near the ostia of the pulmonary veins. Ablation of these ectopic foci, or preferably complete electrical isolation of the pulmonary veins, can be achieved either surgically or by radiofrequency catheter ablation (RCA) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. This strategy may be employed when patients have symptomatic HF after a rhythm-control strategy with antiarrhythmic drug and a rate-control strategy have failed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 58 consecutive patients with New York Heart Association (NYHA) functional class II or higher HF and a left ventricular ejection fraction (LVEF) &lt;45 percent who underwent pulmonary vein isolation by RCA and a group of 58 matched patients without HF who underwent the same, the following findings were noted at a mean of 12 months after the last procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Successful ablation (maintenance of sinus rhythm without symptomatic or documented AF) was achieved without antiarrhythmic drug therapy in 69 percent of those with HF and 71 percent of those without HF. Successful maintenance of AF when drug therapy was included was achieved in 78 and 84 percent, respectively.",
"     </li>",
"     <li>",
"      Mean NYHA class improved significantly among HF patients (from 2.3 to 1.4). Quality of life, exercise capacity, and exercise time improved significantly in both groups.",
"     </li>",
"     <li>",
"      Mean LVEF improved significantly among HF patients (from 35 to 56 percent). Significant improvement in LVEF was seen whether or not structural heart disease was present and whether or not rate control had been adequate prior to ablation. Left ventricular enlargement also decreased significantly. The greatest improvement was seen within the first three months.",
"     </li>",
"     <li>",
"      Among the subset of patients with presumed tachycardia-mediated cardiomyopathy (without structural heart disease and with inadequate prior rate control), 92 percent had a marked improvement in LVEF with ablation (an increase of &ge;20 percent or an increase to a final LVEF of &ge;55 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"       \"Tachycardia-mediated cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the data are mounting, the long-term efficacy of atrial fibrillation ablation in this setting remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92813644\">",
"    <span class=\"h1\">",
"     PVI VERSUS AV NODE ABLATION WITH BIV PACING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative efficacy of pulmonary vein isolation (PVI) for rhythm control and AV node ablation with biventricular (BiV) pacing for rate control was addressed in a prospective, randomized trial of 81 patients with class II or III HF who had symptomatic, drug-refractory AF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/30/24042/abstract/61\">",
"     61",
"    </a>",
"    ]. At six months, PVI was associated with statistically significant improvements in left ventricular ejection fraction (LVEF) (35 versus 28 percent), six-minute walk distance (340 versus 297 meters), and score on the Minnesota Living With Heart Failure questionnaire. The improvements in LVEF and functional capacity were greater for those with nonparoxysmal compared to paroxysmal AF. In addition, approximately 30 percent of patients treated with AV node ablation and BiV pacing had progressive AF (eg, paroxysmal to persistent AF); such progression was not seen in patients treated with PVI. Presently, however, the data are not considered robust enough to recommend routine ablation in patients with atrial fibrillation and, if sinus rhythm is considered the most reasonable alternative for patients as an explanation for symptoms or worsening severity of heart failure, cardioversion or an attempt at an antiarrhythmic drug, such as,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    would proceed any attempt that PVI ablation or AV junctional ablation. The role of biventricular pacing in patients with AF is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/983?source=see_link&amp;anchor=H2#H2\">",
"     \"Cardiac resynchronization therapy in atrial fibrillation\", section on 'Use of crt in af'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1418201\">",
"    <span class=\"h1\">",
"     THROMBOEMBOLISM AND ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most AF patients with HF meet criteria for long-term anticoagulation due to the significantly increased risk of embolization, irrespective of whether a rate or rhythm-control strategy is employed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=see_link&amp;anchor=H7#H7\">",
"     \"Risk of embolization in atrial fibrillation\", section on 'CHADS2 score'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H4338483#H4338483\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Dabigatran'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, anticoagulation is required prior to, during, and after cardioversion, either pharmacologic or electrical. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=see_link\">",
"       \"Patient information: Heart failure and atrial fibrillation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is common in patients with heart failure (HF) and can worsen symptoms. Both rate and rhythm-control strategies are effective in controlling symptoms and have comparable survival rates. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Rhythm versus rate control'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most AF patients with HF meet criteria for long-term anticoagulation due to the significantly increased risk of embolization, irrespective of whether a rate- or rhythm-control strategy is employed. (See",
"    <a class=\"local\" href=\"#H1418201\">",
"     'Thromboembolism and anticoagulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following are recommendations for rate or rhythm control in patients with AF and HF related to systolic left ventricular dysfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest a rate- as opposed to a rhythm-control strategy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients who may benefit from an attempt at rhythm control include those for whom reasonable efforts at rate control do not achieve adequate symptom relief. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Rhythm control'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Rhythm versus rate control'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link&amp;anchor=H356406633#H356406633\">",
"       \"Overview of atrial fibrillation\", section on 'Rate versus rhythm control'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients in whom a rate-control strategy is chosen, we recommend beta blockers as initial therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The initiation or increase in the dose of beta blocker should be done with caution in patients with decompensated heart failure. If a second agent is necessary to achieve adequate rate control,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      should be considered. (See",
"      <a class=\"local\" href=\"#H2666291\">",
"       'Rate control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a lenient (resting heart rate &lt;110 beats per minute) as opposed to a strict (resting heart rate &lt;80 beats per minute and heart rate during moderate exercise &lt;110 beats per minute) approach for the rate-control goal (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients who remain symptomatic with lenient rate control, a trial of stricter rate control may be helpful. (See",
"      <a class=\"local\" href=\"#H107635149\">",
"       'Rate-control goal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who fail a rate-control strategy using medication and are either not candidates for or have failed a rhythm-control strategy, atrioventricular (AV) nodal ablation with pacing is a reasonable therapeutic option. (See",
"      <a class=\"local\" href=\"#H2666305\">",
"       'AV node ablation with pacing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients in whom a rhythm-control strategy is chosen, there are three steps involved: control of the ventricular response, restoration of sinus rhythm, and subsequent maintenance of sinus rhythm. The timing of electrical cardioversion, if needed, is discussed above. (See",
"      <a class=\"local\" href=\"#H107635608\">",
"       'Cardioversion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      as the antiarrhythmic drug of choice (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       Dofetilide",
"      </a>",
"      is an option when amiodarone cannot be used or is ineffective. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Rhythm control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who fail rhythm control with drug therapy and in whom a rhythm-control strategy continues to be preferred over a rate-control strategy, pulmonary vein isolation (either surgical or catheter-based ablation) is a therapeutic option. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pulmonary vein isolation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"       \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"       \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/1\">",
"      Parthenakis FI, Patrianakos AP, Skalidis EI, et al. Atrial fibrillation is associated with increased neurohumoral activation and reduced exercise tolerance in patients with non-ischemic dilated cardiomyopathy. Int J Cardiol 2007; 118:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/2\">",
"      Pardaens K, Van Cleemput J, Vanhaecke J, Fagard RH. Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart 1997; 78:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/3\">",
"      Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107:2920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/4\">",
"      Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/5\">",
"      Carson PE, Johnson GR, Dunkman WB, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87:VI102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/6\">",
"      Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996; 28:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/7\">",
"      Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/8\">",
"      Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001; 142:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/9\">",
"      Mahoney P, Kimmel S, DeNofrio D, et al. Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Am J Cardiol 1999; 83:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/10\">",
"      Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91:2D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/11\">",
"      Ruo B, Capra AM, Jensvold NG, Go AS. Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol 2004; 43:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/12\">",
"      Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/13\">",
"      Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/14\">",
"      Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/15\">",
"      Johnstone D, Limacher M, Rousseau M, et al. Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD). Am J Cardiol 1992; 70:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/16\">",
"      Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100:2312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/17\">",
"      Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/18\">",
"      Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/19\">",
"      Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/20\">",
"      Tsang TS, Gersh BJ, Appleton CP, et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002; 40:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/21\">",
"      Francis GS. Development of arrhythmias in the patient with congestive heart failure: pathophysiology, prevalence and prognosis. Am J Cardiol 1986; 57:3B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/22\">",
"      Cha YM, Redfield MM, Shen WK, Gersh BJ. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 2004; 109:2839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/23\">",
"      Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/24\">",
"      Kieny JR, Sacrez A, Facello A, et al. Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J 1992; 13:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/25\">",
"      Redfield MM, Kay GN, Jenkins LS, et al. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 2000; 75:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/26\">",
"      Fujino T, Yamashita T, Suzuki S, et al. Characteristics of congestive heart failure accompanied by atrial fibrillation with special reference to tachycardia-induced cardiomyopathy. Circ J 2007; 71:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/27\">",
"      Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005; 16:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/28\">",
"      Pozzoli M, Cioffi G, Traversi E, et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998; 32:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/29\">",
"      Crijns HJ, Tjeerdsma G, de Kam PJ, et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000; 21:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/30\">",
"      Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006; 47:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/31\">",
"      Wasywich CA, Whalley GA, Gamble GD, et al. Does rhythm matter? The prognostic importance of atrial fibrillation in heart failure. Heart Lung Circ 2006; 15:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/32\">",
"      Rienstra M, Damman K, Mulder BA, et al. Beta blockers and outcome in heart failure and atrial fibrillation. JACC Heart Fail 2013; 1:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/33\">",
"      Khand AU, Rankin AC, Kaye GC, Cleland JG. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J 2000; 21:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/34\">",
"      Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/35\">",
"      Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/36\">",
"      Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001; 104:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/37\">",
"      Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/38\">",
"      Suman-Horduna I, Roy D, Frasure-Smith N, et al. Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure. J Am Coll Cardiol 2013; 61:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/39\">",
"      Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/40\">",
"      Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/41\">",
"      Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002; 288:3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/42\">",
"      Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003; 107:2932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/43\">",
"      Gasparini M, Regoli F, Galimberti P, et al. Cardiac resynchronization therapy in heart failure patients with atrial fibrillation. Europace 2009; 11 Suppl 5:v82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/44\">",
"      Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992; 20:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/45\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/46\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/47\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/48\">",
"      Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/49\">",
"      Weinfeld MS, Drazner MH, Stevenson WG, Stevenson LW. Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure. J Heart Lung Transplant 2000; 19:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/50\">",
"      Torp-Pedersen C, M&oslash;ller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/51\">",
"      Brendorp B, Elming H, Jun L, et al. Qtc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation 2001; 103:1422.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/09/news_detail_001344.jsp&amp;murl=menus/news_and_events/news_and_events.jsp&amp;mid=WC0b01ac058004d5c1.",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm243762.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/54\">",
"      Piccini JP, Hasselblad V, Peterson ED, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009; 54:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/55\">",
"      K&oslash;ber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358:2678.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm240110.htm.",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm240011.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/58\">",
"      Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996; 94:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/59\">",
"      Hsu LF, Ja&iuml;s P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004; 351:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/60\">",
"      Chen MS, Marrouche NF, Khaykin Y, et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 2004; 43:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/30/24042/abstract/61\">",
"      Khan MN, Ja&iuml;s P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008; 359:1778.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 977 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24042=[""].join("\n");
var outline_f23_30_24042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE AND PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFECT ON CARDIAC FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2667459\">",
"      GENERAL MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RHYTHM VERSUS RATE CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2666291\">",
"      RATE CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107635149\">",
"      Rate-control goal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2667550\">",
"      Patients with preserved left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2666305\">",
"      AV node ablation with pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RHYTHM CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107635608\">",
"      Cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antiarrhythmic drug therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Dofetilide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19977042\">",
"      - Dronedarone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1417883\">",
"      - Sotalol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1417890\">",
"      - Class IC drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6868902\">",
"      Beta blockers for rhythm control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Possible role of angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pulmonary vein isolation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92813644\">",
"      PVI VERSUS AV NODE ABLATION WITH BIV PACING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1418201\">",
"      THROMBOEMBOLISM AND ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/977\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/977|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/36/20045\" title=\"figure 1\">",
"      Cumulative incidence of AF in individuals with HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/52/21325\" title=\"figure 2\">",
"      Dofetilide in AF and HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/977|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/11/5309\" title=\"table 1\">",
"      Side effects of amiodarone",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20503?source=related_link\">",
"      ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30438?source=related_link\">",
"      Calcium channel blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/983?source=related_link\">",
"      Cardiac resynchronization therapy in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11545?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Implantation and other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=related_link\">",
"      Drugs that should be avoided or used with caution in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=related_link\">",
"      Management of new onset atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=related_link\">",
"      Pathophysiology of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=related_link\">",
"      Patient information: Heart failure and atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=related_link\">",
"      Rationale for and mechanisms of benefit of cardiac resynchronization therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=related_link\">",
"      Therapeutic use of dofetilide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_30_24043="Selection of patients allo-HCT";
var content_f23_30_24043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F87815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F87815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selection of patients for allogeneic hematopoietic cell transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Good risk candidates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Young age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No comorbid conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No active infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphohematopoietic disease in remission or responsive to therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Good socioeconomic support system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HLA-matched donor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low risk of post-transplantation relapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High risk candidates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Older age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comorbid conditions present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refractory/relapsed disease (diagnosis-dependent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aggressive prior therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High risk/complex karyotype",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Deeg HJ, Sandmaier BM. Who is fit for allogeneic transplantation? Blood 2010; 116:4762. &copy; 2010 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24043=[""].join("\n");
var outline_f23_30_24043=null;
var title_f23_30_24044="ACC AHA ESC revert AF before 7d";
var content_f23_30_24044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/ESC guidelines: recommendations for pharmacologic cardioversion of AF &le;7 days duration*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antiarrhythmic drug*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route of administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class of recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Drugs proven effective",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dofetilide",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flecainide",
"       </td>",
"       <td>",
"        Oral or intravenous",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ibutilide",
"       </td>",
"       <td>",
"        Intravenous",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Propafenone",
"       </td>",
"       <td>",
"        Oral or intravenous",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amiodarone",
"       </td>",
"       <td>",
"        Oral or intravenous",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Drugs that are less effective or incompletely studied",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Disopyramide",
"       </td>",
"       <td>",
"        Intravenous",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Procainamide",
"       </td>",
"       <td>",
"        Intravenous",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Quinidine",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Drugs that should not be given",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Digoxin",
"       </td>",
"       <td>",
"        Oral or intravenous",
"       </td>",
"       <td>",
"        III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sotalol",
"       </td>",
"       <td>",
"        Oral or intravenous",
"       </td>",
"       <td>",
"        III",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The doses of medications used in these studies may not be the same as those recommended by the manufacturers.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48:e149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24044=[""].join("\n");
var outline_f23_30_24044=null;
var title_f23_30_24045="Pravastatin CARE trial";
var content_f23_30_24045=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benefit of pravastatin post-MI in the CARE trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 230px; background-image: url(data:image/gif;base64,R0lGODlhaQHmAOYAAP///wAAAP8AAO7u7gAz/3d3d4iIiKqqqjMzMxEREbu7u0RERN3d3SIiIszMzJmZmf/f32ZmZv8gIP9AQP9gYFVVVf93dxBA/+/y///v7/8QEP8zM/9VVWCA//+IiIig//+fnzBZ/8/Z//+vr39/fzNc/xFB//+Pj/+/vyBN/5+y//9QUP9wcP9/f3eS/0Rp/88wMN/l//8REb/M///MzEBm/8zW///u7v9ERH+Z//+qqlV3/3CN/5mt/+7x/4+l/6+////Pz/+7uyJO///d3QCZAN3k/1Bz/6q7//8iIv+ZmY9vb59/f/9mZu/v7/f395d3d6enp98/P4+Pj9+/v9/f38fHx6+Pj+9QUM/Pz/8wMLe3t9fX17+goM+vr7vJ/6BToAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABpAeYAAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx7wgGgwsB+AEK8vz9gw/46glaINCfQX8E7RU8yBBewoH5FjaciO4hIYAOCuXbGICiR20WCenT+LFkt4cMEDAAYCDBAJImY1oDmE/BgHsBGuyDKbPnuI4+t+0g8MFSCaLtgAaN5oKAUwIlkAAYWrTS0arrlC591tQFACQETExFapVs1q1MCXj14dQIVQBH/52WsCHogwmnYm28cDpE6tEdQwi88AFAr1y6uQa8LKUVLbOuAHpAHYsVwAcCQywLHuRjyBAfNsLCVQtg7wcfd20YMWGCcC0HFRrgS7DgwKjGjpU1ffrCCOXIe/GO7jFI8lOnNq5qfiE58/BaEWYjQCA7wILFn3DnRgaZENUvYW2AFXuUuKDmhZRfZo5ZUHlaB6zbHgQ7QIFQ2rcb6z6I6njNYq3H2V1FGTGYclehRoBqrLkmywESDQIhfvo9Rpp3SAV3lFiW3SWaYU7tMJqHXhWmIWLg5Ffhip1EUNACD9zG4oygDIBAAYrZeJ8oKtLooyQFcBSQjD8WaUmQHF1HpP+RTBpywEqJDOBijow1Cc9xpySw4yI5Ykehle5gaUoBEXR5SEsbzfclmOyIScoAQnopSAIcqQlKj2yCE0MOKbg5CpwcyQlAAhWYuWSe5KhQAwEdzLBKl4odUkChVB6K6Dcx8HBBCD9g8EqkiCBQp6WXaoOBCiFc0IEIsDCA0wJQFiJqmqSWao0IHWyqgqexVIcPAohASgqetjaDwQ+p8hADLQoEYIBiBoxkiAEIRPCASrUW68wMHRBQgwq3xAclAwHYKUh0AQCbQISdEKvtMMelkEIOy+JCbgMFFCBbrILAGUEFwN6Y7bvGHAdEL9FGZAicBxQALL4DE0yMn7sokO//ToZQt0AD92B8p8TKYNDtU8s4QCc+EQwLMjIihFADr8wwYIABBTxgbnYrGwPEBTlAQ91L8cXIY87EaHrwM3DumHTERN+CQQgh1EuMsIXAWYEgDtjHdNO0zKDqMejmI+g9Fegr7Zpc6/LDBeAa02yghpicT8pbp+0KBkekwOoxzT5bqSEy11yl3beIkMIRMBejGD2GFqKAxyoTXosKF/yQDJJxGrIAsKe4K/kpuTp6uZD4CHoAAo2j/XkrMUCdODKQ/k3IrPnc3O7qr+zMg887OYCtrKMOjTsrOVxwtDMMK0au7VRLQs8gCtCZAOQAeD48JxjUEMLeztC+EfUsVXst/7+N0FTQuiwlYIj1119yHAGvM+M9yoegqy67jDyU9SABZCRS+6SIAQFIQEACTMNGNgFV1QLwr4BtCRIPeUADBtEAc7EPgJCIAbKcQkASGBAVAghhCE3BgHyZcGHlchgAICaJCE5QEBXUCOkwWAkR8CBVHQACBt6XChGOsBS+Kl3GOMaxs0FQIPsDAJz8xz8aYsKGKVDV8VoBggn4UAClaBbZAHYIudFvEhZBX0vW50RKACFXKeAB91qRgRZIQAIguGIp4jOAddVRUAAInNAiQRN87CN6AZgeGcvoCAyccVNqjAUEKCCAFaCAFeKaTnRsB4ADPGlwhDTE+45AAE5J7f8VI5iABlgAAVfAaWazERSavii8TBZigAX8wSddkYETvPEEGYjFYmhGvjmla1aU3MQFPzeDRXXwg7CAAAs0MIER0EJK9CjAAg6RALo164E4cyUAVCCvHPDwFShYgQAoUMpazKoAzWLiICaVowA8AI/CzCQG+JSCts0CBG9sQS5tER9q4ahcGSMdNjkxzJxl6gI1EB0srjgBEOiCjjfK2s3mh4+BxhODuGLUGl0RhDj6kBfk2tjG1HeI2MFTEwV9VzEvoKxXZGAELRClBsT5UV4kbEiwSKmtuDmv+J0CBSeggAQEMAEWjKCccuyFxdBZiAkdwqnZlNw85WVPVEBgBCz/sKIEKHCCRxrDpF6KT20IUR+LojRt70OoQkdxxRVogJktGME+kYE5uA0CXQmYTnWU9DGuwdKDGw1FR68IgiA8o64bkRNsZsWxYJ61aT/4KzI/8dKYvpWmIpTGAJYHLc6V9KS3y9kMUhCCb3ICqEIlqlGRWtNo9FMQAAFfKnRKIxHUgG2fuGpWBbDVrn4ja9U0m2xRQdsViYxnPpVEW986gbjONRx1pdsriquf4nVglpYgrGHTsdQ9Tldb3EzoJqqY1H48jhADOABoM0HdrRSznppo4xs9mll/TKdL8XEsey8Vg1z1LBOLbKRXKUJRgLbSSvNUVXIjEcpRlvMjBdYv/ybaGxPK1SCwkqjlLZ8bDxs9K1Soy1F+67adGYQgBWulhDKZ6cyDAIpQ1DvvINK73gkX6X2Wu0Q4x/lghsgMJ4wbBM1MaMJehtZHkr0EPiWgT5NcKx+CBECESbyUJEeCoQ41SQRORqgtz2dWCyCykQn6IxWY9hHlLQmggqzExQzAALKBkSkofBDKYbgR5G2tSRqgTkQkTML7nZGdM+xGOKa5JFpSxAAKQKffUTkmubpzIgLsyNyQKXUAYLR13qlA1eUm0pBoMCm3A6jEzo50gLYEneXRgRAsuBAalgAuOWEBH25AB6OoNQcSoQMByEAQHhDArnWZuUFM+cCOafWrB/+x4mZ+otYWAECvfy0KXfPa17iI3cK0/WiKKJsROyZnKKANgBuEkAgbEEATkrABc4sQBzcQArYBgAMBKKHWIZSBEsrNARFyINgi1AG+fa0EGvjQAsHedbo5kO52i2PV7cCbqxex5CZXWwDRVoIANgCAdIeQ44OodxM6LgAdEEEASSCEvAVAhH5HexDWVvm5pw1sYZM82un2wCpKSORYQHwdT5u4IbBsioELAAdEILnOgZ0EfwMg2E0IdrRp0G8R0qAJIcSBBW4AgJhT3Yc0oPnTbZ5zALh8FUEMQI0jt5SnIQ4Rh841xgtR9rG329o3kIEM6k0DAMhAAB5wd98tUG//lHfd5n4HvODFnnClm33uqdBiACrAxZxu5WkdQESe61t0yA+i7rXGAb0RX3WOu1sIK++7IDSe8mCL/vSplze1G1/2s6eCjnZ0CXpNyvaeYN4Q8jW0nklBbkLUHd0fR3yvAV/zjYeQBh4/et+RX3KAe7zvhUc42Zlve1REsloGriTpwt9X34cg84Sg9IAvdcqE6V4Q8UF1t+Uhgq8NQtQ9ttUuC0A+sPa+JPWHfrE2ayDTPOg1ZPkyZhD0PTwBgLjVbC22MmEjRIVQAcFjCSHRgB5RfyoQbvknMW9jaoWQVxzDaH0GRvhTPSZRf2CQTxy2Mn2DaUpULgtwNQiQaoqA/xPOMkgT8T4N9TmMIzv94k6MVoSbgBEyJCT+QABF0ISTZTelJjYZUwFZgw842AhGpIINUUVM6ISrE4UU+FQFcIWIkBIr0RJy8nPZEHwgcGaEw22F4CL24F2TcBP4oBM8KA/q50Sugg+wsjA3kiMCg2zugH+EFESeJQiIhVOepg4D+IIAFINvZkSLyFeNeA4QqE3iNy7kp0RT0mmXSA4eqImCcC/5si8Lg4D8N3/TQFguSIqEcFM7aAgWSCuE+A1EB4uGsFSyRYJhlgAneGTgMFjDp4vwp4AzeAA1KGVkKAlq+AuVJVOY9UPGSAiJFiVEqCXXGIrRgFpDVVRHJQhxZ/+MlyaEgoAAVFg7rLgLSaVbWsVV61eNjACGaodehNAwzeiMzQABywVXciWPdVhs4ucABpCPlfCMqxBg2gWQmACHAxmI5ugJCGlVjAQDTDCODCkJfWgd/FKFQmKQjzCRpRBgMLAEU5AFGJmRkICIhaBpF1h+wkCSSxAFVaCSnSCJ0UI9nwiKUQUMJAkFW+AENukJ4lKKnThjESmMvUCSTGAFTzCUn2CKZtNLq2SF65iQFXkFXACVoiCL7HIy6niLtkCSXSCUXDkKvIgIhCKDEnkLHMFIUuAFT3mWocBLpVgA7MJOSUlmtnBFWEAFdPkn1kEIC0BSwGOL3NgKKRmYmxD/NBdxlPMDko4gkpMwAovJmJkwYhJylG22lxclCxAgSpeJmZeQNVczCBZ4glLSaJI5mbPQAqMEiaQJCvdwIw4zmLS4EQmAjIEGThIwAds1m6ZgIxuBAMFYTQyQXugjlqcAAW51AsK5Cg+QL3Q4Y+5kbGb1matwAhpAAbIZnbCAAMF1D9WplD+lBVoQj+AJH2A5TVdZCRlAARoAneupC3qESabAnSvwgfVpC2xpnoI1ARKgnv1ZC1XJmXw5ChmwTC1QoLwAllbJnJiwTyDATPzpoLWwlp75WJ3Ajz4UgRiqC3rJk23JCQpZjCF6C5H5noXAlKOZouH5kj1ZCTJ5ki8K/6Of8p8JqmIVOZM1iaPqoFM/GZRAyg4FxZROWaRJEQkkqZVKSg6AFGX/4whkKZS0daWqlqUHqaWUgKVb+qVdmgxiZJhNxAgBFpdzqYVhCqaT4KVr+qZtyqVxyqb6eAxJVD19piJ+CZgaGAluOqdwWqeB6qdyKqiAeqjEIEEUZEGJgJF/aqiQSqh0KqmDCgmPSqmIOgyKCkMWNH4BcEWeGqqiOqqkWqqmeqqomqqquqqs2qqu2qrIkERLhGYo+qTlMKa2GhNROly52qu++qtcyQBSOpy1mADlKQphk4Ki0CzHGgo6mIWkkDDu6RHowqtRaZyZRpmykhEAsXacIKzGmv8KGXgKDhOMFAGtp6AAL6QK1JIKA9AAcNastKmsoTCrPYGuphABvPkJNGGuznofDSCvn6CD9NoJ8VEd0vUR+Bqt/koKD/B+pSBNMCSwoYCEpvCwK2EyrYkOCysKY+UKHdsJz8pArBCynBA9CmESJtsJKVGwn6AAf4iGaEex34otMjuc6JM11ioPE4gKIYgPNKsJG4mHM4sKdpgTO3uT1eGywNq0Tvu0UBu1Uju1VFu1Vnu1WJu1Wru1XNu1Xvu1YBu2Yju2ZAuVtSkIFpiIZbsNwlouVZi0aysNQdIAFkg3DoATMYQ54Rof1VQuEpQPDRu3ulAduveuDTAAwEUIb8OBAPEXEIHkrYKLC/EnEH0EuPUBuHxrlIEkOJErDIDiPwCxrr70LPjgAJkLfy4ZtJ07C5/bL3RSD64CKI9TuqdLCLKhuqtLbP1DHzp4NQkzK6YbSPC3EUybu8Z7vMibvMq7vMzbvM77vNAbvdI7vdRbvdZ7vdibvdq7vdzbvd5rEoEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier analysis of the incidence of coronary death or nonfatal myocardial infarction (MI) in post-MI patients who had average levels of cholesterol and were randomized to therapy with pravastatin or placebo. The incidence of these endpoints was significantly reduced by therapy with pravastatin (p = 0.003). A similar percent benefit was seen in the subgroup of patients with near normal levels of LDL-cholesterol (125 to 150 mg/dL [3.2 to 3.9 mmol/L]).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Sacks FM, Pfeffer MA, Move LA, et al for the Cholesterol and Recurrent Events Trial Investigators, N Engl J Med 1996; 335:1001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24045=[""].join("\n");
var outline_f23_30_24045=null;
var title_f23_30_24046="Traumatic shock initial management algorithm";
var content_f23_30_24046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Traumatic shock: Initial management",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 459px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24046=[""].join("\n");
var outline_f23_30_24046=null;
var title_f23_30_24047="Cystic hygroma CT II";
var content_f23_30_24047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic hygroma in newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan shows several large cystic structures in the left chest wall and anterior mediastinum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_30_24047=[""].join("\n");
var outline_f23_30_24047=null;
